A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Reference |
|---|
| "The onset of psoriasis is observed before the age of 10 years in 15% of all patients." | ( Beylot, C; Bioulac, P; Doutre, MS; Pringuet, R; Puissant, A; Saurat, JH, 1979) |
| "Psoriasis is a disease characterized by benign but unrestricted epithelial growth." | ( Voorhees, JJ, 1977) |
| "Although psoriasis is a genetically transferred disease, little is known of the factors causing spontaneous eruption of a proliferative lesion in apparently normal epidermis." | ( Plummer, NA, 1979) |
| "A case of EAC type psoriasis is reported." | ( Rajka, G; Thune, PO, 1979) |
| "Psoriasis is a chronic, relapsing dermatosis characterised by scaling, erythema, and less commonly pustulation." | ( Comaish, JS; Hodge, L, 1977) |
| "We conclude that psoriasis is a genetically determined disorder that may, to a limited extent, be modified by environmental influences." | ( Brandrup, F; Eriksen, B; Hauge, M; Henningsen, K, 1978) |
| "Psoriasis is a prototype of several common, glucocorticoid responsive, inflammatory proliferative skin diseases." | ( Anderson, TF; Duell, EA; Hamberg, M; Hammarström, S; Stawiski, MA; Voorhees, JJ, 1977) |
| "The chemotherapy of psoriasis is reviewed in 246 patients from 1964 to 1974 treated with methotrexate, 92 patients from 1971 to 1974 with hydroxyurea, and 36 patients from 1972 to 1974 with azaribine." | ( Moschella, SL, 1976) |
| "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0." | ( Frost, P; Gomez, EC, 1976) |
| "Psoriasis is a autosomal hereditary disease of the skin, which has been treated with a great number of possibly carcinogenic substances." | ( Bohnert, E; Jung, EG, 1975) |
| "Psoriasis is a common disorder characterized by marked increases in keratinocyte proliferation, abnormal patterns of keratinocyte differentiation, prominent alterations in dermal capillary vasculature and the presence of dermal and epidermal T cells, monocytes/macrophages and neutrophils." | ( Das, UN; Koratkar, R; Madhavi, N; Padma, M; Ramesh, G; Sagar, PS; Sravankumar, G; Suryaprabha, P; Vijaykumar, K, 1992) |
| "Psoriasis is suggested to be an autoimmune disease and in severe, uncontrollable psoriasis CsA and Mx are of value in reducing disease activity." | ( Hammer, JH; Nielsen, HJ, 1992) |
| "Psoriasis is a chronic inflammatory skin disease of unknown etiology." | ( Bjerke, JR, 1992) |
| "CsA therapy for psoriasis is hampered by side-effects." | ( Korstanje, MJ, 1992) |
| "Psoriasis is a humorally controlled systemic disease." | ( Holzmann, H; Hör, G; Maul, FD; Werner, RJ, 1992) |
| "Psoriasis is a disorder of abnormal keratinocyte proliferation mediated by T lymphocytes." | ( Fry, L, 1992) |
| "Psoriasis is a common skin disease in which retinoids have beneficial effects." | ( Donnadieu, M; Evain-Brion, D; Gerbaud, P; Gu, XF; Raynaud, F, 1991) |
| "Psoriasis is a genetically determined chronic disease of the skin, and an accelerated proliferation of epidermal keratinocytes is one of the pathophysiological characteristics of psoriatic lesion." | ( Ikeda, N; Kitano, Y; Okano, M, 1991) |
| "Psoriasis is an inflammatory disease of the skin associated with increased epidermal proliferation." | ( Maibach, HI; Tung, JP, 1990) |
| "Since psoriasis is thought to involve hyperproliferative expansion of the basal compartment from one to about three cell layers in thickness, the samples were screened with antibodies to intermediate filament determinants associated with basal cells, suprabasal cells and hyperproliferating keratinocyte-derived cell lines, respectively." | ( Lane, EB; Leigh, IM; Pulford, KA; Ramaekers, FC, 1985) |
| "BKH in active psoriasis are associated with electron-lucent areas suggestive of proteolytic enzyme release." | ( Chase, DG; Heng, MC; Kloss, SG; Kuehn, CS, 1986) |
| "Psoriasis is a common papulosquamous skin disease." | ( Gottlieb, AB; Granelli-Piperno, A; Grossman, RM; Krueger, J; Kupper, TS; May, LT; Murphy, DP; Sehgal, PB; Yourish, D, 1989) |
| "Psoriasis is associated with abnormally exaggerated epidermal cellular turnover." | ( Morimoto, S; Yoshikawa, K, 1989) |
| "Psoriasis is a hyperproliferative epidermal disease in which EGF receptor expression is altered and phospholipase C activity is increased." | ( Elder, JT; Fisher, GJ; Lee, CS; Pike, MC; Voorhees, JJ, 1989) |
| "Psoriasis is difficult to manage in general practice, mainly because the standard treatments produce side effects, or are ineffective in both the short and long term." | ( Harrington, CI, 1989) |
| "Psoriasis is a hereditary disease primarily affecting the skin and characterized by an abnormally high proliferation rate of the epidermal cells." | ( Späder, M; Unteregger, G, 1989) |
| "Because psoriasis is a very complex disease and its activity is often unpredictable, clinical studies on adverse drug effects on psoriasis have been difficult to conduct." | ( Abel, EA; DiCicco, LM; Farber, EM; Fraki, JE; Orenberg, EK, 1986) |
| "Severe psoriasis is commonly associated with depression and may be its cause." | ( Baker, H; Barth, JH, 1986) |
| "As psoriasis is a proliferative skin disease, the activity of this enzyme was assayed in 35 psoriatic Danes and in 25 long-term local hotel workers, as well as in 34 volunteers drinking low-selenium water." | ( Even-Paz, Z; Livshitz, T; Robberecht, H; Rubinstein, N; Shani, J; Van Grieken, R, 1985) |
| "Psoriasis is a common papulosquamous skin disease which frequently presents a therapeutic challenge to physicians." | ( Lowe, NJ, 1983) |
| "Psoriasis is a disease where changes in epidermal proliferation may be an important factor." | ( Ashton, R; Connor, MJ; Lowe, NJ; Wortzman, M, 1984) |
| "Because psoriasis is a disease of unknown etiology, all treatments are based on empirical experience and diverse scientific theories." | ( Abel, EA; Charuworn, A; Farber, EM, 1983) |
| "The disease of psoriasis is examined as to its incidence, etiology, clinical manifestations, and possible complications." | ( Bryant, BG, 1980) |
| "Psoriasis is a disease of major importance, the cause of which is unknown and treatment often difficult." | ( Cram, DL, 1981) |
| "Psoriasis is currently considered an incurable skin disorder whose etiology is unknown." | ( Dellon, AL, 1982) |
| "Psoriasis is marked by loss of glycoalyx." | ( Kunze, D; Meffert, H; Metz, D; Rüstow, B, 1981) |
| "Although psoriasis is characterized by the accumulation of activated proliferating lymphoid cells in the psoriatic skin lesion, it is not known whether these cells are activated and proliferating before entry into the psoriatic plaque." | ( Alzona, CP; Edwards, S; Herrod, R; Jeffes, EW; Lee, GC; Linden, KG; McCullough, JL; Sabahi, M; Said, S; Soundararajan, D, 1995) |
| "Psoriasis is a common inherited skin disease that is characterized by hyperproliferation of epidermal keratinocytes and excessive dermal angiogenesis." | ( Dixit, VM; Mitra, RS; Nickoloff, BJ; Polverini, PJ; Varani, J, 1994) |
| "Psoriasis is characterized by alterations in both the epidermis and dermis of the skin." | ( Battat, L; Gilleaudeau, P; Gottlieb, AB; Heftler, N; Hodak, E; Krueger, JG; Nabeya, R; Vallat, VP; Wolfe, J, 1994) |
| "Treatment of psoriasis is rapidly changing with improved understanding of the pathogenesis of the disease." | ( Lewis, HM, 1994) |
| "Psoriasis is characterized by immune activation and increased epidermal proliferation." | ( Gilleaudeau, P; Gottlieb, AB; Gottlieb, SL; Heftler, NS; Johnson, R; Krueger, JG; Vallat, VP; Wolfe, J, 1995) |
| "The pathogenesis of psoriasis is not fully understood, but two mechanisms seem important, i." | ( Panizzon, R, 1995) |
| "Psoriasis is a benign but hyperproliferative skin disease." | ( Bhardwaj, R; Buchegger, F; Goerdt, S; Grunert, F; Hagemeier, HH; Sorg, C; von Kleist, S, 1993) |
| "Scalp psoriasis is associated with hair loss and an increased telogen/anagen ratio." | ( Kuijpers, AL; van Baar, HM; van de Kerkhof, PC; van Gasselt, MW, 1995) |
| "Psoriasis is a skin disorder characterized by hyperproliferation of epidermal keratinocytes." | ( Chen, ML; Chen, TC; Heinrich, G; Holick, MF; Perez, A; Sanan, DK, 1996) |
| "Psoriasis is characterized by hyperproliferation and impared differentiation of epidermal keratinocytes (KCs)." | ( Fogh, K; Jøhnke, H; Kragballe, K; Sølvsten, H, 1996) |
| "Psoriasis is a heterogeneous disorder not only in regard to its variability in clinical expression and age at onset, but also in the degree to which genetic and immunological factors such as T cells and cytokines contribute." | ( Christophers, E, 1996) |
| "Psoriasis is an inherited condition that may require specific environmental factors to become activated; immunological factors are clearly important in pathogenesis." | ( Weller, PA, 1996) |
| "Psoriasis is a chronic skin disease characterized by epidermal hyperproliferation, disturbed differentiation, and inflammation." | ( Boezeman, JB; de Jongh, GJ; Schalkwijk, J; van Erp, PE; van Ruissen, F, 1996) |
| "Psoriasis is associated with production of gamma interferon (IFN gamma), which induces the expression of keratin K17 by activating transcription factor STAT1." | ( Blumenberg, M; Freedberg, IM; Komine, M, 1996) |
| "psoriasis) are discussed." | ( Boezeman, JB; Brons, PP; van Erp, PE, 1996) |
| "Psoriasis is a T-cell-mediated inflammatory skin disease which can be treated successfully with immunosuppressive drugs." | ( Bos, JD; De Rie, MA; Out, TA; Van Lier, RA; Witkamp, L; Zonneveld, IM, 1996) |
| "Psoriasis is characterized by immune activation, increased proliferation and abnormal differentiation of keratinocytes." | ( Gilleaudeau, P; Gottlieb, AB; Gottlieb, S; Heftler, N; Kamber, M; Krueger, JG; Lu, I; McLane, JA, 1996) |
| "Psoriasis is a common chronic skin disease mediated by cellular immune mechanisms and characterized by an intense neutrophil cell infiltrate and proliferative activation of epidermal keratinocytes." | ( Bruch-Gerharz, D; Fehsel, K; Kolb-Bachofen, V; Michel, G; Ruzicka, T; Suschek, C, 1996) |
| "Psoriasis is characterized by abnormal cell proliferation, inflammation and increased biosynthesis of various cytokines." | ( Cohen, S; Eitan, A; Gilhar, A; Grossman, N; Kahanovicz, S; Reuveni, H, 1996) |
| "Psoriasis is a chronic inflammatory disorder characterized by epidermal hyperproliferation." | ( Hatta, N; Hirone, T; Kawara, S; Takata, M; Takehara, K, 1997) |
| "PUVA treatment of psoriasis is usually given with broad-band fluorescent UVA lamps." | ( de Berker, DA; Diffey, BL; Farr, PM; Matthews, JN; Sakuntabhai, A, 1997) |
| "Psoriasis is a common condition which, at times, can be difficult to treat." | ( Crutchfield, CE; Lewis, EJ; Zelickson, BD, 1997) |
| "Pustular psoriasis is a rare form of psoriasis that can be divided into generalized and localized forms." | ( Tay, YK; Tham, SN, 1997) |
| "Psoriasis is a T-cell mediated inflammatory skin disease which has been associated with group A, beta-haemolytic streptococcal infections." | ( Good, MF; Jonsdottir, I; Sigmundsdottir, H; Sigurgeirsson, B; Troye-Blomberg, M; Valdimarsson, H, 1997) |
| "Psoriasis is a chronic immune-mediated disease that is characterized by the hyperproliferation and abnormal differentiation of keratinocytes and by inflammation." | ( Asano, AT; Chandraratna, RA; Duvic, M; Nagpal, S, 1997) |
| "Psoriasis is a skin disease that appears to result from a dysfunction in the normal mechanism(s) that regulates wound healing." | ( Morhenn, VB, 1997) |
| "Pustular psoriasis is a rare skin disease that is observed in about 1% of all patients with psoriasis." | ( Amano, T; Nakayama, Y; Seki, K, 1997) |
| "Psoriasis is a chronic genetic disease characterized by hyperproliferation and inflammation of the epidermis and dermis." | ( McClelland, PB, 1997) |
| "Psoriasis is such one disease holding great interest for dermatology owing to its high rate of incidence and complexity of treatment." | ( Biagini, G; Carraro, S; Cataldi, I; Giardino, R; Lucarini, G; Mattei, G; Ricotti, G; Solmi, R; Tosi, L; Tucci, MG, 1997) |
| "Psoriasis is a chronic T-cell-mediated inflammatory skin disease which can be treated with topical medication, phototherapy or systemic medication." | ( Bos, JD; de Rie, MA; Out, TA, 1998) |
| "Psoriasis is probably no more common in HIV infection than in the general population; however, it may appear for the first time or pre-existing psoriasis may worsen and be difficult to treat in HIV disease." | ( Bunce, M; Bunker, CB; Easterbrook, PJ; Gotch, FM; Mallon, E; Newson, R; Young, D, 1998) |
| "Psoriasis is associated with upregulation or downregulation of several of these markers." | ( Asano, AT; Duvic, M; Hager, C; Mays, S, 1998) |
| "Psoriasis is common, chronic and currently incurable." | ( Griffiths, CE, 1998) |
| "Pruritus in psoriasis is coupled to disease severity." | ( Bräutigam, M; Hultsch, T; Lotz, J; Schopf, RE, 1998) |
| "Psoriasis is a common dermatosis, affecting from 1 to 3 percent of the population." | ( Federman, DG; Froelich, CW; Kirsner, RS, 1999) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Nave, B; Ott, R; Severin, E; Ständer, M; Traupe, H, 1999) |
| "Psoriasis is a T cell-mediated inflammatory skin disease that has been associated with infections by group A beta-haemolytic streptococci." | ( Good, MF; Gudmundsdottir, AS; Jonsdottir, I; Sigmundsdottir, H; Sigurgeirsson, B; Valdimarsson, H, 1999) |
| "Because psoriasis is not cured by PUVA, patients receive many treatments over their lifetime and develop a significant risk for the development of skin cancers (primarily squamous cell carcinomas)." | ( Gasparro, FP; Peritz, AE, 1999) |
| "Psoriasis is a T-cell mediated autoimmune disease." | ( Avgerinou, G; Barkis, J; Degiannis, D; Demetriou, Z; Economidou, J; Katsambas, A; Psarra, K; Vareltzidis, A, 1999) |
| "Psoriasis is characterized by hyperproliferation of keratinocytes associated with an inflammatory infiltrate in the epidermis." | ( Ben-Bassat, H; Chaouat, M; Chen, H; Gazit, A; Harzstark, Z; Klein, BY; Levitzki, A; Levitzki, R; McCollough, J; McMahon, J; Narog, B; Powell, TJ; Shawver, L; Shenoy, N; Tang, C, 1999) |
| "Psoriasis is a common and persistent disease characterized chiefly by marked epidermal and endothelial cell proliferation and inflammation." | ( Auerbach, R; Burack, LH; Cardinale, I; Coven, TR; Gilleaudeau, P; Krueger, JG; Murphy, FP, 1999) |
| "Psoriasis is a chronic inflammatory skin disease, and besides inflammation, disturbed differentiation and hyperproliferation are its hallmarks." | ( Goossen, JW; Mommers, JM; van De Kerkhof, PC; van Erp, PE, 2000) |
| "Pustular psoriasis is a rare but serious form of psoriasis." | ( Barker, JN; Wakelin, SH; Whittam, LR, 2000) |
| "Psoriasis is often treated with agents that activate nuclear hormone receptors for glucocorticoids, retinoids, and vitamin D." | ( Benson, SC; Chi, Y; Ellis, CN; Fisher, GJ; Kurtz, TW; Pershadsingh, HA; Varani, J; Zeigler, ME, 2000) |
| "Treatment of psoriasis is rapidly changing, and there have been dramatic additions such as topical vitamin D analogs and a topical retinoid to the therapeutic armamentarium in recent years." | ( Müller, K, 2000) |
| "Psoriasis is a heterogeneous disease in which several reports suggest the presence of a susceptibility gene in or in the proximity of the human leukocyte antigen complex in chromosome 6p." | ( Enerbäck, C; Enlund, F; Inerot, A; Martinsson, T; Samuelsson, L; Swanbeck, G; Wahlström, J, 2000) |
| "Psoriasis is still a relatively poorly understood inflammatory dermatosis that is resistant to many therapies." | ( Danby, FW; Rowlands, CG, 2000) |
| "Nail psoriasis is often difficult to cure, but may respond to a range of different approaches used alone or together." | ( de Berker, D, 2000) |
| "Psoriasis is one of the most common skin disorders affecting approximately 2% of the population; the disease is recurrent and can be very debilitating." | ( Chandraratna, RA; DiSepio, D, 2000) |
| "Given that psoriasis is a chronic recurrent disease for most patients, longer trials are needed to determine whether the addition of topical calcipotriene to systemic therapy improves the risk-benefit ratio by reducing the long-term risk of toxic effects." | ( Ashcroft, DM; Griffiths, CE; Li Wan Po, A; Williams, HC, 2000) |
| "Psoriasis is a chronic inflammatory skin disease that rarely involves the oral cavity." | ( Brice, DM; Danesh-Meyer, MJ, 2000) |
| "Psoriasis is a chronic inflammatory skin disease in which epidermal hyperplasia results from the release of cytokines by infiltrating type 1 T cells." | ( Blaschke, V; Garbe, C; Lippert, U; Maurer, C; Middel, P; Neumann, C; Reich, K; Westphal, G, 2001) |
| "Psoriasis is currently considered to be an inflammatory disease of the skin mediated by T-lymphocytes." | ( Svecova, D, 2000) |
| "Psoriasis is a complex disorder that negatively impacts quality of life." | ( Feldman, S, 2000) |
| "Psoriasis is a chronic inflammatory skin disease in which epidermal proliferation is closely associated with excessive microvascular expansion within the papillary dermis." | ( Fleischmajer, R; Kuroda, K; Lebwohl, M; Sapadin, A; Shoji, T, 2001) |
| "Psoriasis is a disease marked by keratinocyte hyperproliferation, neutrophil and lymphocyte infiltration, and aberrant epidermal and dermal expression of cytokines." | ( Hunter, JA; McKenzie, RC; Szepietowski, J; Walker, C, 2001) |
| "Psoriasis is a hyperproliferative skin disorder estimated to be present in 1-3% of most populations." | ( Karlsen, G; Leigh, IM; Navsaria, H; Raman, A; Sampson, JH, 2001) |
| "Scalp psoriasis is a frequent expression of the common skin disease psoriasis, and scaling and itching are the two major complaints." | ( van de Kerkhof, PC; van der Vleuten, CJ, 2001) |
| "Psoriasis is a chronic skin disease characterized by epidermal hyperproliferation, which may be regulated by several mechanisms including apoptosis." | ( Fukuya, Y; Higaki, M; Higaki, Y; Kawashima, M, 2002) |
| "Psoriasis is recognized as the most common T cell-mediated inflammatory disease in humans." | ( Dorner, AJ; Gilleaudeau, P; Kikuchi, T; Krueger, JG; Oestreicher, JL; Schwertschlag, U; Surette, J; Trepicchio, WL; Walters, IB, 2001) |
| "Psoriasis is characterized by defects in the normal cycle of epidermal development that lead to epidermal hyperproliferation, altered maturation of skin cells, vascular changes and inflammation." | ( Ari, Z; Durkan, K; Gündüz, K; Onur, E; Tanülkü, S; Uyanik, BS, 2002) |
| "Psoriasis is a common skin disease, with a clinical appearance of red, scaly lesions, known as plaques." | ( Savill, NJ; Sherratt, JA; Weller, R, 2002) |
| "Psoriasis is an inflammatory skin disorder with hyperproliferation of keratinocytes, that can be the result of insufficient inhibitory effect of transforming growth factors-beta (TGF-beta)." | ( Chodynicka, B; Flisiak, I; Flisiak, R; Porebski, P, 2002) |
| "Psoriasis is a chronic, debilitating skin condition that affects millions of people and is attributed to both genetic and environmental factors." | ( Gordon, KB; McClure, SL; Valentine, J, 2002) |
| "Mild to moderate psoriasis is a disease that can often be treated with topical medications." | ( Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M, 2003) |
| "Psoriasis is one of the diseases associated with increased atherothrombosis." | ( Alver, A; Cimşit, G; Orem, A; Uydu, HA; Vanizor Kural, B; Yandi, YE, 2003) |
| "Psoriasis is an immunogenetic disorder." | ( Arrese, JE; Hermanns-Lê, T; Piérard, GE; Piérard-Franchimont, C; Quatresooz, P; Uhoda, I, 2003) |
| "Psoriasis is a disease characterized by inflammation and increased population of hyperproliferative keratinocytes." | ( Chen, J; Guo, Z; Li, Q; Tang, L; Yan, M; Yu, Y, 2003) |
| "Acute pustular psoriasis is characterized by fiery-red erythema followed by formation of pustules." | ( Welsch, MJ, 2003) |
| "Psoriasis is a chronic inflammatory T-cell-mediated immune dermatosis, characterized by the cutaneous expression of adhesion molecules belonging to the beta1 and beta2 integrin subfamilies, such as intracellular adhesion molecule (ICAM)-1, ICAM-3, lymphocyte function associated antigen (LFA)-1, vascular cell adhesion molecule (VCAM)-1 and endothelial adhesion molecule (ELAM)-1." | ( Caproni, M; Fabbri, P; Floriani, I; Pestelli, E, 2003) |
| "Psoriasis is an autoimmune disease affecting 2-4% of the Caucasian population." | ( Ghoreschi, K; Mrowietz, U; Röcken, M, 2003) |
| "Psoriasis is an inflammatory disorder characterized by a T helper type 1 cell cytokine pattern." | ( Namazi, MR, 2003) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Joshi, R; Langguth, P; Merkle, HP; Werdenberg, D; Wolffram, S, 2003) |
| "Psoriasis is a disease characterized by an abnormal pattern of keratinocyte growth and differentiation." | ( Agozzino, M; Baroni, A; Donnarumma, G; Paoletti, I; Ruocco, E; Tufano, MA, 2004) |
| "Psoriasis is a common, chronic inflammatory skin disease with unknown etiology." | ( Api, H; Atik, U; Baz, K; Cimen, MY; Eskandari, G; Ikizoglu, G; Kokturk, A; Yazici, AC, 2003) |
| "Psoriasis is a common skin disease characterized by hyperplastic regenerative epidermal growth and infiltration of immunocytes." | ( Chiba, H; Imai, Y; Kawasaki, S; Michibata, H; Mitsui, H; Okubo, K; Seishima, M; Torii, H; Wakimoto, K, 2004) |
| "Psoriasis is a common, chronic, cell-mediated, inflammatory skin disease." | ( Carboni, I; Chimenti, S; De Felice, C; De Simoni, I; Soda, R, 2004) |
| "Psoriasis is a common skin disorder associated with significant morbidity." | ( Elias, AN, 2004) |
| "Psoriasis is a multifactorial, chronically relapsing, inflammatory skin disease occurring in 1-3% of the world's population." | ( Aldebani, S; Alhaddar, J; Benghazil, M; Duweb, G; Elzorghany, A, 2003) |
| "Psoriasis is regarded as a Th1-cell type disease." | ( Dziankowska-Bartkowiak, B; Sysa-Jedrzejowska, A; Wyczółkowska, J; Zalewska, A, 2004) |
| "Psoriasis is a common chronic cutaneous disease affecting 1-3% of general population." | ( Baran, E; Nockowski, P; Szepietowski, JC; Ziarkiewicz, M, 2004) |
| "Since psoriasis is exacerbated in HIV infection possibly due to the increased staphylococcal colonization, and psoriatic keratinocytes could aggravate HIV infection through production of TNF-alpha, it could be reasoned that in HIV-positive psoriatics a strong vicious cycle is present between the degree of immune deficiency and the staphylococcal colonization, explaining the poor prognosis of both AIDS and psoriasis in these patients." | ( Namazi, MR, 2004) |
| "Psoriasis is a chronic condition that shows variability in phenotype and severity." | ( Ho, VC, 2004) |
| "Psoriasis is uncommonly seen in Africans, probably partly due to genetic factors." | ( Namazi, MR, 2004) |
| "Psoriasis is recognized as a chronic inflammatory disease characterized by epidermal hyperproliferation." | ( Chiba, H; Imai, Y; Kawasaki, S; Michibata, H; Mitsui, H; Okubo, K; Seishima, M; Torii, H; Wakimoto, K, 2004) |
| "Psoriasis is recognized as the most prevalent T-cell-mediated inflammatory disease in humans, with predominantly activated T-helper (Th) 1 cell effectors." | ( Barba-Gómez, JF; Guevara-Gutiérrez, E; Ornelas-Aguirre, JM; Rodríguez-Castellanos, MA; Salazar-Páramo, M; Tlacuilo-Parra, JA, 2004) |
| "Psoriasis is a complex disease with a spectrum of clinical manifestations." | ( van de Kerkhof, PC; Vissers, WH, 2004) |
| "Psoriasis is a chronic inflammatory skin disorder characterized by accumulation of Th1-type T cells and neutrophils, regenerative keratinocyte proliferation and differentiation, and enhanced epidermal production of antimicrobial peptides." | ( Beckmann, I; Hallermann, C; Mössner, R; Neumann, C; Reich, K, 2004) |
| "Psoriasis is a chronic inflammatory skin disease that is known to have a strong genetic predisposition." | ( Holm, SJ; Mallbris, L; O'Brien, KP; Sánchez, F; Ståhle, M, 2004) |
| "Psoriasis is a common condition, affecting 1." | ( Cooper, AJ; Ilchef, R; Russo, PA, 2004) |
| "Psoriasis is a common benign skin disease characterized by hyperproliferation and abnormal differentiation of keratinocytes." | ( Dam, TN; Iversen, L; Johansen, C; Kragballe, K; Rasmussen, M, 2004) |
| "Psoriasis is a common disease and may have a significant impact on patients' quality of life (QoL)." | ( van de Kerkhof, PC, 2004) |
| "Psoriasis is a chronic inflammatory skin disease that can be successfully treated with a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use." | ( Litjens, NH; Mattie, H; Nibbering, PH; Thio, HB; van Dissel, JT; van Gulpen, C; van Strijen, E, 2004) |
| "Psoriasis is a common, chronic dermatological disorder." | ( Kapuścińska, R; Niczyporuk, W; Wysocka, J; Zelazowska, B, 2004) |
| "Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population." | ( Saini, R; Tutrone, WD; Weinberg, JM, 2005) |
| "Psoriasis is believed to be a T cell-mediated autoimmune disease, but also exhibits autoantibody production." | ( Kawara, S; Matsushita, Y; Sato, S; Shimada, Y; Takehara, K, 2005) |
| "Psoriasis is a clinical conundrum that affects an estimated 1-3% of the world's population." | ( Namazi, MR, 2005) |
| "Psoriasis is a common, persistent skin disorder characterized by recurrent erythematous lesions thought to arise as a result of inflammatory cell infiltration and activation of keratinocyte proliferation." | ( Arbiser, J; Babichev, YO; Chang, W; Chen, S; Cruz, M; Dagnino, L; Dumont, DJ; Haninec, A; Jones, J; Jones, N; Jothy, S; Kerbel, RS; Klement, G; Master, Z; Sturk, C; Tran, J; Van Slyke, P; Voskas, D; Ward, N, 2005) |
| "Psoriasis is a T cell-mediated inflammatory skin disease." | ( Fan, JY; Li, W; Liu, YF; Shen, Z; Wang, G, 2005) |
| "Erythrodermic psoriasis is an aggressive form of the disease and can be precipitated by numerous factors including stress to the body." | ( Das, SR; Deiraniya, AK; Jha, PK; Kingston, TP; Lakshmanan, S; Musleh, GS, 2005) |
| "Psoriasis is a frequent dermatosis, its prevalence is estimated of between 1 and 3 p." | ( Amal, S; Charioui, S; Hocar, O; Houass, S; Jalal, O; Laissaoui, K, 2005) |
| "Psoriasis is a chronic, recurrent disease that affects between 1% and 3% of the population." | ( Griffiths, CE; Naldi, L, 2005) |
| "Psoriasis is very common and causes substantial morbidity." | ( Afifi, T; de Gannes, G; Huang, C; Zhou, Y, 2005) |
| "Psoriasis is believed to be characterized by a type 1 cytokine pattern; interferon-gamma, interleukin (IL)-2 and tumour necrosis factor (TNF)-alpha are predominantly expressed in this disorder." | ( Namazi, MR, 2005) |
| "Psoriasis is a genetically determined disease characterized by hyperproliferation and disordered maturation of the epidermis." | ( Halsall, JA; Hutchinson, PE; Osborne, JE; Pringle, JH, 2005) |
| "Psoriasis is a common, chronic, distressing skin disorder that frequently affects the scalp, skin, nails and joints." | ( Kimball, AB; Reid, DC, 2005) |
| "Psoriasis is a chronic skin disease, whose prevalence in population is connected with interaction between genetic and environmental factors." | ( Chodorowska, G; Kwiatek, J, 2004) |
| "Psoriasis is a common skin disorder that may be triggered by hormonal disturbances, among other factors." | ( Ezquerra, GM; Millet, PU; Regaña, MS, 2005) |
| "Treatment of nail psoriasis is difficult." | ( Llambí Mateos, F; Martín Ezquerra, G; Sánchez Regaña, M; Umbert Millet, P, 2005) |
| "Psoriasis is considered as a T-cell-mediated inflammatory skin disease which is characterized by hyperproliferation and poor differentiation of epidermal keratinocytes." | ( Wolters, M, 2005) |
| "Psoriasis is a chronic skin disease with substantial impact on patients' social and relational ways of living and subsequently on their quality of life." | ( de Boo, T; Krabbe, PF; Prins, M; Swinkels, QO; van de Kerkhof, PC; van der Valk, PG, 2005) |
| "Inverse psoriasis is a chronic disease frequently treated with topical corticosteroids." | ( Choi, C; Kwong, PC; Steele, JA, 2005) |
| "The dogma in psoriasis is that due to pathogen-induced inflammatory responses, an autoreactive immune response is induced that leads to tissue destruction." | ( Caspary, F; Das, PK; Elliott, G; Nagelkerken, L; Navé, BT; Nieland, JD; Rohrbach, M; Verzaal, P, 2005) |
| "Psoriasis is a common disease which often requires long-term maintenance therapy." | ( Asilian, A; Khalesi, E; Khoddami, L; Mohammady, M; Shahtalebi, M; Vali, A, 2005) |
| "Psoriasis is a chronic, inflammatory, hyperproliferative skin disease that affects 1-2% of the general population in the UK and US." | ( Ashcroft, DM; Fairhurst, DA; Griffiths, CE, 2005) |
| "Psoriasis is a chronic inflammatory skin disease whose pathogenesis is modulated by numerous genetic and immunologic factors." | ( Zargari, O, 2005) |
| "Psoriasis is associated with abnormal plasma lipid metabolism and a high frequency of cardiovascular events." | ( Allen, MH; Barker, JN; Burden, AD; Campalani, E; Crook, MA; Fairhurst, D; Griffiths, CE; Mendonca, CO; Smith, CH; Young, HS, 2006) |
| "The cause of psoriasis is still unknown." | ( Abuhamida, M; Alhaddar, J; Duweb, G, 2005) |
| "Psoriasis is characterized by three main pathogenic features: abnormal differentiation, keratinocyte hyperproliferation and inflammation." | ( Abuhamida, M; Alhaddar, J; Duweb, G, 2005) |
| "Psoriasis is known to be an autoimmune skin disease characterized by Th1 cell-mediated hyperproliferation of keratinocytes, and the type 1 helper T (Th1) cell subset increased with imatinib therapy." | ( Akiyama, T; Fujimi, A; Kida, M; Kuroda, H; Matsunaga, T; Niitsu, Y; Sato, T; Shimizu, K; Shirao, S; Tanaka, I; Watanabe, H, 2005) |
| "Psoriasis is one of the most frequent inflammatory skin diseases in which abnormal individual immune reactivity plays an important role." | ( Andrýs, C; Borská, L; Ettler, K; Fiala, Z; Hamáková, K; Krejsek, J; Kremlácek, J; Vokurková, D, 2006) |
| "Psoriasis is a T-cell-mediated autoimmune disease, but certain medications and infections are well-known risk factors." | ( Luba, KM; Stulberg, DL, 2006) |
| "Psoriasis is a chronic inflammatory dermatosis that affects 0." | ( Guillen, S; Khachemoune, A, 2006) |
| "Palmoplantar psoriasis is a chronic disease, which is very resistant to treatment and often leads to severe disabilities." | ( Korpusik, D; Mahnke, N; Neumann, NJ; Ruzicka, T; Stege, H, 2006) |
| "Psoriasis is a chronic inflammatory skin disorder of multifactorial etiology." | ( Farshi, S; Mansouri, P, 2006) |
| "Psoriasis is a common skin disorder that needs a long-term management, not only because, of its prevalence but also because of the profound impact it can have on patients quality of life." | ( Bardazzi, F; Dika, E; Maibach, HI; Varotti, C, 2006) |
| "As psoriasis is a chronic disease, long-term treatment may be required, so there is a need to investigate the safety of its use over a longer period of time." | ( Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Jolliffe, D; Kragballe, K; Peyri, J; Svensson, A; Toole, J; Wozel, G, 2006) |
| "Psoriasis is a T-helper (Th)1 cytokine-mediated chronic skin disease and interleukin (IL)-12 has been shown to play a major role in the development of Th1 responses." | ( Asahina, A; Kishimoto, E; Komine, M; Mitsui, H; Saeki, H; Tada, Y; Takekoshi, T; Tamaki, K, 2006) |
| "Psoriasis is a chronic skin disease that often requires long-term therapy to control the symptoms." | ( Aydin, F; Canturk, T; Senturk, N; Turanli, AY, 2006) |
| "Since treatment of psoriasis is generally long-term, the objective of this study was to investigate the efficacy and safety of transferring patients to maintenance treatment with calcipotriene cream (Dovonex cream) following a 4-week treatment period with the two-compound product." | ( Bibby, A; Cambazard, F; Foster, R; Haverkamp, C; Martinez Escribano, JA; Naeyaert, JM; Thaçi, D; Vender, R; White, S, 2006) |
| "Psoriasis is a T cell mediated inflammatory skin disease characterized by hyperproliferation and reduced differentiation of epidermal keratinocytes." | ( Wolters, M, 2006) |
| "Psoriasis is a common skin condition affecting approximately 2." | ( Janiga, J; Lim, HW; Rivard, J, 2006) |
| "Psoriasis is characterized by the hyperproliferation of keratinocytes in the epidermis and the accumulation of activated CD4+ T lymphocytes in the upper dermis." | ( Cai, JP; Chin, YH; Falanga, V, 1990) |
| "Psoriasis is a systemic chronic inflammatory disorder." | ( Bock, D; Philipp, S; Wolff, G, 2006) |
| "Psoriasis is a common cutaneous disorder characterized by abnormal epidermal differentiation, proliferation and inflammation mediated by dermal infiltrates, such as T cells, neutrophils, dendritic cells and macrophages." | ( Bevelacqua, V; Curatolo, S; Gangemi, P; La Greca, S; Libra, M; Malaponte, G; Massimino, D; Mazzarino, MC; Merito, P; Nicotra, G; Plumari, A; Stivala, F; Valente, G, 2006) |
| "Psoriasis is a common skin disease, the pathogenesis of which has not yet been resolved." | ( Haase, I; Hartmann, K; Krieg, T; Markur, D; Pasparakis, M; Peters, T; Rupec, RA; Scharffetter-Kochanek, K; Stratis, A; van Rooijen, N, 2006) |
| "Psoriasis is a chronic, recurrent, inflammatory, and hyperproliferative disease." | ( Gurer, MA; Ilter, N; Ozden, MG; Sancak, B; Tekin, NS, 2006) |
| "Psoriasis is a complex disease that requires safe, long-term treatment." | ( Gorgievska Sukarovska, B; Lipozencić, J, 2006) |
| "The pathogenesis of psoriasis is incompletely understood but cutaneous neurogenic inflammation is probably involved." | ( Griffiths, CE; Kleyn, CE; Saraceno, R; Terenghi, G, 2006) |
| "Currently, psoriasis is seen as a T-cell-mediated autoimmune disease that is characterized by an increased expression of pro-inflammatory cytokines." | ( Dissemond, J; Grabbe, S, 2006) |
| "Psoriasis is an inflammatory disease also characterised in part by epidermal keratinocyte hyper-proliferation." | ( Wilkinson, JD; Williamson, EM, 2007) |
| "Thyroid disease and psoriasis are common associated conditions." | ( Oakley, A; Simpkin, S, 2007) |
| "Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage." | ( Altomare, A; Altomare, GF; Colombo, MD; Franchi, C; Frigerio, E; Garutti, C, 2007) |
| "Psoriasis is a chronic inflammatory skin disease in which several Th1 cytokines such as interleukin-1 beta (IL-beta) have been shown to play a pivotal role." | ( Alicino, D; Mastrolonardo, M; Pasquini, P; Picardi, A; Zefferino, R, 2007) |
| "Comorbid RA and psoriasis are unusual, and our patients exhibited a clear link between anti-TNF-alpha administration and cutaneous lesions, suggesting a direct effect in both cases." | ( Albert, C; Breuil, V; Brocq, O; Euler-Ziegler, L; Euller-Ziegler, L; Giacchero, D; Lacour, J; Leccia, N; Perrin, C; Roux, CH, 2007) |
| "Psoriasis is a common disease in children and adolescents." | ( Ceović, R; Husar, K; Kostović, K; Lipozencić, J; Murat-Susić, S; Pasić, A; Skerlev, M, 2006) |
| "Psoriasis is a chronic skin disorder affecting up to 2." | ( Koo, J; Leon, A; Letsinger, J; Nguyen, A, 2007) |
| "Psoriasis is a frequent, chronic, clinically variable inflammatory disease of unknown etiology, affecting primarily the skin and the joints." | ( Gyulai, R; Kemény, L, 2006) |
| "Psoriasis is characterised by the presence of neutrophil overactivation and overproduction of interleukin (IL)-6 and IL-8 from keratinocytes." | ( Alli, N; Artuz, F; Gür, G; Lenk, N; Polat, M; Tamer, E; Yalcin, B, 2007) |
| "AA and psoriasis are rare in our series." | ( Chen, W; Cheng, YW; Lai, CS; Yang, YC, 2007) |
| "Psoriasis is a chronic inflammatory skin disease characterized by an accelerated turnover of epidermal cells and an incomplete differentiation in epidermis with lesion." | ( Barut, F; Sipahi, EY; Tekin, IO; Tekin, NS, 2007) |
| "Nail psoriasis is common in adult psoriatic patients and it causes serious psychological and physical distress." | ( Berth-Jones, J; Vlachou, C, 2007) |
| "Psoriasis is a common skin disease affecting 1%-3% of the world's population with significant impacts on quality of life." | ( Toole, JW, 2007) |
| "Psoriasis is a chronic skin disease that affects millions of people throughout the world." | ( Jiaravuthisan, MM; Muhn, CY; Murphy, F; Sasseville, D; Vender, RB, 2007) |
| "Psoriasis is characterized by excessive proliferation of keratinocytes accompanying acanthosis and incomplete differentiation." | ( Hwang, HY; Kim, SY; Kim, TY; Kim, Y, 2007) |
| "Psoriasis is a chronic skin disorder affecting approximately 2% of the US population." | ( Balin, AK; Clark, SD; Fleming, T; Flores, J; Glinert, RJ; Graeber, M; Kempers, S; Lebwohl, M; Liu, Y; Menter, A; Pariser, DM; Powers, J; Weiss, J, 2007) |
| "Psoriasis is a common, chronic, relapsing, papulo-squamous dermatitis, with overlying silvery scales." | ( De Rosa, G; Mignogna, C, 2007) |
| "Facial psoriasis is a prognostic marker indicating a poor prognosis of psoriasis." | ( Austad, J; Cambazard, F; Duvold, LB; Ljungberg, A; Murphy, GM; van de Kerkhof, PC, 2007) |
| "Psoriasis is a chronic inflammatory skin disease characterized histologically by hyperproliferation and aberrant differentiation of epidermal keratinocytes." | ( Che, CT; Cheng, CH; Lin, ZX; Tse, WP; Zhao, M, 2007) |
| "Psoriasis is a common chronic inflammatory skin disease." | ( El-Shabrawi, Y; Hofer, A; Kerl, H; Renner, W; Salmhofer, W; Weger, W; Wolf, P, 2007) |
| "Psoriasis is a chronic inflammatory cutaneous disorder." | ( Ben Osman Dahri, A; Boubacker, MS; Cherif Ben Hmida, F; Hechmi-Louzir, M; Samoud El Kissi, S, 2007) |
| "Psoriasis is a chronic inflammatory skin disease, where specific immunity and/or innate immunity may be of importance in the disease pathogenesis." | ( Nordlind, K; Thorslund, K, 2007) |
| "Hand and foot psoriasis is a chronic and debilitating disease that manifests as plaque-type or pustular-type lesions." | ( Kircik, L, 2007) |
| "Psoriasis is a multifactorial disease in which genetic and inflammatory factors play important roles." | ( Aydin, F; Bagci, H; Bek, Y; Canturk, MT; Gunes, S; Kara, N; Senturk, N; Turanli, AY, 2007) |
| "Cutaneous psoriasis is an example, of which several cases have been reported." | ( Aubin, F; Balblanc, JC; Briançon, D; Brousse, A; Deprez, P; Humbert, P; Lohse, A; Wendling, D, 2008) |
| "Psoriasis is a class effect that has been reported with all the currently available TNFalpha antagonists." | ( Aubin, F; Balblanc, JC; Briançon, D; Brousse, A; Deprez, P; Humbert, P; Lohse, A; Wendling, D, 2008) |
| "While psoriasis is one of the most common skin disorders in humans, effective, safe and inexpensive treatments are still largely unavailable." | ( Chang, S; Demerjian, M; Elias, PM; Feingold, KR; Lee, SH; Man, M; Man, MQ; Shi, Y, 2008) |
| "Psoriasis is an immune mediated, inflammatory skin condition affecting approximately 1." | ( Alegre de Miguel, V; Martínez Casimiro, L; Sánchez Carazo, JL, 2008) |
| "Psoriasis is a complex genetic disease of unresolved pathogenesis with both heritable and environmental factors contributing to onset and severity." | ( Blakytny, R; Holmdahl, R; Kess, D; Lindqvist, AK; Peters, T; Scharffetter-Kochanek, K; Sindrilaru, A; Wang, H; Wlaschek, M, 2008) |
| "Psoriasis is a lifelong, chronic and immune-mediated skin disease affecting approximately 1-3% of the Caucasian population." | ( Chimenti, S; De Lorenzo, A; Di Renzo, L; Esposito, M; Mazzotta, A; Saraceno, R; Schipani, C, 2008) |
| "Psoriasis is a common chronic inflammatory disease of the skin characterized by epidermal hyperplasia and angiogenesis." | ( Bu, ZY; Cai, SQ; Man, XY; Yang, XH; Zheng, M, 2008) |
| "Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population." | ( Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS, 2008) |
| "Psoriasis is a common chronic inflammatory skin disease, characterized by epidermal hyperplasia, immune cell infiltration, increased dermal angiogenesis and local up-regulation of a variety of inflammatory mediators." | ( Hvid, H; Kemp, K; Kvist, PH; Svensson, L; Teige, I, 2008) |
| "Psoriasis is an important disorder in the adolescent population and has a tremendous physical and psychological impact on patients." | ( Belazarian, L, 2008) |
| "Psoriasis is likely associated with an increased risk of myocardial infarction, metabolic syndrome, Crohn's disease, and depression; it is difficult to assess the implications in the adolescent population." | ( Belazarian, L, 2008) |
| "Psoriasis is not rare in the adolescent population." | ( Belazarian, L, 2008) |
| "Psoriasis is a common chronic and recurrent inflammatory skin disease associated with increased thrombosis." | ( Dogan, B; Erikci, AA; Harmanyeri, Y; Karabudak, O; Solmazgul, E; Ulusoy, RE, 2008) |
| "Psoriasis is a chronic skin disease characterized by a thickening and disorganization of the skin's protective barrier." | ( Jean, J; Lapointe, M; Pouliot, R; Soucy, J, 2009) |
| "Psoriasis is a disease presenting cutaneous, immunological and vascular abnormalities." | ( Ohtsuka, T, 2008) |
| "As psoriasis is considered an autoimmune disease, lower levels of soluble HLA-G (sHLA-G) might be expected in psoriatic patients than in healthy controls." | ( Altieri, E; Baricordi, O; Borghi, A; Fogli, E; Melchiorri, L; Rizzo, R; Stignani, M; Virgili, A, 2008) |
| "Psoriasis is a disorder characterized by faster than normal skin growth, resulting in a buildup of thickened areas with a scaly appearance." | ( Draelos, ZD, 2008) |
| "Psoriasis is a common, chronic inflammatory skin disease that affects the scalp more commonly than any other site." | ( Brown, BC; Griffiths, CE; Warren, RB, 2008) |
| "Chronic plaque psoriasis is frequently associated with obesity." | ( Del Giglio, M; Di Francesco, V; Girolomoni, G; Gisondi, P; Zamboni, M, 2008) |
| "Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life." | ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009) |
| "Linear psoriasis is a very unusual clinical variation of psoriasis." | ( Bröcker, EB; Garbaraviciene, J; Hamm, H; Seitz, CS, 2009) |
| "Psoriasis is a type I interferon-driven T cell-mediated disease characterized by the recruitment of plasmacytoid dendritic cells (pDC) into the skin." | ( Albanesi, C; Bosisio, D; Daniele, R; De Pità, O; Fortugno, P; Franssen, JD; Girolomoni, G; Gonzalvo-Feo, S; Madonna, S; Pallotta, S; Parmentier, M; Scarponi, C; Sozzani, S, 2009) |
| "Psoriasis is an inflammatory skin disorder characterized by increased activation of CD4(+) T lymphocytes, and systemic and local overexpression of pro-inflammatory cytokines such as interleukin 2 (IL-2), gamma interferon (IFN-gamma), IL-6 and tumour necrosis factor alpha, indicating that immunopathogenesis of the disease is T helper 1 (Th1) mediated." | ( Bhattacharya, SN; Das, S; Jain, S; Kaur, IR; Singh, A, 2009) |
| "Psoriasis is a chronic disease characterized by abnormal epidermal proliferation, inflammation and angiogenesis." | ( Abdalmoati, A; Al-Makhzangy, I; Attwa, E; Nassar, A; Nofal, A, 2009) |
| "Psoriasis is a common chronic and recurrent inflammatory skin disease with unknown etiology that has been associated with abnormal plasma lipid metabolism and oxidative stress." | ( Akçay, F; Aksoy, H; Kadi, M; Toker, A; Yildirim, AK, 2009) |
| "Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation and infiltration of inflammatory leukocytes." | ( Higaki, M; Higaki, Y; Kawashima, M, 2009) |
| "Psoriasis is a chronic inflammatory disease causing important physical and psychological morbidity." | ( Laffitte, E; Thielen, AM, 2009) |
| "Nail psoriasis is often refractory to traditional treatments, and patients with nail psoriasis usually demand a therapeutic option." | ( Fernández-Guarino, M; García-Morales, I; Harto, A; Jaén, P; Sánchez-Ronco, M, 2009) |
| "Plaque-type psoriasis is a chronic and immune-mediated skin disease affecting approximately 1-3% of the Caucasian population." | ( Chimenti, S; Frascione, P; Gramiccia, T; Saraceno, R, 2009) |
| "Psoriasis is a very common dermatological disease affecting a large part of the world population." | ( Buggiani, G; Lotti, T; Prignano, F, 2009) |
| "Scalp psoriasis is reported to occur in 50-80% of psoriasis sufferers." | ( Brouda, I; Edison, B; Green, B; Johnson, C, 2009) |
| "Psoriasis is characterized by an accelerated keratinocyte proliferation, resulting in increased epidermal thickness." | ( Dagnaes-Hansen, F; Dam, TN; de Darkó, E; Kamp, S; Rosada, C; Stenderup, K, 2010) |
| "Psoriasis is strongly associated with streptococcal throat infection, and patients have increased occurrence of such infections." | ( Gudjonsson, JE; Johnston, A; Sigurdardottir, SL; Thorleifsdottir, RH; Valdimarsson, H, 2009) |
| "Erythrodermic psoriasis is a severe and disabling variant of psoriasis." | ( Calvieri, S; Carboni, V; Carlomagno, V; Giancristoforo, S; Maiani, E; Mattozzi, C; Richetta, AG, 2009) |
| "Psoriasis is a common and chronic immune-mediated skin disorder, for which there is currently no cure." | ( Chan, HH; Ho, SG; Yeung, CK, 2010) |
| "Psoriasis is a common chronic inflammatory disease that is associated with serious comorbidities, including psoriatic arthritis, reduced quality of life, depression, malignancy, and cardiovascular comorbidities." | ( Dann, F; Gottlieb, AB, 2009) |
| "Psoriasis is a skin disease associated with hyperproliferation and aberrant differentiation of keratinocytes." | ( Che, CT; Cheng, CH; Fan, RQ; Ho, WK; Jiao, BW; Lam, KY; Lin, ZX; Mok, CF; Tse, WP; Yang, ZJ; Zhao, M; Zuo, Z, 2010) |
| "Psoriasis is a chronic inflammatory skin disease characterised by elevated red scaly plaques on specific body sites." | ( Prens, EP; Rácz, E, 2009) |
| "Blaschko-linear psoriasis is a rare disease about which only a few publications have appeared in the literature." | ( Cribier, B; Guillaume, JC; Roth-Mall, B; Sfia, M; Tortel, MC, 2009) |
| "Psoriasis is a chronic, recurring inflammatory disease affecting the skin, joints and nails that has a significant negative impact on the quality of life." | ( Kanwar, AJ; Kaur, I; Mahajan, R, 2010) |
| "Psoriasis is a papulosquamous disease of multifactorial etiology." | ( Charrow, EJ; Forman, L; Lal, S; Lamba, G; Palaniswamy, C; Shah, D; Singh, T; Vinnakota, R, 2011) |
| "(1) Plaque psoriasis is the most common form of psoriasis in children." | ( , 2009) |
| "Psoriasis is well-known immune-mediated skin disease often associated with co-morbidities, including dyslipidaemia and obesity." | ( Chodorowska, G; Dybiec, E; Jastrzebska, I; Juszkiewicz-Borowiec, M; Krasowska, D; Maciejewski, R; Pietrzak, A; Schwartz, RA, 2009) |
| "Psoriasis is a disease characterized by epidermal hyperproliferation that results in the formation of lesional plaques covered by scale." | ( Fournier, C; Tisman, G, 2010) |
| "Psoriasis is an immune-mediated disease typically associated with cutaneous neutrophilic infiltration and Munro microabscesses." | ( Ferran, M; Galván, AB; Giménez-Arnau, A; Pujol, RM; Santamaría-Babi, LF, 2010) |
| "Psoriasis is a chronic, systemic inflammatory disorder manifesting primarily in skin and potentially in joints, frequently necessitating treatment with conventional systemic therapies, phototherapy or biological agents." | ( Cooper, AJ; Dolianitis, C; Foley, PA; Hack, SP; Quirk, C; Sullivan, JR; Thirunavukkarasu, K, 2010) |
| "Psoriasis is a skin disorder that is associated with arthritis." | ( Akman, A; Alpsoy, E; Cay, HF; Cevikol, C; Kaçar, C; Kocabaş, H; Melikoğlu, MA; Sezer, I, 2010) |
| "Psoriasis is a chronic inflammatory disease of the skin." | ( Hou, R; Jia, Y; Li, X; Niu, X; Yin, G; Zhang, J; Zhang, K, 2010) |
| "Psoriasis is a chronic inflammatory disease in which pruritus is a common symptom." | ( Amatya, B; El-Nour, H; Nigam, R; Nordlind, K, 2010) |
| "Psoriasis is a hyperproliferative, cutaneous disorder with the potential to lower levels of folate." | ( Graham, IM; Hand, EB; Hughes, R; Kirby, B; Leong, T; Tobin, AM, 2011) |
| "Childhood psoriasis is common, but it has not been adequately reported in China." | ( Feng, AP; Huang, CZ; Li, JW; Lin, Y; Liu, HJ; Wu, Y, 2010) |
| "Psoriasis is a chronic and relapsing inflammatory skin disease associated with various immunologic abnormalities." | ( Chen, XC; Chen, XJ; Deng, HX; Huang, NY; Kan, B; Li, J; Li, XL; Li, Y; Liu, CY; Mao, YQ; Qiu, J; Wang, YS; Wei, YQ; Wen, YJ; Yang, HS; Yang, L; Zhang, Y; Zhang, YB; Zhao, X; Zhou, XK, 2010) |
| "Psoriasis is a chronic inflammatory skin disease, which affects approximately 2." | ( Jensen, P; Skov, L; Zachariae, C, 2010) |
| "Psoriasis is a noncontiguous common and chronic skin disorder." | ( Afridi, HI; Arain, MB; Baig, JA; Jamali, MK; Kandhro, GA; Kazi, N; Kazi, TG; Khan, S; Kolachi, NF; Shah, AQ; Shah, F; Wadhwa, SK, 2011) |
| "Hand and foot psoriasis is a disabling condition associated with significant quality-of-life issues." | ( Di Lernia, V; Guareschi, E, 2010) |
| "Psoriasis is a common disorder affecting 1-3 percent of the general global population." | ( Enshaieh, S; Faghihi, G; Iraji, F; Joia, A; Shahmoradi, Z; Siadat, AH; Soleimani, F, 2010) |
| "Psoriasis is a common disease with the population prevalence ranging from 2% to 3%." | ( Chodorowska, G; Michalak-Stoma, A; Pietrzak, A; Szepietowski, JC, 2010) |
| "Psoriasis is a chronic, debilitating disease that commonly involves the scalp." | ( Kircik, LH; Kumar, S, 2010) |
| "Psoriasis is a common skin disease affecting about 1-3% of the world population." | ( Glowacka, E; Lewkowicz, P; Rotsztejn, H; Zalewska, A, 2010) |
| "Psoriasis is a prevalent chronic inflammatory condition that affects the skin." | ( Smith, CH; Woolf, RT, 2010) |
| "Psoriasis is a common chronic skin disease characterized by recurrent erythromatous skin plaques that exhibit epidermal hyperplasia, variable inflammatory cell infiltrate, and abnormalities of the dermal vascularization." | ( Keshavarz, M; Mansouri, K; Motlagh, HR, 2011) |
| "Psoriasis is associated with premature atherosclerosis although the underlying mechanism remains unclear." | ( Chan, HH; Chan, HT; Lam, KF; Tam, S; Tse, HF; Wong, RM; Yan, GH; Yeung, CK; Yiu, KH; Yue, WS, 2011) |
| "Psoriasis is a chronic and recurrent inflammatory skin disease, known as an oxidative stress condition." | ( Attwa, E; Swelam, E, 2011) |
| "Psoriasis is thought to be associated with an increased risk of lymphoma." | ( Brocard, A; Dréno, B; Knol, AC; Peuvrel, L; Quéreux, G; Renaut, JJ, 2010) |
| "Psoriasis is a common skin disorder; knowledge of the factors that may induce, trigger, or exacerbate the disease is of primary importance in clinical practice." | ( Ashok, NM; Basavaraj, KH; Praveen, TK; Rashmi, R, 2010) |
| "Psoriasis is a common chronic inflammatory skin disease and many patients require lifelong treatment." | ( Freeman, K, 2011) |
| "Scalp psoriasis is difficult to treat." | ( Affleck, AG; Auland, M; Bottomley, JM; Jackson, P; Ryttov, J, 2011) |
| "Severe psoriasis is associated with significant cardiovascular mortality." | ( Beschmann, H; Boehncke, S; Boehncke, WH; Diehl, S; Fichtlscherer, S; Garbaraviciene, J; Hardt, K; Salgo, R; Thaçi, D, 2011) |
| "Psoriasis is an inflammatory hyperproliferative skin disorder with a strong genetic predisposition." | ( O'Rielly, DD; Rahman, P, 2011) |
| "Psoriasis is a common, chronic disease which affects nearly 3% of the population." | ( Oz, A; Sarıcaoglu, H; Turan, H, 2011) |
| "Severe psoriasis is associated with significant cardiovascular mortality." | ( Beschmann, H; Boehncke, S; Boehncke, WH; Diehl, S; Fichtlscherer, S; Garbaraviciene, J; Hardt, K; Salgo, R; Thaçi, D, 2011) |
| "The pathogenesis of psoriasis is thought to depend on the activation of immune cells and their secreted cytokines, chemokines and growth factors like IGF-1 which may contribute to the epidermal hyperplasia of psoriasis." | ( Amin, I; El-Komy, M; Kadry, D; Shaker, O; Zeid, OA; Zidan, A, 2011) |
| "Psoriasis is a chronic inflammatory, immune-mediated skin disease, which affects 2%-3% of the population worldwide." | ( Ferrazzi, A; Girolomoni, G; Gisondi, P, 2010) |
| "Psoriasis is a hyperproliferative and inflammatory skin disorder that affects roughly 2 percent of the worldwide population." | ( Brodell, RT; Bruce, S; Colón, LE; Gottschalk, RW; Hudson, CP; Johnson, LA; Weiss, JS, 2011) |
| "Childhood psoriasis is a well-known entity, which is different from adult onset psoriasis in many ways." | ( Augustin, M; Beikert, F; Fölster-Holst, R; Herberger, K; Radtke, MA, 2011) |
| "Psoriasis is a chronic immune-mediated inflammatory skin disorder affecting approximately 2% of the population worldwide." | ( Lotti, T; Pescitelli, L; Prignano, F; Ricceri, F; Ruffo, G, 2011) |
| "Psoriasis is an inflammatory disease associated with abnormalities in lipid profile, lipid peroxidation, antioxidant capacity, eicosanoid metabolism and increased frequency of cardiovascular events." | ( Aukrust, P; Berge, RK; Bohov, P; Livden, JK; Morken, T; Skorve, J; Ulvik, R, 2011) |
| "Psoriasis is an inflammatory disease with dynamic interactions between the immune system and the skin." | ( Benson, JM; DiGiovanni, J; Elloso, MM; Gutshall, LL; Iwakura, Y; Kamijima, R; Kanda, T; Miyoshi, K; Nakajima, H; Nakajima, K; Naso, MF; Sano, S; Shiga, T; Takaishi, M; Tarutani, M, 2011) |
| "Palmoplantar psoriasis is a difficult to treat variant of plaque psoriasis." | ( Bissonnette, R; Bolduc, C; Guenther, L; Lynde, CW; Nigen, S; Poulin, Y, 2011) |
| "Scalp psoriasis is a common life-altering skin condition causing a great deal of distress." | ( Kircik, L, 2011) |
| "On the other hand, psoriasis is rare, and has been reported to occur within weeks of starting the treatment." | ( Chong, VH, 2011) |
| "Psoriasis is a skin disease characterized by the presence of red plaques on the skin." | ( Jean, J; Pouliot, R; Soucy, J, 2011) |
| "Moderate to severe psoriasis is associated with increased alcohol intake and excessive mortality from alcohol-related causes." | ( Collins, P; Cunningham, S; Kirby, B; Mason, DL; McAleer, MA; McCormick, PA; O'Shea, SJ; Rogers, S; Stone, C, 2011) |
| "Psoriasis is a complex, multifactorial inflammatory skin disease with genetic and environmental interactions." | ( Kamo, A; Negi, O; Ogawa, H; Takamori, K; Taneda, K; Tengara, S; Tominaga, M, 2011) |
| "Moderate to severe psoriasis is common in childhood and adolescence and is often a challenge for the treating dermatologist." | ( Domm, S; Gerdes, S; Mrowietz, U, 2011) |
| "Psoriasis is now considered a genetically programmed, immune-mediated, inflammatory disease, in which intralesional T lymphocytes trigger keratinocytes to proliferate and perpetuate the disease process." | ( de Panfilis, G; Di Marcantonio, D; Gobbi, G; Micheloni, C; Mirandola, P; Ruscitti, F; Vaccarezza, M; Vitale, M, 2011) |
| "Psoriasis is a disorder with genetic and immunologic background." | ( Abdel Hay, RM; Rashed, LA, 2011) |
| "In Germany, psoriasis is often treated with systemic corticosteroids though these are not recommended by the S3-guideline." | ( Augustin, M; Glaeske, G; Radtke, M; Reich, K; Schäfer, I, 2011) |
| "Psoriasis is a common inflammatory disease with a range of clinical presentations and a chronic relapsing course." | ( Chiu, MW; Hillman, JD; Monroe, HR, 2011) |
| "Psoriasis is a very common chronic skin disease, affecting 2-3% of the world's population or more than 125 million individuals worldwide." | ( Belinka, BA; Dam, TN; Kachlany, SC; Rosada, C; Salerno, E; Stenderup, K, 2011) |
| "Psoriasis is a common chronic autoimmune condition of the skin characterized by hyperplasia of epidermal keratinocytes associated with pro-inflammatory cytokines." | ( Alves-Filho, JC; Asquith, DL; Graham, GJ; Hueber, AJ; Liew, FY; McInnes, IB; Michels, C; Millar, NL; Miller, AM; Reilly, JH, 2011) |
| "Psoriasis is a chronic, autoimmune skin disease affecting approximately 2% of the world's population." | ( Badıllı, U; Sen, T; Tarımcı, N, 2011) |
| "Psoriasis is a chronic inflammatory skin disease that affects approximately 2-4% of the population." | ( Bacsa, S; Bari, L; Bata-Csörgo, Z; Dobozy, A; Kemény, L; Sonkoly, E; Széll, M, 2011) |
| "Psoriasis is an autoimmune disease that affects about 2% of the world population." | ( Cheung, PH; Foreman, O; Hain, HS; Kaur, P; Kavirayani, A; Saha, S; Tung, D, 2011) |
| "Psoriasis is a chronic condition with serious quality-of-life ramifications." | ( Colón, LE; Gottschalk, R; Hudson, CP; Johnson, LA; Kempers, S; Menter, A; Papp, K; Smith, S; Sofen, H, 2011) |
| "As psoriasis is now considered to be a T cell-mediated disease we decided to challenge peripheral blood mononuclear cells (PBMCs) in vitro from randomly selected patients with well-defined wheat proteins/peptides to explore the possibility of identifying a specific antigen with T cell activating properties in a subgroup of patients." | ( Geisner, B; Marcusson, JA; Marsh, J; Shewry, PR; Skavland, J, 2012) |
| "Psoriasis is a common inflammatory skin disease and obesity constitutes a risk factor for the disease." | ( Faurschou, A; Knop, FK; Skov, L; Vilsbøll, T; Zachariae, C, 2011) |
| "Scalp psoriasis is a difficult to treat and usually chronic manifestation of psoriasis." | ( Barber, K; Berg, M; Kerrouche, N; Lynde, C; Papp, K; Poulin, Y; Prinz, JC; Rives, VP, 2012) |
| "Psoriasis is a chronic immune-mediated disease that appears on the skin." | ( Morimoto, S; Okuro, M, 2011) |
| "Psoriasis is a frequent inflammatory skin disease of unknown cause determined by multigenic predisposition, environmental factors, and aberrant immune response." | ( Dziarski, R; Gupta, D; Hurwich, R; Kim, CH; Park, SY, 2011) |
| "Psoriasis is characterized by lower stratum corneum (SC) hydration and dermal inflammation." | ( Elias, PM; Luo, W; Lv, C; Man, MQ; Song, S, 2012) |
| "New-onset psoriasis is extremely rare in hemodialysis (HD) patients, and several trials of dialysis therapies (HD and peritoneal dialysis) in psoriasis have indicated remarkable improvement in skin lesions and well-being even in patients without renal impairment." | ( Aggelakou-Vaitis, S; Dousdampanis, P; Gellner, K; Triga, K, 2012) |
| "Psoriasis is an independent risk factor for subclinical atherosclerosis." | ( Badr, T; El Zohiery, AK; Elhilaly, R; Enany, B, 2012) |
| "Psoriasis is a common chronic autoimmune skin disease of unknown cause that involves dysregulated interplay between immune cells and keratinocytes." | ( de Heusch, M; Dumoutier, L; Dunussi-Joannopoulos, K; Fouser, LA; Hendrickx, E; Lemaire, MM; Renauld, JC; Van Belle, AB; Warnier, G, 2012) |
| "Psoriasis is associated with ischemic heart disease (IHD)." | ( Chang, YT; Chen, CM; Chen, TT; Chen, YJ; Shen, JL; Wang, CB; Wu, CY, 2012) |
| "Psoriasis is a chronic skin disease resulting from abnormal immune function and is characterized by the presence of scaly psoriatic plaques which are areas of inflammation and excessive skin production." | ( Guihen, E; Ho, WL; Hogan, AM; Leahy, MJ; O'Connell, ML; O'Connor, WT; Ramsay, B, 2012) |
| "Psoriasis is a common, chronic, recurrent, inflammatory, hyper proliferative disorder of the skin, which has a relatively high prevalence in the general population (0." | ( Aggarwal, RK; Albert, L; Buttar, BS; Gandhi, G; Hasan, Q, 2011) |
| "Psoriasis is an immune-mediated skin disorder frequently associated with obesity and type 2 diabetes (T2D)." | ( Buysschaert, M; Preumont, V; Tennstedt, D, 2012) |
| "Psoriasis is a common inflammatory skin disease that is associated with joint, psychiatric, and cardiovascular comorbidities." | ( Armstrong, AW; Johnson, MA, 2013) |
| "Psoriasis is a chronic inflammatory disease." | ( Chen, GS; Chen, YC; Chin, YY; Ko, YC; Lan, CC; Li, WC; Lu, YW; Wu, CS; Yang, YH; Yu, HS, 2012) |
| "Psoriasis is a Th1 immune-mediated, inflammatory disease, in which skin lesions appear many years before the related metabolic and cardiovascular comorbidities, according to the theory of the 'psoriatic march'." | ( Campanati, A; Di Primio, R; Gorbi, S; Offidani, A; Orciani, M; Regoli, F, 2012) |
| "Psoriasis is a common chronic condition of the skin that is resistant to many therapies." | ( Nilforoushzadeh, MA; Sadeghian, G; Ziaei, H, 2011) |
| "Psoriasis is a chronic inflammatory skin disease of unknown aetiology, and an active form of vitamin D(3) (1α,25-dihydroxyvitamin D(3)) and its analogues (VD3As) are widely used topical reagents for psoriasis treatment." | ( Chou, B; Hiromatsu, K; Imafuku, S; Ishii, K; Nakayama, J; Sato-Deguchi, E, 2012) |
| "Psoriasis is characterized by hyperplasia of the epidermis and infiltration of leukocytes into both the dermis and epidermis." | ( Barsoum, J; Cardinale, I; Chu, J; Gottlieb, AB; Jacobson, E; Kantor, AB; Khatcherian, A; Krueger, JG; Tatsuta, N; Wada, Y, 2012) |
| "Psoriasis is a benign, chronic skin disease characterized by keratinocyte hyperproliferation and abnormal differentiation." | ( Han, J; Hu, J; Sun, J; Zhao, Y; Zhu, Q, 2012) |
| "Psoriasis is a frequent and often severe autoimmune skin disease, clinically characterized by altered epidermal homeostasis, of which the molecular pathomechanisms are only little understood." | ( Boehncke, S; Boehncke, WH; Buerger, C; Diehl, S; Hardt, K; Malisiewicz, B; Richter, B; Salgo, R; Woth, K, 2012) |
| "Psoriasis is a common, relapsing inflammatory skin disease characterized by erythematous scaly plaques." | ( Becher, B; Haak, S; Heppner, FL; Ingold, B; Kulig, P; Navarini, AA; Pantelyushin, S, 2012) |
| "Psoriasis is a noncontagious, chronic skin disease affecting 1 in 50 people worldwide." | ( Afridi, HI; Kazi, N; Kazi, TG; Khan, S; Kolachi, NF; Shah, F; Wadhwa, SK, 2012) |
| "Psoriasis is a chronic autoimmune hyperproliferative skin disease." | ( Dayalan, H; Elango, T; Gnanaraj, P; Malligarjunan, H; Subramanian, S, 2012) |
| "Psoriasis is a common genetic disorder that may be initiated (drug-induced psoriasis) or exacerbated (drug-triggered psoriasis) by some drug intakes." | ( Piérard, GE; Piérard-Franchimont, C, 2012) |
| "Psoriasis is a chronic, inflammatory skin condition with negative impacts both physical and psychological." | ( Kamangar, F; Koo, JY; Nguyen, TV; Wong, JW, 2012) |
| "Psoriasis is a chronic immunoinflammatory disease that affects 2-3% of the population and shares pathophysiologic mechanisms and risk factors with cardiovascular diseases." | ( Ahlehoff, O; Gislason, G; Hansen, PR; Lindhardsen, J; Skov, L, 2012) |
| "Psoriasis is a multi-systemic chronic inflammatory skin disease targeting 2% to 3% of the general population." | ( Kircik, LH; Onumah, N, 2012) |
| " Psoriasis is an inflammatory disease of the skin and joints." | ( Anandan, S; Madanagobalane, S, 2012) |
| "Psoriasis is a systemic disease associated with metabolic disorders and vascular complications." | ( Chen, GS; Ko, YC; Lan, CC; Li, WC; Lu, YW; Su, YS; Wu, CS; Yang, YH; Yu, HS, 2013) |
| "Psoriasis is a common skin disorder characterized by chronic inflammatory lesions that are frequently vexing for patients and difficult for physicians to treat." | ( Feldman, S; Pellerin, M; Shutty, B; West, C, 2012) |
| "Psoriasis is a chronic inflammatory skin disease characterized by excessive cellular replication." | ( Amani, M; Ebrahimi, A; Eftekhari, K; Khodarahmi, R; Nemati, H; Rahmani, A, 2013) |
| "Psoriasis is a chronic, recurrent skin disorder, with a poorly understood pathogenesis." | ( Basavaraj, KH; Rashmi, R; Yuti, AM, 2012) |
| "Psoriasis is a chronic immune-mediated disease of unknown etiology that affects the skin and mucous membranes." | ( Brown, GC; Dreyer, LN, 2012) |
| "Psoriasis is a chronic, immune-mediated skin disease characterized by production of reactive oxygen species due to the activation of tumor necrosis factor alpha (TNF-α), which is thought to be an important factor in inducing and maintaining psoriatic lesions." | ( Erturan, İ; Flores-Arce, M; Nazıroğlu, M; Tamtürk, B; Yıldız, K, 2012) |
| "Patients with psoriasis are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism." | ( Asefi, M; Bahrehmand, F; Ebrahimi, A; Kiani, A; Nomani, H; Pourmotabbed, T; Rahimi, Z; Tavilani, H; Vaisi-Raygani, A, 2012) |
| "Psoriasis is a Th-1/17 mediated inflammatory disease associated with increased risk of cardiovascular disease (CVD)." | ( Baer, A; DerOhannesian, S; Farver, W; Gelfand, JM; Krishnamoorthy, P; Li, R; Mehta, NN; Rader, DJ; Raper, A; Reilly, MP; Rodrigues, A; VanVoorhees, A; Wilcox, M; Wolfe, M; Yu, Y, 2012) |
| "Psoriasis is among the top dermatologic diagnoses for older adult patients, and the number of older adult psoriasis patients is expected to rise." | ( Davis, SA; Feldman, SR; Koo, JY; Wong, JW, 2012) |
| "Psoriasis is a chronic inflammatory skin disease that is characterized by thickened red plaques covered with silvery scales." | ( Bhutani, T; Koo, JY; Nguyen, TV; Wong, JW, 2012) |
| "Psoriasis is a chronic inflammatory skin disease that is thought to be related to oxidative stress." | ( Baek, JO; Byamba, D; Kim, TG; Lee, MG; Wu, WH, 2012) |
| "Psoriasis is a chronic inflammatory disorder associated with cardiovascular morbidity and mortality." | ( Ahlehoff, O; Dam, TN; Gislason, G; Gniadecki, R; Hansen, PR; Iversen, L; Kristensen, SL; Lasthein, S; Lindhardsen, J; Skov, L; Torp-Pedersen, C, 2013) |
| "Psoriasis is an important systemic inflammatory disease that often leads to severe vascular diseases." | ( Chen, GS; Chin, YY; Ko, YC; Lan, CC; Li, WC; Lu, YW; Wu, CS; Yang, YH; Yu, HS, 2013) |
| "Psoriasis is a chronic inflammatory skin disease triggered by interplay between immune mediators from both innate and adaptive immune systems and skin tissue, in which the IL-23/IL-17 axis is critical." | ( Dapavo, P; Hirsch, E; Ji, H; Okkenhaug, K; Perino, A; Roller, A; Soro, E, 2012) |
| "Psoriasis is an autoimmune disease mediated mainly by dysfunctional peripheral blood T cells." | ( Hou, R; Li, J; Li, X; Yin, G; Zhang, J; Zhang, K, 2012) |
| "Psoriasis is a chronic inflammatory multisystem disease involving skin and joints affecting 1-3 % of the world population." | ( Al-Haddad, A; Al-Mutairi, N, 2013) |
| "Psoriasis is a chronic inflammatory disease associated with increased risks of myocardial infarction and stroke." | ( Bissonnette, R; Bolduc, C; Guertin, MC; Harel, F; Pressacco, J; Tardif, JC, 2013) |
| "Psoriasis is a chronic relapsing inflammatory skin disorder affecting 2-3% of world population." | ( Thapa, RK; Yoo, BK, 2014) |
| "Psoriasis is a chronic recurrent inflammatory skin disorder with multifactorial etiology, including genetic background, environmental factors, and immune system disturbances with a strong cytokine component." | ( Andersen, ML; Araújo, MS; Hirotsu, C; Rydlewski, M; Tufik, S, 2012) |
| "In addition, psoriasis is characterized by an upregulation of STAT3 signaling pathway that is related to the epidermal hyperplasia." | ( Andrés, RM; Herrero, M; Montesinos, MC; Navalón, P; Payá, M; Terencio, MC; Ubeda, A; Vergés, J, 2013) |
| "Psoriasis is a chronic, inflammatory skin disease with a significant impact on health-related quality of life (HRQoL)." | ( Harness, J; Mamolo, C; Menter, A; Tan, H, 2014) |
| "Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation." | ( Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R, 2012) |
| "Psoriasis is a chronic papulosquamous cutaneous disease." | ( Lovoshitski, R; Rozenman, D; Ziv, M; Zoabi, A, 2012) |
| "Psoriasis is a chronic proliferative skin disease and is usually treated with topical glucocorticoids, which act through the glucocorticoid receptor (GR), a component of the physiological systems essential for immune responses, differentiation, and homeostasis." | ( Cai, SQ; Chen, JQ; Landeck, L; Li, CM; Li, W; Man, XY; Mu, Z; Zhang, KH; Zheng, M; Zhou, J, 2013) |
| "Psoriasis is a chronic inflammatory skin disease that involves the induction of T-helper 1 (Th1) and T-helper 17 (Th17) cell responses and the aberrant expression of proinflammatory cytokines, including IL-1β." | ( Agrawal, S; Bhagat, L; Jiang, W; Kandimalla, ER; La Monica, N; Tang, JX; Yu, D; Zhu, FG, 2013) |
| "Psoriasis is an immune-mediated, chronic, inflammatory skin disease which affects approximately 2% of the world's population." | ( Chan, LC; Chang, CC; Heng, A; Tang, MM, 2013) |
| "Nail psoriasis is difficult to treat." | ( Chiang, YY; Chou, CL; Huang, YC, 2013) |
| "Psoriasis is a common skin disease that can also involve the nails." | ( Bogaards, NA; de Vries, AC; Hooft, L; Lebwohl, M; Pasch, M; Spuls, PI; Velema, M, 2013) |
| "Radiotherapy for psoriasis is not used in common practice." | ( Bogaards, NA; de Vries, AC; Hooft, L; Lebwohl, M; Pasch, M; Spuls, PI; Velema, M, 2013) |
| "Psoriasis is a chronic inflammatory skin disease with a global prevalence of 2-3%." | ( Gyldenløve, M; Knop, FK; Skov, L; Vilsbøll, T; Zachariae, C, 2013) |
| "Psoriasis is a heterogeneous inflammatory disorder that targets the skin and joints." | ( Tidman, MJ, 2013) |
| "Pathophysiology of psoriasis is complex and characterized by microscopic, specific changes." | ( Agozzino, M; Ardigò, M; Berardesca, E; Conti, A; Di Lernia, V; Longo, C; Pellacani, G, 2013) |
| "Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red and silver scaly plaques." | ( McCann, FE; McNamee, KE; Palfreeman, AC, 2013) |
| "Psoriasis is a chronic hyperproliferative inflammatory skin disease, characterized by a generalized redox imbalance." | ( Barygina, VV; Becatti, M; Fiorillo, C; Lotti, T; Nassi, P; Prignano, F; Soldi, G; Taddei, N; Wright, D, 2013) |
| "Psoriasis is an inflammatory cutaneous disorder characterized by marked epidermal thickening and Th1 and Th17 cell infiltration." | ( Asano, Y; Ishiura, N; Kadono, T; Kamata, M; Sato, S; Shibata, S; Sugaya, M; Tada, Y; Tedder, TF; Yanaba, K, 2013) |
| "Psoriasis is one of the most prevalent immune-mediated illness worldwide." | ( Perez, JJ, 2013) |
| "Psoriasis is treated with several classes of treatments that may be used in combination, but the ways combination therapies are used are not well characterized." | ( Davis, SA; Feldman, SR, 2013) |
| "Psoriasis is a chronic inflammatory autoimmune disease with undefined etiology." | ( Hu, J; Li, H; Wen, C; Yang, R; Zhao, H; Zhao, M; Zhou, Q, 2013) |
| "Psoriasis is a common chronic inflammatory skin disease and its underlying pathogenesis is still not fully understood." | ( Fu, LX; Tang, DM; Wang, Y; Yan, HX; Yang, XN, 2013) |
| "Psoriasis is an autoinflammatory skin disease of unknown etiology." | ( Becher, B; Cheong, C; Clausen, BE; Haak, S; Holzmann, B; Kant, M; Ober-Blöbaum, JL; Onderwater, S; Pantelyushin, S; Prens, EP; Reizis, B; Weighardt, H; Wohn, C; Zahner, SP, 2013) |
| "Psoriasis is a complex chronic inflammatory skin disease with a worldwide distribution." | ( Prashant, BS; Saraswathy Devi, S; Sinniah, B, 2010) |
| "Plaque psoriasis is an inflammatory disease affecting approximately 2% of the population." | ( Berneburg, M; Eberlein, B; Guenova, E; Herzinger, T; Hoetzenecker, W; Maetzke, J; Meisner, C; Rampf, J; Rocken, M; Schaefer, T; Scharffetter-Kochanek, K, 2013) |
| "Chronic plaque psoriasis is the most common type of psoriasis and is characterized by redness, thickness and scaling." | ( Cork, MJ; Dooley, G; Hancock, H; Mason, AR; Mason, JM, 2013) |
| "Psoriasis is a chronic inflammatory skin disease featuring abnormal keratinocyte proliferation and differentiation." | ( Austin, HR; Batie, SF; Haussler, MR; Hoss, E; Jurutka, PW; Whitfield, GK, 2013) |
| "Moderate-to-severe psoriasis is a chronic skin condition that often requires systemic therapy and biologics are the newest systemic treatment available." | ( Gupta, R; Koo, J; Levin, E; Liao, W; Wu, JJ, 2014) |
| "Psoriasis is a chronic dermatological disorder that has a negative impact on quality of life (QoL)." | ( Ismail, R; Low, WY; Min, AK; Nyunt, WW; Sockalingam, S, 2015) |
| "Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted due to chronicity of the disease and frequent remissions and relapses." | ( Bhari, N; Khandpur, S, 2013) |
| "Psoriasis is a chronic inflammatory disease related to genome-wide and surroundings, it is important to develop a suitable animal model to research psoriasis pathogenesis and evolve pharmacotherapeutics." | ( Hu, JH; Li, H, 2013) |
| "Psoriasis is a chronic inflammatory disorder associated with increased cardiovascular mortality." | ( Curcic, S; Heinemann, A; Holzer, M; Inzinger, M; Marsche, G; Pasterk, L; Trieb, M; Weger, W; Wolf, P, 2014) |
| "Psoriasis is a chronic disease that significantly impacts patients' quality of life." | ( Ahn, CS; Awadalla, F; Dabade, TS; Feldman, SR; Huang, KE; Yentzer, B, 2013) |
| "Psoriasis is a chronic inflammatory disorder of the skin and joints." | ( Chimenti, S; Costanzo, A; Magina, S; Morais, P; Osório, F; Papoutsaki, M; Torres, T, 2013) |
| "Psoriasis is a chronic, immune-mediated inflammatory and refractory disease." | ( Hui, Y; Li, CR; Yu, RX, 2013) |
| "Psoriasis is a chronic, auto-inflammatory disease affecting millions of individuals worldwide." | ( Laquer, V; Nguyen, T; Ta, T; Tan, B, 2013) |
| "Psoriasis is an autoimmune, chronic, inflammatory skin disease characterized by epidermal hyperplasia, proliferation of blood vessels, and infiltration of leukocytes in dermis and epidermis." | ( Garg, T; Goyal, AK; Parnami, N; Rath, G, 2014) |
| "Psoriasis is a common immune-mediated inflammatory disease that affects the skin and joints." | ( Agerbeck, C; Bonefeld, CM; Dyring-Andersen, B; Geisler, C; Gúdjonsdottir, SD; Lauritsen, JP; Skov, L, 2014) |
| "Psoriasis is an inflammatory disease of the skin affecting 2-3% of the population, characterized by a thickening of the epidermis and immune infiltrates throughout the dermis and epidermis, causing skin lesions that can seriously affect quality of life." | ( Flutter, B; Nestle, FO, 2013) |
| "Psoriasis is an inflammatory skin disease that may be associated with an adverse cardiometabolic profile including modulated plasma adiponectin and leptin levels." | ( DerOhannessian, S; Doveikis, J; Gelfand, JM; Krishnamoorthy, P; Li, RC; Mehta, NN; Rader, DJ; Reilly, MP; Thomas, P; Van Voorhees, A; Wilcox, M, 2014) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting 1." | ( Burden, AD; Burfield, L, 2013) |
| "Psoriasis is a chronic, systemic and difficult to treat condition which negatively affects the patient's quality of life." | ( Bartosińska, J; Chodorowska, G; Dreiher, J; Gawlik-Dziki, U; Maciejewski, R; Pietrzak, A; Podhorecka, M; Szepietowski, JC, 2013) |
| "Psoriasis is a chronic inflammatory skin disease characterised by hyperkeratosis, dermal inflammatory infiltrate and increased angiogenesis." | ( Dikić, D; Oršolić, N; Skurić, J; Stanić, G, 2014) |
| "Psoriasis is an inflammatory disease associated with multiple comorbidities and cardiovascular risk factors." | ( Brown, L; Churton, S; Korman, NJ; Shin, TM, 2014) |
| "Psoriasis is a complex inflammatory skin disease that presents a wide variety of clinical manifestations." | ( Bracke, S; Carretero, M; Del Rio, M; Desmet, E; Guerrero-Aspizua, S; Illera, N; Lambert, J; Navarro, M, 2014) |
| "Psoriasis is a systemic inflammatory immune-mediated skin disease." | ( Balduzzi, V; Bernardini, N; La Viola, G; Mancini, MT; Nicolucci, F; Pampena, R; Potenza, C; Proietti, I; Skroza, N; Soccodato, V; Tolino, E; Zuber, S, 2013) |
| "Psoriasis is thought to be initiated by abnormal interactions between the cutaneous keratinocytes and systemic immune cells, triggering keratinocyte hyperproliferation." | ( Chen, X; Cui, K; Deng, G; Deng, H; Edwards, CK; Guan, T; Hu, Z; Huang, N; Li, J; Liu, N; Liu, X; Luo, C; Sun, C; Teng, X; Wang, X; Wang, Z; Wei, X; Wei, Y; Xu, M; Ye, N; Zhou, X, 2014) |
| "Psoriasis is most often treated using topical therapies such as the once-daily fixed combination of calcipotriol and betamethasone dipropionate, which is available as a gel and an ointment." | ( Hol, CW; Lambert, J; Vink, J, 2014) |
| "Psoriasis is a common chronic inflammatory skin disease that involves dysregulated interplay between immune cells and keratinocytes." | ( Honda, T; Kabashima, K; Malissen, B; Nakamizo, S; Nakamura, M; Ohmori, S; Sawada, Y; Sugita, K; Tokura, Y; Yoshiki, R; Yoshioka, H, 2014) |
| "Psoriasis is a common inflammatory skin disease with limited treatment options that is characterized by a complex interplay between keratinocytes, immune cells, and inflammatory mediators." | ( Concha-Garzón, MJ; Daudén, E; Delgado, Y; Guinea-Viniegra, J; Jiménez, M; Navarro, R; Obad, S; Schonthaler, HB; Tschachler, E; Wagner, EF, 2014) |
| "Psoriasis is a chronic inflammatory skin disease resulting from immune dysregulation." | ( Choi, EJ; Hong, MP; Kie, JH; Kim, HR; Lee, A; Lee, HK; Lim, W; Moon, BI; Seoh, JY, 2014) |
| "Psoriasis is a chronic inflammatory skin disorder mediated by cross-talk occurring between epidermal keratinocytes, dermal vascular cells and immunocytes." | ( Chowdhari, S; Saini, N, 2014) |
| "Psoriasis is associated with a systemic inflammation and an increased frequency of the metabolic syndrome, both of which are believed to link psoriasis to an increased risk of cardiovascular disease." | ( Bivik, C; Ekman, AK; Enerbäck, C; Sigurdardottir, G; Ståhle, M, 2014) |
| "Psoriasis is an inflammatory skin disease with accelerated epidermal cell turnover." | ( Abe, J; Ishii, S; Kita, Y; Matsushima, K; Nakamura, M; Sato, S; Shimizu, T; Sumida, H; Yanagida, K, 2014) |
| "Psoriasis is a chronic inflammatory process associated with an increased risk of cardiovascular risk factors." | ( Adiloğlu, A; Akkaya, VB; Başak, PY; Ceyhan, AM; Ersoy, IH; Erturan, I; Kilinç, O; Korkmaz, S; Köroğlu, BK; Tamer, N, 2014) |
| "Psoriasis is associated with increased risk of cardiovascular disease (CVD), possibly due to chronic low-grade systemic inflammation." | ( Gyldenløve, M; Hansen, PR; Jensen, P; Løvendorf, MB; Skov, L; Zachariae, C, 2015) |
| "Psoriasis is a chronic T cell-mediated inflammatory skin disease." | ( Chen, L; Cheng, X; Huang, L; Li, S; Pei, H; Qiu, N; Wang, W; Wang, X; Wen, J; Xie, C, 2014) |
| "Psoriasis is a chronic debilitating disease in which dermatologists take a frontline role in improving the quality of life of affected patients." | ( Han, G, 2014) |
| "Psoriasis is a chronic inflammatory skin disease characterized by excessive proliferation of keratinocytes." | ( Dong, YY; Guan, LL; Li, HY; Li, XK; Liu, XM; Mmi, XG; Wang, FW; Wang, N; Wang, YF; Xia, JX; Yang, J; Yao, N, 2014) |
| "Patients with psoriasis are increasingly turning to the use of alternative and complementary medicine to manage their psoriasis." | ( Bhatia, BK; Debbaneh, M; Koo, J; Liao, W; Millsop, JW, 2014) |
| "Psoriasis is a common chronic and recurrent inflammatory skin disorder characterized by hyperproliferation of keratinocytes and infiltration of T cells, monocytes/macrophages and neutrophils into dermal and epidermal layers of the skin." | ( HajHeydari, Z; Hedayati, MT; Shokohi, T; Taheri Sarvtin, M, 2014) |
| "Psoriasis is a chronic skin disease characterized by keratinocyte hyperproliferation and anti-apoptotic features." | ( Andrys, C; Borska, L; Borsky, P; Fiala, Z; Hamakova, K; Krejsek, J; Kremlacek, J; Ranna, D, 2014) |
| "Psoriasis is an autoimmune inflammatory disease which is associated with increased inflammatory markers and atherosclerosis." | ( Akkoyun, DC; Akyuz, A; Alpsoy, S; Erfan, G; Guzel, S; Kaya, S; Kulac, M; Topcu, B, 2014) |
| "Psoriasis is a disorder caused by genetic and immunological factors." | ( Choi, JH; Kim, NI; Lee, JW; Lim, HK; Oh, YJ, 2014) |
| "Psoriasis is a chronic inflammatory disease that encompasses a large spectrum of clinically distinct subtypes." | ( Liu, SW; Merola, JF; Patel, M; Qureshi, A, 2014) |
| "Psoriasis is a chronic inflammatory skin disease with an unknown aetiology that has been associated with abnormal plasma lipid metabolism and oxidative stress." | ( Ali, E; Ebrahimi, A; Houshang, N; Khodarahmi, R; Mansour, R; Masoud, S; Nemati, H; Reza, K; Rezaei, M; Sadeghi, M; Vaisi-Raygani, A, 2014) |
| "Psoriasis is a common inflammatory disease that is associated with increased risk of cardiovascular disease, including myocardial infarction." | ( Ahlehoff, O; Gislason, GH; Hansen, PR; Khalid, U; Kristensen, SL; Skov, L; Torp-Pedersen, C, 2014) |
| "Psoriasis is a systemic inflammatory skin disease." | ( Gyldenløve, M; Løvendorf, MB; Røpke, MA; Skov, L; Zibert, JR, 2014) |
| "As psoriasis is an incurable disease, the goal of the MTX treatment is to suppress psoriasis, achieving long-term remissions with minimal treatment-related adverse events (AEs)." | ( Baran, W; Batycka-Baran, A; Bieniek, A; Szepietowski, JC; Zychowska, M, 2014) |
| "Psoriasis is a chronic inflammatory dermatosis leading to the development of systemic inflammatory reaction." | ( Kacalak-Rzepka, A; Kiedrowicz, M; Maleszka, R, 2013) |
| "Psoriasis is characterized by an apoptosis-resistant and metabolic active epidermis, while a hallmark for allergic contact dermatitis (ACD) is T cell-induced keratinocyte apoptosis." | ( Albanesi, C; Cavani, A; Eyerich, K; Eyerich, S; Garzorz, N; Grosber, M; Harlfinger, AT; Jaeger, T; Knapp, B; Mattii, M; Mempel, M; Nasorri, F; Pennino, D; Quaranta, M; Ring, J; Scarponi, C; Schmidt-Weber, CB; Schnopp, C; Theis, FJ, 2014) |
| "Psoriasis is a chronic inflammatory skin disease characterized by abnormal keratinocyte proliferation and differentiation and by an influx of inflammatory cells." | ( Ha, HL; Kim, JC; Morasso, MI; Pisitkun, P; Siebenlist, U; Tang, W; Tassi, I; Udey, MC; Wang, H, 2014) |
| "Psoriasis is a chronic auto-inflammatory skin disease of unknown etiology affecting millions of people worldwide." | ( Clausen, BE; Ober-Blöbaum, JL; Pantelyushin, S; Wohn, CT, 2014) |
| "Psoriasis is a common skin disease, which is associated with multiple extracutaneous manifestations." | ( Filev, FS; Herbert, VG; Klemm, M; Lögering, B; Reich, K; von Gruben, V, 2014) |
| "Psoriasis is one of the most common inflammatory skin disorders." | ( Domm, S; Gerdes, S; Mrowietz, U; Steinz, K, 2014) |
| "Psoriasis is a chronic and inflammatory skin disease." | ( Akbulak, O; Akdeniz, N; Bilgili, SG; Karadag, AS; Ozkanli, S; Zemheri, E; Zenginkinet, T; Zindanci, I, 2015) |
| "Psoriasis is a multifactorial process associated with immunologic dysregulation." | ( Del Rosso, JQ, 2014) |
| "Psoriasis is a chronic, relapsing, inflammatory skin disease, in which regulatory T cells (Tregs) play an important role." | ( Fang, X; Han, L; Huang, Q; Ma, Y; Yan, KX; Zhang, HY, 2015) |
| "Psoriasis is a common disease and is associated with cardiovascular diseases." | ( Ahlehoff, O; Bryld, LE; Gislason, G; Gniadecki, R; Hansen, PR; Iversen, L; Kristensen, SL; Lasthein, S; Lindhardsen, J; Skov, L; Torp-Pedersen, C, 2015) |
| "Psoriasis is a T-cell-mediated skin autoimmune disease characterized by the aberrant activation of dermal dendritic cells (DCs) and the sustained epidermal expression of antimicrobial peptides." | ( Chamilos, G; Conrad, C; Demaria, O; Durr, S; Frasca, L; Ganguly, D; Gilliet, M; Lande, R; Schröder, J, 2015) |
| "Psoriasis is a common inflammatory hyperproliferative skin disorder that involves cross-talk between different cell types, including immune cells and keratinocytes." | ( Bollag, WB; Choudhary, V; Helwa, I; Kaddour-Djebbar, I; Karempelis, P; Patel, R, 2015) |
| "Psoriasis is a common, chronic, inflammatory skin disease with the majority of individuals having limited disease, treated with topical medication." | ( Bachelez, H; de Jong, EM; Gisondi, P; Mrowietz, U; Puig, L; Reich, K; Warren, RB; Zschocke, I, 2015) |
| "Psoriasis is frequently associated with obesity, which may favor the development of hyperuricemia." | ( Gisondi, P, 2014) |
| "Psoriasis is a chronic inflammatory disease that significantly impacts life quality, being associated with stress and mental disorders." | ( Benseñor, IM; Brunoni, AR; Lotufo, PA; Sabbag, C; Santos, IS, 2014) |
| "Psoriasis is a model disease for the development of pharmacogenomic markers of treatment response, with ready access to diseased tissue and objective validated outcome measures." | ( Foulkes, AC; Warren, RB, 2015) |
| "Psoriasis is associated with higher CAC values, mainly in individuals with severe psoriasis." | ( Benseñor, IM; Bittencourt, MS; de Souza Santos, I; Goulart, AC; Lotufo, PA; Sabbag, C; Sharovsky, R; Staniak, HL, 2014) |
| "Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation and aberrant keratinocyte differentiation." | ( Adhami, VM; Afaq, F; Chamcheu, JC; Elmets, CA; Mukhtar, H; Pal, HC; Wood, GS, 2015) |
| "Psoriasis is a common chronic immune-mediated inflammatory disease." | ( Huo, R; Li, H; Li, N; Shen, B; Sun, Y; Wu, P; Zhai, T; Zhang, J; Zhou, Z; Zhu, X, 2015) |
| "Psoriasis is a chronic inflammatory disorder of skin and joints for which conventional treatments that are effective in clearing the moderate-to-severe disease are limited due to long-term safety issues." | ( Adhami, VM; Afaq, F; Ayehunie, S; Boylan, BT; Chamcheu, JC; Elmets, CA; Khan, N; Mukhtar, H; Noubissi, FK; Pal, HC; Siddiqui, IA; Syed, DN; Wood, GS, 2015) |
| "Psoriasis is a chronic, immune-mediated inflammatory disease that classically presents with well-demarcated, scaly, erythematous plaques on the extensor surfaces of the extremities, scalp, and trunk." | ( Mahmood, T; Menter, A; Zaghi, D, 2015) |
| "Psoriasis is a chronic skin disorder that exhibits three main features: lymphocytic infiltration into the dermis and epidermis, uncontrolled proliferation and abnormal differentiation of keratinocytes." | ( Adone, B; Cozza, V; d'Elia, I; De Filippis, A; Del Giudice, E; Del Giudice, M; Del Giudice, N; Iride, L; Menghi, E; Tedeschi, A; Tufano, MA, 2015) |
| "Psoriasis is a chronic inflammatory skin disease affecting 2-5% of the population worldwide and it severely affects patient quality of life." | ( Du, L; Jin, Y; Kang, H; Li, M; Zhang, B; Zhang, X, 2015) |
| "Psoriasis is a chronic inflammatory skin disorder that is accompanied by an imbalance between the proliferation and differentiation of keratinocytes." | ( Fukami, K; Kanemaru, K; Matsuyuki, A; Nakamura, Y, 2015) |
| "Severe psoriasis is a systemic inflammatory disease involving major arteries and internal organs." | ( Kang, SY; Kim, SA; Lee, WW; Park, GY; Youn, SW, 2015) |
| "People with psoriasis are at higher cardiovascular risk." | ( Azzaretto, L; Campanati, A; Consales, V; Ganzetti, G; Giannoni, M; Giuliodori, K; Guanciarossa, F; Liberati, G; Offidani, A; Postacchini, V; Vichi, S, 2015) |
| "Plaque-type psoriasis is a chronic inflammatory skin disorder associated with chemoattractants driving neutrophils into the epidermis." | ( Flagler, ND; Janardhan, KS; King, D; Myers, P; Petranka, JG; Putney, JW; Steinckwich, N, 2015) |
| "Inverse psoriasis is clinically defined by chronic inflammatory lesions in intertrigineous areas." | ( Reich, K; Weisenseel, P, 2015) |
| "Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the world population and is mainly characterized by epidermal hyperplasia, scaling, and erythema." | ( Dejager, L; Grine, L; Libert, C; Vandenbroucke, RE, 2015) |
| "Psoriasis is a common, disfiguring and stigmatizing skin disease associated with impaired quality of life." | ( Aimetti, M; Ercoli, E; Manavella, V; Romano, F, 2015) |
| "Plaque psoriasis is a debilitating skin condition that affects approximately 2% of the adult population and for which there is currently no cure." | ( Buonanno, M; Papp, KA; Pariser, D; Tan, H; Tyring, SK; Valdez, H; Valenzuela, F; Wang, J; Wolk, R, 2015) |
| "Psoriasis is a disease of both localized and systemic low-grade inflammation." | ( Jessen, N; Kjær, TN; Pedersen, SB; Stenderup, K; Thorsen, K, 2015) |
| "Psoriasis is a chronic inflammatory skin disease expressing immune and hyperproliferative features." | ( Barreira, SM; Cabrini, DA; Carrenho, LZ; Dietrich, M; Duarte, ME; Ducatti, DR; Gomes Junior, R; Gonçalves, AG; Moreira, CG; Noseda, MD; Otuki, MF; Paludo, K; Vandresen, CC, 2015) |
| "Psoriasis is a common chronic skin disease that can also affect the mucous membranes and joints." | ( Abdel Raheem, HM; Abozaid, NA; Ezzat, MA; Nagui, NA; Rashed, LA, 2016) |
| "Psoriasis is a chronic autoimmune human skin disorder that is characterized by excessive proliferation of keratinocytes, scaly plaques, severe inflammation and erythema." | ( Arora, N; Pandey-Rai, S; Shah, K, 2016) |
| "Psoriasis is a common, immune-mediated inflammatory skin disease characterized by red, heavily scaled plaques." | ( Broadhurst, D; Dunn, WB; Goodacre, R; Griffiths, CE; Hollywood, KA; Winder, CL; Xu, Y, 2015) |
| "Guttate psoriasis is frequently associated with a preceding pharyngeal or perianal streptococcal infection in children." | ( Hernandez, M; Simms-Cendan, J; Zendell, K, 2015) |
| "Psoriasis is a chronic, inflammatory skin disease involving both environmental and genetic factors." | ( Chen, F; Chen, Y; Cheng, L; Hao, F; Niu, J; Qian, T; Shi, X; Song, Z; Wang, H; Yan, H; Zhai, Z; Zhang, D; Zhang, N; Zhong, B, 2015) |
| "Psoriasis is a chronic inflammatory skin condition characterized by well-circumscribed erythematous plaques with thick silvery scale." | ( Alavi, A; Bakshi, A; Gelfand, JM; Gholami, S; Takeshita, J, 2015) |
| "Psoriasis is a systemic immune-mediated chronic inflammatory disease." | ( Batycka-Baran, A; Hattinger, E; Prinz, JC; Ruzicka, T; Summer, B; Szepietowski, JC; Thomas, P; Wolf, R; Zack Howard, OM; Zwicker, S, 2015) |
| "Psoriasis is a common inflammatory skin disease of undetermined etiology and poor prognosis." | ( Ding, Y; Gao, Y; Yi, X; Zhou, J, 2015) |
| "Psoriasis is characterized by the unregulated proliferation of epidermal keratinocytes and increased expression of proinflammatory mediators in the skin." | ( Chen, ML; Chen, X; He, HL; Li, D; Yao, MZ, 2015) |
| "Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inflammation." | ( Chen, X; Huo, R; Li, H; Li, N; Shen, B; Shen, Z; Sun, Y; Wang, B; Wu, P; Zhai, T; Zhang, J; Zhou, Z, 2015) |
| "Psoriasis is a chronic immune-mediated disorder that can be triggered by environmental changes, illness, smoking, or medications." | ( Bongiorno, MA; Meyerle, JH; Rivard, SSC, 2015) |
| "Psoriasis is a chronic inflammatory skin disease characterized by excessive proliferation and abnormal keratinocyte development, in which T helper type 17 cells and signal transducer and activator of transcription 3 (STAT3) activation have pivotal roles." | ( Aihara, M; Komitsu, N; Watanabe, T; Watanabe, Y; Yamaguchi, Y, 2015) |
| "Psoriasis is an inflammatory disease in which joints involvement may be insidious and difficult to detect." | ( Bartosińska, J; Chodorowska, G; Juszkiewicz-Borowiec, M; Kowal, M; Michalak-Stoma, A, 2015) |
| "Psoriasis is a chronic inflammatory disease with a well-documented negative effect on the quality of life of affected patients." | ( Bangsgaard, N; Rørbye, C; Skov, L, 2015) |
| "Psoriasis is one of the most common skin disorders characterized by erythematous plaques that result from hyperproliferative keratinocytes and infiltration of inflammatory leukocytes into dermis and epidermis." | ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Al-Hosaini, KA; Al-Sharary, SD; Ansari, MA; Attia, SM; El-Sherbeeny, AM; Nadeem, A; Siddiqui, N; Zoheir, KM, 2015) |
| "Psoriasis is a chronic immune-mediated inflammatory condition that affects 2-3% of the population." | ( Beroukhim, K; Danesh, MJ; Koo, J; Levin, E; Nguyen, C, 2015) |
| "Psoriasis is associated with metabolic activity of adipose tissue which produces pro- and anti-inflammatory adipokines." | ( Andrys, C; Borska, L; Fiala, Z; Hamakova, K; Kondelkova, K; Krejsek, J; Kremlacek, J; Rehacek, V; Rendarova, S, 2015) |
| "Psoriasis is increasingly recognised as a skin disease with far-reaching systemic effects, associated with a high prevalence of comorbid disease such as cardiometabolic dysfunction, shifting the focus from a single organ disease confined to the skin to a systemic inflammatory condition." | ( Gooren, L; Haider, A; Saad, F, 2016) |
| "Psoriasis is a chronic inflammatory skin disorder which can impair general routine activities and has been closely related to poor quality of life." | ( Albuquerque, RG; Andersen, ML; Hirotsu, C; Nogueira, H; Tomimori, J; Tufik, S, 2015) |
| "Psoriasis is a common chronic inflammatory skin disease." | ( Arias-Santiago, S; García-Serrano, JL; González Gallardo, MD; Gonzalez-Andrades, M; McAlinden, C, 2017) |
| "Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system and release of pro-inflammatory mediators." | ( Bianchi, L; Buonomo, O; Chimenti, MS; Chimenti, S; Chiricozzi, A; Garofalo, V; Gramiccia, T; Perricone, R; Saraceno, R, 2015) |
| "Psoriasis is a chronic inflammatory skin condition that can markedly reduce life quality." | ( Abbott, R; Atwan, A; Bauer, A; Ingram, JR; Kelson, MJ; Pickles, T; Piguet, V, 2015) |
| "Psoriasis is a systemic inflammatory disease." | ( Armstrong, AW; Blauvelt, A; Krueger, GG, 2015) |
| "Palmoplantar psoriasis is a chronic debilitating type of psoriasis." | ( Klufas, DM; Strober, BE; Wald, JM, 2015) |
| "Psoriasis is a chronic inflammatory skin disease, characterized by hyperproliferation of keratinocytes and by skin infiltration of activated T cells." | ( D'Amico, F; Gangemi, P; Granata, M; Longo, V; Mazzarino, MC; Mosca, A; Pettinato, M; Rossi, GA; Skarmoutsou, E; Trovato, C, 2015) |
| "Psoriasis is a chronic inflammatory disease associated with several comorbidities, including depression." | ( da Silva Souza, C; Godoy, AL; Lanchote, VL; Rocha, A, 2016) |
| "Psoriasis is a chronic inflammatory skin disease and topical therapy remains a key role for treatment." | ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "Psoriasis is an inflammatory skin disease affecting ∼2% of the world's population, but the aetiology remains incompletely understood." | ( Abbatiello, B; Ajami, NJ; Belkaid, Y; Chen, Q; Chen, W; Chen, ZJ; Chia, C; Jiao, X; Kasagi, S; Konkel, JE; Nakatsukasa, H; Petrosino, JF; Smith, DP; Wu, R; Zanvit, P; Zhang, D, 2015) |
| "Psoriasis is a common immune-mediated, chronic, inflammatory skin disease characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells." | ( Bertelsen, T; Hailfinger, S; Iversen, L; Johansen, C; Lorscheid, S; Mose, M; Ommen, P; Schulze-Osthoff, K; Vinter, H, 2015) |
| "Pustular psoriasis is an uncommon psoriasis variant, clinically characterized as small sterile pustules on an erythematous base." | ( Divito, SJ; Enamandram, M; Merola, JF; Sheu, JS, 2016) |
| "Psoriasis is a chronic inflammatory skin disease of unknown etiology." | ( Bajenoff, M; Chelbi, R; Dalod, M; Henri, S; Jorquera, A; Malissen, B; Malosse, C; Tamoutounour, S; Terhorst, D; Wohn, C, 2015) |
| "Psoriasis is a T-cell mediated chronic systemic inflammatory skin disease." | ( Ananthanarayanan, PH; Chandrashekar, L; Indhumathi, S; Negi, VS; Rajappa, M; Thappa, DM, 2016) |
| "Chronic plaque psoriasis is an inflammatory skin disease affecting 2-3% of the world population." | ( Katare, OP; Raza, K; Sharma, G; Singh, B; Wadhwa, S, 2016) |
| "Psoriasis is a chronic inflammatory skin disease characterized by a relapsing-remitting disease course and correlated with increased expression of proinflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin 22 (IL22)." | ( Charpin-El Hamri, G; Fussenegger, M; Geering, B; Schukur, L, 2015) |
| "Psoriasis is a skin disease associated with hyperproliferation and abnormal differentiation of keratinocytes." | ( Amnuaikit, T; Chorachoo, J; Musthafa, KS; Saeloh, D; Sretrirutchai, S; Srichana, T; Voravuthikunchai, SP, 2016) |
| "Psoriasis is a common, chronic, inflammatory skin disease." | ( Cannizzaro, MV; Caposiena, D; Chimenti, S; Chiricozzi, A; Garofalo, V; Saraceno, R, 2016) |
| "Psoriasis is a T-helper (Th)1/Th17-mediated, chronic inflammatory dermatosis related to metabolic syndromes and serum LCN2 levels are elevated in psoriatic patients." | ( Fukusato, T; Hau, CS; Kanda, N; Sato, S; Shibata, S; Tada, Y; Uozaki, H; Watanabe, S, 2016) |
| "Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options." | ( Aldredge, L; Armstrong, AW; Yamauchi, PS, 2016) |
| "Psoriasis is a one of the most common chronic skin diseases, which affects 0." | ( An, J; Dong, Y; Huo, J; Li, Z; Ren, J, 2016) |
| "Treatment of psoriasis is very complex and there are no still universal, nor unique treatment modalities." | ( Golusin, Z; Jovanović, M; Magda, N; Matić, M; Petrović, A; Stojanović, S, 2015) |
| "Psoriasis is a chronic skin disease of unknown aetiology but increasing evidence suggests that cutaneous angiogenesis plays an important role." | ( Liu, JH; Luo, DQ; Wu, HH; Xie, WL; Zhao, YK, 2016) |
| "Psoriasis is a chronic inflammatory skin disease with genetic and environmental factors having an important role in its aetiology." | ( Ananthanarayanan, PH; Chandrashekar, L; Indhumathi, S; Negi, VS; Rajappa, M; Thappa, DM, 2015) |
| "Psoriasis is a chronic immune-mediated inflammatory skin disease with both genetic and environmental factors contributing to its pathogenesis." | ( Corbelli, E; Fargnoli, MC; Gaudio, E; Pellegrini, C; Peris, K; Sferra, R; Vetuschi, A, 2014) |
| "Psoriasis is associated with increased cardiovascular disease in adults, but the risk profile of children with psoriasis remains to be fully characterized." | ( Admani, S; Eichenfield, LF; Joshi, AA; Mehta, NN; Natarajan, B; Playford, MP; Tom, WL, 2016) |
| "Moderate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM)." | ( Ahern, TB; Hughes, R; Kelly, G; Kirby, B; Lynch, M; O'Shea, D; Sweeney, C; Timoney, I; Tobin, AM, 2016) |
| "Chronic plaque psoriasis is partially mediated by elevation of proinflammatory cytokines, including several within the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway." | ( Bissonnette, R; Chen, X; Fidelus-Gort, R; Flores, R; Jackson, S; Luchi, M; Menter, A; Newton, R; Scherle, P; Yeleswaram, S; Zhang, H, 2016) |
| "Psoriasis is a chronic inflammatory skin disease characterized by altered proliferation and differentiation of keratinocytes as well as infiltration of immune cells." | ( Malik, G; Mittal, S; Narasimhan, A; Saini, N; Sardana, K; Varshney, P, 2016) |
| "Psoriasis is a multi-factorial heritable prototypical immune-mediated inflammatory disease, characterized by hyperproliferation of keratinocytes in the affected skin." | ( Ananthanarayanan, PH; Chandrashekar, L; Indhumathi, S; Negi, VS; Rajappa, M; Thappa, DM, 2016) |
| "Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process." | ( Disch, D; Gaich, C; Janes, JM; Macias, W; Menter, MA; Papp, KA; Raman, M; Schlichting, DE; Zhang, X, 2016) |
| "Psoriasis is one of the most common chronic inflammatory diseases of the skin." | ( Ban, CY; Choi, YJ; Kim, HP; Kim, J; Kim, JH; Kim, SC; Kim, SE; Kim, TG; Lee, BH; Park, J; Park, SH; Shin, EC; Song, MY; Sung, YC, 2016) |
| "Psoriasis is a multifactorial skin disease that inconveniences many patients." | ( Bao, YL; Huang, YX; Li, WL; Li, YX; Song, ZB; Sun, LG; Wang, Q; Yang, XG; Yu, CL; Zhang, WJ, 2016) |
| "Psoriasis is a chronic inflammatory skin disorder involving marked immunological changes." | ( Birault, V; Brusq, JM; Bui, T; Cote-Sierra, J; Hofland, H; Jetten, AM; Millerman, E; Neil, J; Nicodeme, E; Peredo, CE; Rickard, D; Smith, SH; Takeda, Y; Therrien, JP; Viviani, F, 2016) |
| "Psoriasis is an inflammatory skin condition that affects approximately 2 % of people worldwide." | ( Lim, HW; Mehta, D, 2016) |
| "Psoriasis is a chronic autoimmune disease of undefined etiology that involves dysregulated interplay between immune cells and keratinocytes." | ( Chao, YH; Chen, DY; Chen, HH; Chung, TW; Li, YR; Lin, CC; Yang, DH, 2016) |
| "Psoriasis is a chronic inflammatory immune-mediated autoimmune skin disorder." | ( Chang, KT; Choo, YK; Kim, CH; Kim, JS; Kim, SU; Lee, JM; Yoo, JK, 2016) |
| "Psoriasis is a common skin disease accompanied by chronic inflammation." | ( Cho, D; Houh, Y; Kim, KE; Park, HJ, 2016) |
| "Psoriasis is a common skin disorder that is associated with impairments in quality of life (QOL) and psychological distress." | ( Dogra, S; Gupta, S; Handa, S; Narang, T; Singh, SM; Verma, AK, 2016) |
| "Annular pustular psoriasis is not typically observed in cases of arthritis." | ( Mikage, H; Nagafuchi, H; Ozaki, S; Watanabe, K, 2016) |
| "Nail psoriasis is challenging to treat." | ( Madan, R; McDermott, L; Rupani, R; Siegel, D, 2016) |
| "Psoriasis is a chronic skin disease that affects approximately 2% of the world's population." | ( Jia, W; Li, J; Li, K; Li, Z; Xiao, T; Yang, W; Zhang, P, 2016) |
| "Psoriasis is a common skin disorder that causes skin inflammation." | ( Morimura, S; Oka, T; Sato, S; Sugaya, M, 2016) |
| "Psoriasis is characterized by resistance to infections, which is regulated by antimicrobial proteins." | ( Cao, T; Fang, H; Hu, J; Jin, L; Li, B; Shao, S; Wang, G; Zhang, J; Zhang, Y, 2016) |
| "Psoriasis is an autoimmune skin disease that is associated with aberrant activity of immune cells and keratinocytes." | ( Hahn, M; Hövelmeyer, N; Karbach, SH; Klebow, S; Nikoalev, A; Waisman, A; Wunderlich, FT, 2016) |
| "Psoriasis is a chronic and recurrent inflammatory skin disease." | ( Chen, JK; Hong, YY; Qin, WL; Sun, LY; Wang, TC; Zhou, DM; Zhou, R; Zhou, ZX, 2016) |
| "Psoriasis is a chronic disease that has a substantial effect on quality of life of patients and often needs long-term treatment." | ( Stein Gold, LF, 2016) |
| "Psoriasis is a common, chronic, recurrent, immune-mediated disorder of the skin and joints." | ( Chantzaras, A; Kontochristopoulos, G; Kouris, A; Petridis, A; Yfantopoulos, J, 2016) |
| "Psoriasis is a potential complication in kidney recipients that may recur when belatacept is used and/or tacrolimus is withdrawn as it could have happened in the first patient." | ( Cicora, F; Roberti, J, 2016) |
| "Psoriasis is a chronic inflammatory skin disease with excessive activation of toll-like receptors (TLRs), which play important roles in developing psoriasis." | ( Shao, F; Sun, Y; Tan, T; Tan, Y; Wu, X; Xu, Q, 2016) |
| "Psoriasis is a chronic skin disease associated with increased morbidity and mortality." | ( Smith, D, 2017) |
| "Psoriasis is one of the most common immune-mediated chronic inflammatory skin disorders, characterized by hyperproliferation of keratinocytes, dilation and growth of dermal capillary vasculature, and cellular infiltration of T cells, dendritic cells (DCs), and neutrophils." | ( Cao, N; Chen, T; Fu, LX; Lu, YH; Yin, B; Zhang, LW; Zhou, PM, 2016) |
| "Psoriasis is a common chronic skin condition characterized by excessive inflammation and aberrant epidermal proliferation." | ( Chong, HT; Cowin, AJ; Ibbetson, J; Kopecki, Z; Sidhu, S; Yang, GN, 2017) |
| "Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population." | ( Bianchi, L; Chimenti, S; Chiricozzi, A; Del Duca, E; Romanelli, M; Saraceno, R, 2016) |
| "Psoriasis is one of the most common inflammatory skin disorders, affecting 3% of the general population." | ( An, J; Dong, Y; Huo, J; Li, T; Li, Z, 2016) |
| "Psoriasis is a chronic inflammatory skin condition characterised by the formation of red scaly plaques on the skin." | ( Al-Mutairi, N; Bachelez, H; Gulliver, S; Gulliver, WP; Randell, S; Young, HM, 2016) |
| "Psoriasis is a chronic inflammatory skin disease in which Th17 cells play a crucial role." | ( Hercogová, J; Hornová, M; Hudcovic, T; Jůzlová, K; Klimešová, K; Kostovčík, M; Kverka, M; Málková, J; Novosádová, I; Rossmann, P; Stehlíková, Z; Štepánková, R; Tlaskalová-Hogenová, H; Zákostelská, Z, 2016) |
| "Psoriasis is a chronic inflammatory skin disease characterized by hyper proliferation of keratinocytes." | ( Dayalan, H; Elango, T; Ethiraj, P; Gnanaraj, P; Subramanian, S; Thirupathi, A, 2017) |
| "Psoriasis is a chronic inflammatory disease of the skin and joints that may also have systemic inflammatory effects, including the development of cardiovascular disease (CVD)." | ( Cao, L; Cooper, KD; Debanne, SM; Feig, RL; Gilkeson, RC; Golden, JB; Grozdev, I; Kast, DR; Korman, NJ; McCormick, TS; Orringer, CE; Santilli, S; Ward, NL, 2016) |
| "Psoriasis is a common inflammatory skin disease characterized by T cell-mediated hyperproliferation of keratinocytes, increased angiogenesis and inflammation." | ( Li, R; Ma, H; Wang, J; Wang, M; Wang, X; Xiao, S; Zhou, J, 2016) |
| "Psoriasis is associated with obesity; patients with psoriasis have a higher incidence of obesity, and obese individuals have a higher risk of developing psoriasis." | ( Iversen, L; Johansen, C; Langkilde, A; Ommen, P; Rosada, C; Stenderup, K; Stjernholm, T, 2017) |
| "Psoriasis is a systemic inflammatory condition that is associated with a higher risk of cardiovascular (CV) disease." | ( Ahlehoff, O; Egeberg, A; Hansen, PR; Qureshi, AA; Robertson, D; Strober, BE; Tan, H; Valdez, H; Wolk, R; Wu, JJ, 2016) |
| "Psoriasis is thought to be initiated by abnormal interactions between cutaneous keratinocytes and systemic immune cells." | ( Cheng, L; Cui, X; Dai, L; Deng, H; Li, C; Li, J; Li, Y; Lin, Y; Liu, Y; Shi, G; Wang, F; Wang, H; Wang, Y; Wei, Y; Xiang, R; Yang, Q; Yang, Y; Yu, D; Zhang, J; Zhang, S; Zhang, X, 2016) |
| "Psoriasis is a chronic T-cell-mediated autoimmune disease, and FMS-like tyrosine kinase 3 (FLT3) has been considered as a potential molecular target for the treatment of psoriasis." | ( Chen, YC; Fang, Z; Huang, SZ; Ji, S; Li, GB; Li, LL; Ma, S; Niu, D; Wang, JH; Wang, LJ; Xiang, R; Xiong, Y; Yang, LL; Yang, SY; Zhang, G; Zhong, JM, 2016) |
| "Psoriasis is a chronic auto-immune inflammation disease with skin lesions and abnormal keratinocyte proliferation." | ( Liu, J; Luo, H; OuYang, Q; Pan, Y; Xuan, C, 2016) |
| "Inverse psoriasis is characterized by the development of erythematous shiny plaques at intertriginous areas of the body." | ( Arjona Aguilera, C; Espinosa Rosso, R; Jiménez Gallo, D; Linares Barrios, M; Rojo Suárez, N, 2017) |
| "Psoriasis is an immune-mediated inflammatory skin disease with a strong genetic background in which activation of IL-17 signaling is central in the pathogenesis." | ( Li, D; Lohcharoenkal, W; Meisgen, F; Nikamo, P; Pivarcsi, A; Sonkoly, E; Srivastava, A; Ståhle, M; Xu Landén, N, 2017) |
| "Psoriasis is an inflammatory skin disease with or without joint involvement." | ( Cubillos, S; Norgauer, J, 2016) |
| "Psoriasis is a debilitating chronic inflammatory disease." | ( Ferris, LK; Ilkovitch, D, 2016) |
| "Psoriasis is a common chronic inflammatory and immune-mediated skin disease." | ( Bertelsen, T; Boye Kjellerup, R; Iversen, L; Johansen, C; Ljungberg, C, 2017) |
| "Psoriasis is a common chronic inflammatory skin disease observed in about 1-3% of the general population." | ( Reich, A; Szepietowski, JC, 2016) |
| "Psoriasis is a chronic inflammatory immune disease with undefined pathogenesis." | ( Fang, F; Liu, X; Mei, L; Wang, H; Zhang, S, 2016) |
| "Scalp psoriasis is commonly the initial presentation of psoriasis, and almost 80 % of patients with psoriasis will eventually experience it." | ( Tsai, TF; Wang, TS, 2017) |
| "Psoriasis is a chronic disease, and long-term adherence is an even bigger problem." | ( Alinia, H; Anderson, KL; Bahrami, N; Farhangian, ME; Feldman, SR; Huang, KE; Jaros, SC; Moradi Tuchayi, S; Richardson, IM; Sandoval, LF; Smith, JA, 2017) |
| "Psoriasis is a chronic inflammatory skin disease with a clear genetic contribution, characterized by keratinocyte proliferation and immune cell infiltration." | ( Finkelstein, D; Gangwar, R; Gingras, S; Häcker, H; Ippagunta, SK; Pelletier, S; Redecke, V; Vogel, P, 2016) |
| "Psoriasis is an autoimmune skin disorder characterized by hyper proliferation and poor differentiation of keratinocytes." | ( Domb, AJ; Doppalapudi, S; Jain, A; Khan, W, 2016) |
| "Plaque psoriasis is the most common phenotype." | ( Choon, SE; Nalini, MN; Ngim, CF; Premaa, S; Tey, KW, 2016) |
| "Psoriasis is associated with cardiovascular disease; it has been proposed that increased cardiovascular risk is caused by low-grade systemic inflammation involving organs and tissues other than the skin and joints." | ( Egeberg, A; Gormsen, LC; Hjuler, KF; Iversen, L; Nielsen, J; Vendelbo, MH, 2017) |
| "Psoriasis is one of the most common immune-mediated chronic inflammatory skin disorders and is accompanied by erythematous scaly plaques." | ( Aoki, M; Furue, Y; Fusamae, Y; Imura, C; Okuda, T; Oshima, I; Shichijo, M; Suzuki, M; Tsujii, K; Ueyama, A; Yamamoto, M; Yasui, K, 2017) |
| "Psoriasis is a complex multifactorial chronic inflammatory skin disorder involving both genetic and environmental susceptibility factors." | ( Chandra, A; Chatterjee, G; Chatterjee, R; Ghosh, S; Senapati, S, 2017) |
| "Psoriasis is an autoimmune skin disease, in which keratinocytes play a crucial pathogenic role." | ( Cao, T; Gao, T; Ge, R; Guo, S; Li, B; Li, C; Liu, L; Wang, G; Wang, H; Zhang, W, 2017) |
| "Psoriasis is associated with metabolic syndrome and cardiovascular disease." | ( Bacharewicz-Szczerbicka, J; Baran, A; Flisiak, I; Myśliwiec, H; Świderska, M, 2017) |
| "Psoriasis is associated with increased risk for cardiovascular disease." | ( Cloutier, M; Dea, K; Guérin, A; Mulani, P; Sundaram, M; Wu, JJ, 2017) |
| "Psoriasis is a chronic, immune-mediated inflammatory disorder with a significant negative impact on quality of life." | ( Bang, B; Lebwohl, M; Paul, C, 2017) |
| "Psoriasis is a high-incident T-cell-mediated autoimmune disease mainly affecting the skin." | ( Chen, W; Fei, C; Gong, Y; Shi, Y; Tong, Y; Wang, X; Wang, Y; Xu, H; Yu, Q; Zhang, X, 2017) |
| "Psoriasis is known today as a T‑cell-mediated autoimmunological systemic disease." | ( Fischer, M; Gilbrich, F; Philipp, S; Wohlrab, J; Wolff, L, 2017) |
| "Psoriasis is a chronic-relapsing skin disorder which requires long-term treatments." | ( Calzavara Pinton, P; Cicchetti, A; Cristaudo, A; Girolomoni, G, 2018) |
| "Psoriasis is known to be associated with an up-regulation of T-helper (Th)-1 & Th-17 cytokines and a relative down-regulation of Th-2 and T-regulatory (T-reg) cytokines." | ( Ananthanarayanan, PH; Chandrashekar, L; Indhumathi, S; Negi, VS; Rajappa, M; Thappa, DM, 2017) |
| "Psoriasis is a chronic inflammatory skin disease with a prevalence of 2-3 %." | ( Florencia, EF; Hekking-Weijma, IM; Onderdijk, AJ; Prens, EP, 2017) |
| "Psoriasis is a chronic, inflammatory and immune-mediated disease." | ( Akbulak, O; Akdeniz, N; Demirkan, S; Karadag, AS; Oguztuzun, S; Ozkanli, S; Ozlu, E; Uzuncakmak, TK, 2017) |
| "Psoriasis is a chronic relapsing immune mediated disorder of the skin." | ( Arumugam, M; Sundarrajan, S, 2017) |
| "Psoriasis is a chronic skin disease also affecting other sites such as joints." | ( Norooznezhad, AH; Norooznezhad, F, 2017) |
| "Psoriasis is a common skin condition, affecting 1." | ( Lyon, CC; Marshall, C; Woodmansey, S, 2017) |
| "Peristomal psoriasis is common but potentially under-recognized." | ( Lyon, CC; Marshall, C; Woodmansey, S, 2017) |
| "Psoriasis is a chronic inflammatory skin disease mediated by dysregulated auto-reactive immune system." | ( Arita, K; Hirai, M; Kurebayashi, Y; Mori, H; Yamaguchi, T, 2016) |
| "Psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques on extensor surfaces, scalp, and back." | ( Alikhan, A; Vangipuram, R, 2017) |
| " BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression." | ( Alexander, BJ; Gold, LS; Lebwohl, MG; Pariser, DM; Pillai, R; Sugarman, JL, 2017) |
| "Psoriasis is a chronic, recurrent, inflammatory dermatosis accompanied by excessive activation of Toll‑like receptors (TLRs) in dendritic cells (DCs), which are primarily responsible for initiating an immune response." | ( Di, T; Li, N; Li, P; Lin, Y; Meng, Y; Wang, M; Wang, Y; Xie, X; Xu, X; Zhai, Y; Zhao, J, 2017) |
| "Psoriasis is an immune-mediated skin disorder, which is triggered by the aberrant activation of dendritic cells in skin." | ( Chen, X; Cun, D; Liu, Z; Sun, L; Tong, HHY; Wang, L; Wang, R; Yan, R; Zheng, Y, 2017) |
| "Psoriasis is a common autoimmune skin disease." | ( Eding, CB; Enerbäck, C, 2017) |
| "Psoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement." | ( Jerome, D; Kim, WB; Yeung, J, 2017) |
| "Psoriasis is a chronic autoimmune disease that cannot be cured." | ( Basri, M; Fard Masoumi, HR; Musa, SH; Salim, N; Shamsudin, N, 2017) |
| "Psoriasis is a refractory inflammatory disease, however, its pathophysiology is still not fully understood." | ( Arito, M; Kato, T; Kurokawa, MS; Matsuura, T; Nagai, K; Okamoto, K; Omoteyama, K; Sato, M; Sato, T; Soma, Y; Suematsu, N, 2017) |
| "Psoriasis is characterized by hyperproliferation and inflammation." | ( Chen, Q; Chi, M; Deng, X; Leavesley, D; Shi, H; Xie, N; Xie, Y; Yang, Y; Zhang, H; Zhou, H, 2017) |
| "Psoriasis is a chronic and persistent inflammatory skin disease seriously affecting the quality of human life." | ( Bai, R; Bi, Z; Dong, Y; Dou, R; Li, D; Liu, Z; Mao, C; Su, W; Xiangfei, D; Yang, P; Yang, Y; Yuan, X, 2017) |
| "Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation." | ( Ip, W; Kirchhof, MG, 2017) |
| "Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events." | ( Aberra, TM; Ahlman, MA; Baumer, Y; Chaturvedi, A; Chung, JH; Dey, AK; Ehrlich, A; Gelfand, JM; Gerson, E; Green, LJ; Harrington, CL; Joshi, AA; Kabbany, MT; Lerman, JB; Lockshin, BN; Mehta, NN; Natarajan, B; Ng, Q; Playford, MP; Prussick, RB; Rivers, JP; Rodante, JA; Sanda, GE; Silverman, JI; Sorokin, AV; Teague, HL, 2017) |
| "Psoriasis is associated with dyslipidemia and metabolic syndrome, and has been linked to an increased cardiovascular risk." | ( DeMicco, DA; Fayyad, R; Laskey, R; Ports, WC; Wolk, R, 2017) |
| "Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia (acanthosis) and leukocyte infiltration of the skin." | ( Fuller, SJ; Geraghty, NJ; Mansfield, KJ; Sluyter, R; Watson, D, 2017) |
| "Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and negative impacts on a patient's quality of life." | ( Puig, L; Torres, T, 2018) |
| "Psoriasis is one of the most common immune-mediated chronic inflammatory skin disorders." | ( Chen, T; Fu, LX; Guo, ZP; Liu, XY; Wu, YB; Zhang, LW, 2017) |
| "Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inflammation." | ( Huo, R; Li, H; Li, N; Shen, B; Shen, Z; Wu, P; Xu, H, 2017) |
| "Psoriasis is a long-term disease, and improving adherence in the short time could improve patient's adherence to treatment in long time." | ( Feldman, SR; Firooz, A; Hasanzadeh, H; Rajabi-Estarabadi, A; Taheri, A, 2018) |
| "Psoriasis is a common chronic immune-mediated skin disease which has a significant impact on patients' quality of life, and is associated with numerous comorbidities (i." | ( Frieder, J; Kivelevitch, D; Menter, A, 2017) |
| "Psoriasis is an inflammatory skin disease with aberrant keratinocyte proliferation, presumably as a result of immune cell activation." | ( Brück, J; Carevic, M; Eberle, FC; Fehrenbacher, B; Ghoreschi, K; Holstein, J; Müller-Hermelink, E; Schäfer, I; Schaller, M; Schittek, B, 2017) |
| "Psoriasis is a skin disease with also systemic involvement: its impact on the eye is not well established and often clinically underestimated." | ( Aragona, E; Aragona, P; Cannavò, SP; Giuffrida, R; Interdonato, A; Postorino, EI; Puzzolo, D; Rania, L, 2018) |
| "Psoriasis is a common chronic dermatosis characterized by keratinocyte hyperproliferation accompanied by inflammatory reactions." | ( Liu, Y; Meng, L; Tan, X; Wei, G; Xu, Q; Zhang, C, 2017) |
| "Psoriasis is considered to be a systemic disease of immune dysfunction." | ( M, R; Mishra, A; P, R; Prabhu, S; Sivaprakasam, TO; Varma, SR, 2017) |
| "Psoriasis is a chronic inflammatory skin disease that affects 2-3% of the global population, and there is still no known possibility of a cure." | ( Chen, H; Duan, X; Gan, L; He, M; Hu, F; Liu, X; Ming, Z; Poorun, D; Wang, X; Xu, J; Zhang, S; Zhu, K, 2017) |
| "Psoriasis is a chronic inflammatory disease of the skin." | ( Ananthanarayanan, PH; Chandrasekaran, A; Chandrashekar, L; Rajappa, M; Satheesh, S; Sudhesan, A; Thappa, DM, 2017) |
| "Psoriasis is a chronic immune-mediated dermatologic disorder affecting approximately 2% of the general population." | ( Meyerle, J; Rosenberg, A, 2017) |
| "Psoriasis is often accompanied by itch, but the mechanisms behind this symptom remain elusive." | ( Akiyama, T; Jensen, LE; Sakai, K; Sanders, KM; Yanushefski, KM; Yosipovitch, G; Youssef, MR, 2017) |
| "Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE)." | ( Ahlman, MA; Egeberg, A; Gelfand, JM; Gislason, GH; Joshi, AA; Lerman, JB; Mallbris, L; Mehta, NN; Rodante, J; Skov, L; Wu, JJ, 2017) |
| "Psoriasis is an inflammatory skin disease with increased neovascularization, keratinocyte hyperproliferation, a proinflammatory cytokine milieu, and immune cell infiltration." | ( Brunner, SM; Ebner, S; Holub, BS; Kofler, B; Koller, A; Lang, R; Reitsamer, HA; Schwarzenbacher, D; Sternberg, F; Stockinger, J; Trost, A; Vidali, S, 2018) |
| "Psoriasis is a chronic inflammatory skin disease affecting 2." | ( Arbiser, JL; Biedermann, T; Bonner, MY; Fritz, Y; Gilbert, LC; Karlsson, I; Lewis, MJ; Michaels, K; Nowak, R; Rao, S; Skabytska, Y; Ward, NL; Yusuf, N, 2017) |
| "Psoriasis is a chronic inflammatory autoimmune disease that can be initiated by excessive activation of endosomal toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9." | ( Chuang, TH; Hsu, LC; Lai, CY; Lin, KI; Su, YW, 2017) |
| "Psoriasis is a chronic inflammatory skin disease that affects about 1%-3% of the world's population." | ( Abdelaziz, EZ; Bayomy, NA; Okasha, EF, 2018) |
| "Psoriasis is a chronic inflammatory skin disease severely affecting patients' physical and psychological well-being." | ( Dang, E; Hu, L; Jiang, M; Li, B; Wang, G; Zhang, J, 2017) |
| "Psoriasis is a common, an inflammatory skin disease." | ( Aleksiejczuk, P; Borawska, MH; Niczyporuk, M; Ostrowska, J; Socha, K; Soroczyńska, J; Wacewicz, M, 2017) |
| "Psoriasis is a chronic inflammatory skin disorder of unknown etiology." | ( Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK, 2018) |
| "Psoriasis is a chronic inflammatory skin disease affecting 2%-3% of the population." | ( Bottoni, U; De Carvalho, N; Del Duca, E; Farnetani, F; Nisticò, SP; Pellacani, G, 2017) |
| "Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life." | ( Greenberg, JD; Guo, N; Holmgren, SH; Karki, C; Lebwohl, M; Mason, M; Strober, B, 2018) |
| "Psoriasis is an independent risk factor for cardiovascular disease; however, the underlying mechanisms are not fully understood." | ( Alba, BK; Alexander, LM; Ferguson, SB; Greaney, JL, 2018) |
| "Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life." | ( Barber, K; Bissonnette, R; Bukhalo, M; Delorme, I; Fowler, JF; Gagné-Henley, A; Gooderham, M; Haydey, R; Jenkin, P; Landells, I; Lynde, CW; Pariser, DM; Poulin, Y; Rosoph, LA, 2018) |
| "Psoriasis is a common and chronic inflammatory disease of the skin." | ( Hu, SC; Lan, CE, 2017) |
| "Psoriasis is a chronic inflammatory skin disorder." | ( Chen, FY; Cheng, HM; Ho, TY; Hsiang, CY; Li, CC; Liao, YF; Lo, HY, 2017) |
| "Psoriasis is a T-cell-mediated skin disease with autoimmune nature that is generally not observed in animals, this lack of a relevant experimental animal model of psoriasis has hindered the investigation of pathogenesis of disease." | ( Bahrami, G; Faridi-Majidi, R; Ghahramani, MH; Izadi, B; Madani, SH; Nemati, H; Tavoosidana, G, 2017) |
| "Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens." | ( Abramovits, W; Gardner, A; Kaur, M; Korman, N; Mukwaya, G; Rottinghaus, ST; Tan, H; Valdez, H; Winthrop, KL, 2018) |
| "Psoriasis is a common, chronic, immune-mediated disease associated with several comorbidities." | ( Azevedo, A; Torres, T, 2018) |
| "Psoriasis is a chronic inflammatory disease of the skin which can occur at any age-group." | ( Chen, Z; Shi, Y; Subedi, S; Yu, Q, 2018) |
| "Psoriasis is a chronic inflammatory skin disease whose pathogenesis is driven by multiple cytokine-mediated pathways." | ( Chiricozzi, A; Gualtieri, B; Panduri, S; Romanelli, M; Tonini, A, 2018) |
| "Psoriasis is an autoimmune skin disease characterized by keratinocyte hyperproliferation and chronic inflammation." | ( Patel, AB; Theoharides, TC; Tsilioni, I; Weng, Z, 2018) |
| "Psoriasis is a hyperproliferative inflammatory skin disease; therefore, it is highly likely that psoriatic skin lesions may transform into malignancies." | ( Cho, JW; Choe, MS; Jung, JW; Kim, SA; Kwon, JI; Ryu, YW, 2018) |
| "Psoriasis is a chronic inflammatory skin disorder that greatly affects the patient's quality of life." | ( Sun, Q; Wang, XL, 2017) |
| "Psoriasis is largely mediated by interleukin (IL)-23/T helper (Th) 17 axis, and IL-21 is a pleiotropic cytokine expressed by Th17 cells." | ( Kim, DS; Kim, HJ; Kim, SH; Kim, TG; Lee, M; Lee, MG; Park, JY, 2018) |
| "Psoriasis is an immune-mediated, inflammatory disease." | ( Goulis, DG; Kyriakou, A; Patsatsi, A; Sotiriadis, D, 2017) |
| "Psoriasis is a chronic inflammatory cutaneous disorder with undefined etiology and is characterized by abnormal cellular proliferation, angiogenesis, and inflammation." | ( Cai, SQ; Chen, JQ; Landeck, L; Li, W; Man, XY; Min, M; Wang, P; Yan, BX; Zheng, M, 2017) |
| "Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation and differentiation." | ( Guo, W; Wang, G; Yang, L; Zhang, S, 2018) |
| "Psoriasis is a chronic inflammatory disease characterized by epidermal hyperplasia and increased T cell infiltration." | ( Chen, M; Chen, W; Chen, X; He, Y; Kuang, Y; Li, J; Liu, P; Su, J; Tao, J; Wang, H; Zhang, J; Zhao, S; Zhu, W, 2018) |
| "Psoriasis is a chronic inflammatory skin disease that accelerates atherosclerosis in humans and provides a compelling model to understand potential pathways linking these diseases." | ( Baumer, Y; Belur, AD; Bleck, CK; Dagur, PK; Dey, AK; Gelfand, JM; Goyal, A; Harrington, CL; Joshi, AA; Kruth, HS; Marinkovich, MP; Mehta, NN; Ng, Q; Playford, MP; Rodante, JA; Rose, SM; Sanda, GE; Silverman, JI; Sorokin, AV; Springer, DA; Teague, HL; Thomas, CL; Varghese, NJ; Winge, MC; Yu, ZX, 2018) |
| "Psoriasis is a chronic T-cell-mediated skin disease with marked social and economic burdens." | ( Barker, RN; Kotb, IS; Lewis, BJ; Ormerod, AD, 2018) |
| "Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection." | ( Queirós, N; Torres, T, 2018) |
| "Psoriasis is a chronic auto-immune inflammation disease with skin lesions and abnormal keratinocyte proliferation." | ( Chen, X; Jia, XK; Kuang, YH; Liao, LQ; Liu, YK; Lu, Y; Qin, QS; Wu, LS; Zhou, XC; Zhu, W, 2018) |
| "Psoriasis is a chronic inflammatory skin disease, which requires long-term, safe and effective treatment." | ( Kokkalis, G; Papadavid, E; Rigopoulos, D; Rompoti, N; Theodoropoulos, K, 2018) |
| "Psoriasis is a chronic inflammatory skin disease characterized by red, scaly and raised plaques." | ( Chen, X; Ji, M; Jin, J; Lai, F; Wang, Y; Xue, N; Zhang, S; Zhang, X, 2018) |
| "Psoriasis is an immune-mediated inflammatory disease of the skin." | ( Saini, N; Varshney, P, 2018) |
| "Psoriasis is a commonly encountered chronic dermatological disease, presenting with inflammatory symptoms in patients." | ( Aboel-Fadl, DM; Fadel, M; Nasr, M; Nour El-Deen, F; Ramez, SA; Soliman, MM; Youness, ER, 2018) |
| "Psoriasis is one of the most common chronic skin diseases, affecting 1%-3% of the general population." | ( Gholam, K; Kravvas, G, 2018) |
| "Psoriasis is a chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales, and keratinocyte hyperproliferation." | ( Kainoh, M; Koga, Y; Takahashi, T, 2018) |
| "Psoriasis is a chronic inflammatory skin disorder associated with several comorbidities, including atherosclerosis." | ( Cardoso, RM; Hansen, PR; Madsen, M; Nielsen, LB; Pedersen, TX; van Eck, M, 2018) |
| "Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world's population." | ( Berti, E; Damiani, G; Fiore, M; Leone, S; Maraolo, AE, 2018) |
| "Psoriasis is a common inflammatory condition found in 1-2% of the population." | ( Arbiser, JL; Elsey, J, 2018) |
| "Psoriasis is an autoimmune and recurrent chronic inflammatory skin disorder with a strong genetic basis." | ( Azizian, Z; Bahraini, P; Chalangari, R; Mansouri, P; Rajabi, M; Sarafian, G, 2018) |
| "Psoriasis is a chronic inflammatory skin disease with systemic manifestations and potential genetic etiology." | ( Chandrasekharan, UM; DiCorleto, PE; Harvey, J; Husni, ME; Lax, JE; Seifarth, FG; Tytell, M, 2018) |
| "Psoriasis is a common, chronic, inflammatory skin disease that affects 2%-4% of the global population." | ( Lai, R; Song, J; Xian, D; Xiong, X; Yang, L; Zhong, J, 2018) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disease with severe consequences for the whole organism." | ( Domingues, P; Gęgotek, A; Skrzydlewska, E; Wójcik, P; Wroński, A, 2018) |
| "Psoriasis is a chronic autoinflammatory skin disease." | ( An, H; Dong, C; Lai, Y; Lee, YH; Liu, K; Lu, H; Shi, Y; Wang, X; Wu, Y; Xu, M; Zhang, J, 2018) |
| "Psoriasis is a chronic skin disease associated with psychiatric co-morbidities, especially depression." | ( Han, J; Kim, BS; Kim, GW; Kim, HS; Kim, MB; Kim, SJ; Ko, HC; Pak, K; Park, MY, 2018) |
| "Psoriasis is a recurrent hyper-proliferative skin disease which is often associated with free radical generation, abnormal lipid metabolism and increased inflammatory secretion that induce cardiovascular risk in these patients." | ( Aggarwal, A; Arora, VK; Asha, K; Sharma, SB; Singal, A, 2017) |
| "Psoriasis is a multi-systemic chronic inflammatory skin disease." | ( Alhan, A; Özdemir, ED; Tuğrul Ayanoğlu, B; Türkoğlu, O, 2018) |
| "Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques." | ( Iwatsuki, K; Katayama, N; Morizane, S; Motoki, T; Omori, M; Sugimoto, S, 2018) |
| "Psoriasis is a common inflammatory disease." | ( Hung, CF; Lee, GA; Li, HJ; Wu, NL, 2018) |
| "Psoriasis is a systemic inflammatory disease with a pathophysiology involving interleukin (IL)-17." | ( Berstein, G; Fitz, L; Fraser, S; Lee, J; Mebus, CA; Quazi, A; Soderstrom, C; Valdez, H; Wolk, R; Zhang, W, 2018) |
| "Psoriasis is a chronic skin condition whose pathogenesis is reported to be due to the activation of the interleukin-23/interleukin-17 (IL-23/IL-17) pathway." | ( Elizei, SS; Ghahary, A; Ghoreishi, M; Kilani, R; Mahmoudi, S; Pakyari, M, 2018) |
| "Psoriasis is a complex inflammatory and hyperproliferative skin disease." | ( Cabrini, DA; Dietrich, M; Fernandes, D; Horinouchi, CDS; Machado, W; Moreira, CG; Olchanheski, LR; Otuki, MF; Paludo, K; Pawloski, PL, 2018) |
| "Psoriasis is a chronic inflammatory disease associated with dyslipidemia, cardiovascular events, and mortality." | ( Ahlman, MA; Alavi, A; Armstrong, AW; Dey, AK; Duffin, KC; Fuxench, ZC; Gelfand, JM; Harrington, CL; Hubbard, RA; Joshi, AA; Kalb, RE; Mehta, NN; Menter, A; Playford, MP; Rader, DJ; Reilly, MP; Shin, DB; Simpson, EL; Takeshita, J; Torigian, DA; Troxel, AB; Tyring, SK; Van Voorhees, AS; Vanderbeek, SB; Werner, TJ, 2018) |
| "Psoriasis is a chronic, debilitating skin condition that affects approximately 125 million individuals worldwide." | ( Conic, R; Cooper, KD; McCormick, TS; Wang, Q; Ward, NL; Xu, R, 2017) |
| "Psoriasis is a chronic inflammatory skin disease dependent on the IL-23/IL-17 axis, a potent inflammatory pathway involved in pathogen clearance and autoimmunity." | ( Carey, CD; Diaz-Perez, JA; Falo, LD; Killeen, ME; Mathers, AR; Yang, Y, 2018) |
| "Psoriasis is a chronic, relapsing inflammatory skin disease." | ( Chen, C; Duan, Q; Liu, J; Liu, Z; Shao, Y; Wang, X; Wu, N; Yang, H; Yang, P; Zhang, M; Zheng, Y, 2018) |
| "Psoriasis is a complex chronic inflammatory skin disease characterized by epidermal thickening on the basis of increased keratinocyte proliferation and insufficient apoptosis." | ( Mizukami, Y; Morita, A; Natsumi, A; Paus, R; Sano, S; Sugawara, K; Tsuruta, D; Yasumizu, M, 2018) |
| "Psoriasis is a chronic inflammatory skin disease, primarily caused by overgrowth and abnormal differentiation of epidermal keratinocytes." | ( Cao, C; Pang, W; Qi, X; Zhang, S, 2018) |
| "Erythrodermic psoriasis is a rare but severe type of psoriasis that may be triggered by human immunodeficiency virus infection." | ( Fernández, J; Sánchez, M; Valenzuela, F; Zamudio, A, 2018) |
| "Psoriasis is a chronic skin disease caused by immune disorder." | ( Fukami, S; Kai, H; Morita, M; Moriuchi, M; Nakano, Y; Piruzyan, M; Shuto, T; Suico, MA; Takada, M; Tsurekawa, Y, 2018) |
| "Psoriasis is a chronic autoimmune disease mediated by dysregulated immune responses in dendritic cells (DC) and T cells." | ( Campbell, NK; Dunne, A; Fitzgerald, HK; Fletcher, JM; Hambly, R; Kirby, B; Malara, A; Sweeney, CM, 2018) |
| "Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression." | ( Green, LJ; Lin, T; Pariser, DM; Pillai, R; Stein Gold, L; Sugarman, JL, 2018) |
| "Psoriasis is a chronic inflammatory skin disease characterized by abnormal proliferation of epidermal keratinocytes and infiltration of inflammatory cells." | ( Chen, C; Duan, Q; Jia, J; Jing, H; Li, C; Li, F; Liu, J; Shao, Y; Wang, N; Wang, Q; Wang, X; Xiao, L; Yang, P; Zheng, Y, 2019) |
| "Psoriasis is a chronic inflammatory disease, affecting more than millions of people in the world." | ( Gao, M; Si, X, 2018) |
| "Introduction Severe psoriasis is a chronic systemic immune‑mediated disease associated with increased cardiovascular (CV) risk and several comorbidities." | ( Bańska-Kisiel, K; Bergler-Czop, B; Biedroń, M; Brzezińska-Wcisło, L; Gąsior, Z; Haberka, M; Okopień, B, 2018) |
| "Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function." | ( Adame, S; Adhami, VM; Babatunde, AS; Bharali, DJ; Chamcheu, JC; Esnault, S; Longley, BJ; Massey, RJ; Mousa, SA; Mukhtar, H; Siddiqui, IA; Wood, GS, 2018) |
| "Psoriasis is a chronic and benign proliferative skin disease." | ( Ho, CT; Li, S; Lin, CC; Wang, P; Yang, G; Yang, Y; Yuan, L; Zhao, H, 2018) |
| "Patients with psoriasis are at increased risk for cardiovascular comorbidities." | ( Huang, YC; Tsai, TY; Yen, H, 2019) |
| "Psoriasis is a multifaceted disease in terms of its pathophysiological mechanisms, inducing and aggravating factors, clinical types and clinical severity, associated comorbidities and therapeutic modalities." | ( Grozdev, I; Tsankov, N, 2018) |
| "Psoriasis is one of the most common chronic autoinflammatory skin disease, associated with hyperproliferation and abnormal differentiation of keratinocytes, inflammation, and angiogenesis." | ( Andreola, F; Calcaterra, A; Camponeschi, C; De Angelis, C; Giovannini, D; Nicotera, G; Pierimarchi, P; Serafino, A; Sferrazza, G; Zonfrillo, M, 2018) |
| "Psoriasis is an autoimmune skin disease characterized by hyperproliferation of keratinocytes due to interplay between keratinocytes and immune cells." | ( Abd El Hassib, DM; Doss, RW; El-Rifaie, AA; Kamal, MA; Sabry, D, 2018) |
| "Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregulated immune response." | ( Augustin, M; French, LE; Krueger, JG; Pincelli, C; Schafer, PH, 2018) |
| "Psoriasis is a chronic condition often managed with topical therapy." | ( Kang, R; Kircik, LH; Lin, T; Pariser, D; Pillai, R; Stein Gold, L; Sugarman, JL, 2018) |
| "Psoriasis is a chronic, immune-mediated inflammatory disease characterized by localized scaling and plaques associated with itching and pain." | ( Cantrell, W; Gooding, K; Gorelick, J; Kucera, K; Veverka, KA, 2018) |
| "Psoriasis is a prevalent cutaneous condition with severe physical and psychological manifestations." | ( Curry, ZA; Feldman, SR; Heath, MS; Sahni, DR, 2018) |
| "Psoriasis is a distressing chronic skin disease." | ( Elgharib, I; Elsaid, HH; Khashaba, SA; Sharaf, MM, 2019) |
| "Psoriasis is characterized by keratinocyte hyperproliferation, erythema, as well as a form of pruritus, involving cutaneous discomfort." | ( Arkless, KL; Aubdool, AA; Brain, SD; Caton, P; Cleary, SJ; Evans, E; Kee, Z; Kodji, X; Pitchford, SC, 2019) |
| "Psoriasis is chronic inflammatory skin condition that imposes a significant physical and psychosocial burden on patients." | ( Armstrong, AW; Singh, S, 2018) |
| "Psoriasis is a chronic autoimmune disease with keratinocyte activation and lymphocyte infiltration in the skin." | ( Hsu, PY; Su, CC; Yang, HJ; Yang, TH, 2018) |
| "Psoriasis is a usual immune-mediated inflammatory skin disease with undefined pathogenesis." | ( Chen, HX; Dong, CZ; Du, ZY; Fang, YX; Li, PH; Li, YL; Liu, GR; Tang, YD; Yan, L; Zhang, K; Zhou, W, 2018) |
| "Psoriasis is an autoimmune and inflammatory skin disease affecting around 2-3% of the world's population." | ( Chen, Y; Dai, Z; Han, L; Liang, CL; Liu, H; Lu, C; Qiu, F; Zhang, Q, 2018) |
| "Psoriasis is a T-helper (Th)1/Th17-mediated chronic inflammatory disease." | ( Chandrashekar, L; Priyadarssini, M; Rajappa, M, 2019) |
| "Psoriasis is a common immune-mediated disease resulting from altered cross-talk between keratinocytes and immune cells." | ( Das Mahapatra, K; Meisgen, F; Pasquali, L; Pivarcsi, A; Sonkoly, E; Srivastava, A; Xia, P; Xu Landén, N, 2019) |
| "Psoriasis is a common skin disease pathogenically driven by TNF and IL-17A-induced epidermal hyperproliferation and inflammatory responses." | ( Auepemkiate, S; Chorachoo, J; Furnholm, T; Johnston, A; Lambert, S; Reingold, L; Roberts, L; Voravuthikunchai, SP, 2018) |
| "Psoriasis is a chronic inflammatory skin disorder that may be initiated or exacerbated by some drug intakes." | ( Badri, T; Charfi, O; El Aidli, S; Kastalli, S; Lakhoua, G; Zaïem, A, 2019) |
| "Psoriasis is a chronic inflammatory systemic disease characterized by a wide range of comorbidities." | ( Airoldi, A; Bragazzi, N; Colombo, D; Conic, R; Cristiano, A; Damiani, G; Goldust, M; Petrou, S; Pigatto, PDM; Radovanovic, D; Rizzi, M; Santus, P, 2018) |
| "Psoriasis is a common skin disorder characterized by hyperproliferation and aberrant differentiation of epidermal keratinocytes and inflammation." | ( Bao, W; Bollag, WB; Chen, X; Choudhary, V; Cohen, E; Hartney, B; Isales, CM; Patel, H; Patel, RR; Uaratanawong, R; Zhong, Q, 2019) |
| "Psoriasis is a common chronic disease with accelerated epidermal cell growth." | ( Chen, J; Chen, M; Chen, X; Huang, X; Wu, X; Zeng, W, 2019) |
| "Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population, which can lead to psoriatic arthritis." | ( Chen, C; Gettas, T; Messiah, R; Metyas, S; Quismorio, A; Tomassian, C, 2019) |
| "Psoriasis is a chronic inflammatory skin disease in which inflammatory cytokines play a major role in its pathogenesis." | ( Hara, Y; Kawada, A; Kitahata, K; Matsuo, K; Naganuma, T; Nakayama, T; Oiso, N, 2018) |
| "Psoriasis is a prevalent, chronic inflammatory skin disease that arises from rapid and excessive growth of keratinocytes induced by abnormal inflammatory responses." | ( Ba, W; Chi, S; Li, C; Wang, R; Wang, Y; Xu, Y; Yang, J; Yin, G, 2019) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disease." | ( Chen, M; Li, Y; Tang, F; Tong, M; Wen, H; Xiao, R; Zhang, G; Zhao, M, 2019) |
| "Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs." | ( Chen, W; Huang, X; Ren, G; Zuo, K, 2018) |
| "Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression." | ( Lebwohl, M; Stein Gold, L; Tanghetti, E, 2018) |
| "Psoriasis is a chronic relapsing, remitting interleukin (IL)-23/IL-17-driven skin disease mediated by the interplay of T cells and polymorphonuclear granulocytes." | ( Becher, B; Cheng, P; Conrad, C; Dummer, R; Flatz, L; Hartwig, T; Navarini, A; Schlapbach, C; Schreiner, B; Yawalkar, N; Zwicky, P, 2018) |
| "Psoriasis is a common chronic inflammatory skin disease which lacks effective strategies for the treatment." | ( Bai, J; Cai, W; Chen, L; Gao, Y; Li, Q; Lou, F; Lu, S; Niu, L; Sun, Y; Wang, H; Wang, Z; Wei, Z; Xu, Z; Yin, Q; Zhang, J; Zhou, A; Zhou, H, 2019) |
| "Psoriasis is a chronic inflammatory disorder that imposes a substantial economic burden." | ( Duvetorp, A; Engerstedt Mattsson, E; Levin, LÅ; Ryttig, L, 2019) |
| "Psoriasis is a chronic inflammatory autoimmune skin disease that often occurs in rubbed areas undergoing a strong mechanical stretch, such as the elbows and knees." | ( Dang, E; Fang, H; Guo, W; Jiang, M; Ke, Y; Qiao, H; Qiao, P; Shen, S; Wang, G; Zhang, J; Zhuang, Y, 2019) |
| "Psoriasis is a chronic inflammatory skin disorder that affects ~2%-3% of the worldwide population." | ( Catherine Jin, SL; Chang, CH; Chuang, TH; Hsu, LC; Lai, CY; Liu, YL; Lu, CH; Su, YW; Yeh, DW, 2018) |
| "Scalp psoriasis is a major therapeutic challenge due to the hindrance caused by hair." | ( Pakornphadungsit, K; Phusuphitchayanan, P; Rattanakaemakorn, P; Suchonwanit, P; Thadanipon, K, 2019) |
| "Psoriasis is a chronic hyperproliferative skin disease characterised by excessive growth of keratinocytes." | ( Chen, H; Duan, J; Duan, X; Gan, L; Liu, D; Liu, X; Lu, X; Poorun, D; Zhang, S, 2019) |
| "Psoriasis is a chronic inflammatory skin disease with unknown aetiology." | ( Aadil, W; Akhtar, T; Chopra, D; Kaur, R; Kumar, S; Narang, T; Rawat, AK, 2018) |
| "Psoriasis is an inflammatory skin disorder characterized by the hyperproliferation of basal epidermal cells." | ( Bivik Eding, C; Ekman, AK; Enerbäck, C; Rundquist, I, 2019) |
| "Nail involvement in psoriasis is common, and the severity of it does not always parallel the intensity of cutaneous disease." | ( Baran, R; Chiheb, S; Daniel, CR; Di Chiacchio, N; Gregoriou, S; Grover, C; Haneke, E; Iorizzo, M; Pasch, M; Piraccini, BM; Rich, P; Richert, B; Rigopoulos, D; Rompoti, N; Rubin, AI; Singal, A; Starace, M; Tosti, A; Triantafyllopoulou, I; Zaiac, M, 2019) |
| "Psoriasis is a chronic recurrent skin inflammatory disease, and inhibition of inflammation may be an effective means of treating psoriasis." | ( Chen, H; Dai, Z; Han, L; Huang, H; Li, L; Lu, C; Lu, Y; Wang, A; Wei, J; Zhong, X, 2019) |
| "Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3." | ( Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ, 2019) |
| "Psoriasis is a chronic inflammatory skin disease that is increasingly being recognized as a complex disorder affecting multiple systems." | ( Chiricozzi, A; Girolomoni, G; Gisondi, P, 2019) |
| "Psoriasis is a chronic skin disorder that manifests as epidermal keratinocyte hyperplasia." | ( Bo, KP; Gao, Q; Ma, AL; Ma, W; Shi, HJ; Song, HB; Wang, L; Zhang, N; Zhou, H, 2019) |
| "Psoriasis is now recognized as an immune-mediated inflammatory dermatosis with increased risk for metabolic syndrome, its individual components, and cardiovascular disease." | ( Bhushan, S; Chauhan, PS; Chauhan, S; Mahajan, VK; Mehta, KS; Sharma, A; Sharma, V; Wadhwa, D; Yadav, RS, 2019) |
| "Psoriasis is a chronic skin disease that affects approximately two per cent of the general population." | ( Droitcourt, C; Dupire, G; Hughes, C; Le Cleach, L, 2019) |
| "Psoriasis is a chronic inflammatory skin disease with unresolved pathogenesis." | ( Feng, L; Guo, M; Huang, W; Kong, L; Shao, F; Song, P; Wu, X; Xu, F; Xu, L; Xu, Q, 2019) |
| "Psoriasis is a chronic skin disease characterized by hyperproliferation and impaired differentiation of epidermal keratinocytes accompanied by increased inflammation, suggesting that molecules with antiproliferation and anti-inflammatory abilities may be effective for its treatment." | ( Cui, J; Gong, Y; Liang, C; Liu, X; Shao, C; Sun, S; Tian, F; Wang, Q; Wei, H; Wu, G; Xia, Y; Xu, B; Xu, M; Yang, G; Zhang, F; Zhang, L; Zhang, X; Zhao, H; Zhou, S; Zou, Y, 2019) |
| "Psoriasis is a chronic inflammatory skin disease arising from a complex interaction between genetics, epigenetics, the host's immune system and the environment." | ( Hirankarn, N; Meephansan, J; Reantragoon, R; Ruchusatsawat, K; Soonthornchai, W; Tangtanatakul, P; Wongpiyabovorn, J, 2021) |
| "Psoriasis is a multisystem disease affecting about 2% of the population, while keratin16 (KRT16) has been reported to participate in psoriasis." | ( Cai, TG; Chen, JG; Fan, HY; Lin, LY; Wang, T, 2019) |
| "Psoriasis is a chronic immune mediated disorder of the skin." | ( Arumugam, M; Jeyaraman, J; Nandakumar, MP; Prabhu, D; Sundarrajan, S, 2020) |
| "Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of the epidermal cells and is clinically presented as thick, bright red to pink plaques with a silvery scale." | ( Gomez, C; Muangnoi, C; Rojsitthisak, P; Sorasitthiyanukarn, FN; Wongpiyabovorn, J, 2019) |
| "Psoriasis is an autoimmune chronic dermatosis that is T cell-mediated, characterized by epidermal thickening, aberrant epidermal differentiation and inflammatory infiltrates, with a dominant Th1 and Th17 profile." | ( Lorthois, I; Morin, S; Pouliot, R; Simard, M, 2019) |
| "Psoriasis is a T helper type 17-mediated immune disease." | ( Eyerich, K; Garzorz-Stark, N, 2019) |
| "The prevalence of psoriasis is increasing, and poses a serious risk to human health and quality of life." | ( Deng, H; Fan, X; Li, F; Meng, Q; Sun, R; Yan, K; Yang, X; Yuan, D, 2019) |
| "Psoriasis is a chronic inflammatory and immune-mediated skin disease." | ( Chen, HX; Dong, CZ; Du, ZY; Gu, YH; Li, PH; Zhang, WJ; Zhao, MC, 2019) |
| "Psoriasis is a common, chronic inflammatory disease characterized by abnormal skin plaques, and the effectiveness of phosphodiesterase 4 (PDE4) inhibitor to lessen the symptoms of psoriasis has been proved." | ( Chen, W; Dong, G; Feng, C; Gu, Z; Li, H; Li, J; Li, M; Liu, H; Tang, W; Xu, Y; Zhang, R; Zhang, X; Zhu, F, 2019) |
| "Treatment of psoriasis is always difficult, which requires intensive scientific research." | ( Duan, Y; Guo, D; Guo, W; Jin, W; Mao, J; Wu, M; Xu, N; Zhang, Y; Zhou, J; Zou, J, 2019) |
| "Psoriasis is a common chronic relapsing immune-mediated inflammatory disease, the prevalence of which has increased in recent years." | ( Jiang, W; Li, B; Li, H; Li, X; Ma, T; Shen, F; Sun, X; Xie, S; Xu, W; Zheng, Q, 2019) |
| "Psoriasis is a chronic, recurrent, immune-mediated, hyperproliferative inflammatory skin disease." | ( Ataide, M; Catarino, JS; Estevam, RB; Furiati, SC; Pereira, SL; Rodrigues, DBR; Rodrigues, V; Silva, MV; Silva, RF; Teodoro, RB, 2019) |
| "Psoriasis is an immune‑mediated cutaneous disorder with a high incidence and prevalence." | ( Gao, XH; Qi, RQ; Sun, YZ; Zhang, YJ, 2019) |
| "Psoriasis is a common inflammatory skin disease." | ( Chen, H; Chen, Y; Dai, Z; Deng, J; Han, L; Huang, H; Liu, C; Liu, H; Lu, C; Wei, J; Xu, YY; Yan, Y, 2019) |
| "Psoriasis is a chronic inflammatory disease associated with multiple comorbidities, particularly in patients with arthritis or more severe forms of the disease." | ( Aguado, P; Carrascosa, JM; Daudén, E; Muñoz-Torres, M; Rivera, R, 2019) |
| "Psoriasis is an autoimmune disorder disease with pink-colored plaques and excessive proliferation which is hard to be cured completely." | ( Cao, X; Cheng, G; Cheng, X; Li, J; Piao, H; Yin, X; Zou, M, 2019) |
| "Psoriasis is a chronic inflammatory disease that affects 1." | ( Arnone, M; Azulay-Abulafia, L; Bernardo, WM; Bortoletto, MCC; Bressan, AL; Carvalho, AVE; Felix, PAO; Fieri, LC; Jaime, TJ; Magalhaes, RF; Neffá, JM; Nunes, DH; Oliveira, MFSP; Ramos, AMC; Romiti, R; Souza, CDS; Takahashi, MDF; Terena, AC, 2019) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disease, and the inflammatory response plays an important role in its development and progression." | ( Cheng, YG; Guan, W; Guo, S; Kuang, HX; Liu, Y; Tan, JY; Yang, BY, 2019) |
| "Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation." | ( Chen, J; Chen, Y; Chen, Z; Fan, H; Gu, J; Shi, Y; Wang, Y; Yu, Z; Zhang, X; Zhou, Q, 2019) |
| "Psoriasis is a common chronic inflammatory skin disease, and the infiltrated macrophages in psoriatic skin lesions play a key role in the progression of this uncontrolled cutaneous inflammation." | ( Chen, W; Deng, G; Gu, Z; Ji, X; Sun, Y; Wang, P; Wang, X; Zhan, T; Zheng, W, 2019) |
| "Psoriasis is a chronic inflammatory skin disease characterized by excessive growth of keratinocytes and hyperkeratosis in the epidermis." | ( Chen, SL; Ho, TC; Tsao, YP; Yeh, SI, 2019) |
| "Psoriasis is an immune-mediated chronic inflammatory skin disease that is seen in 1%–3% of the population." | ( Akdeniz, N; Elmas, ÖF; Kızılyel, O; Metin, MS, 2019) |
| "Psoriasis is a common chronic inflammatory multisystemic disease with a complex pathogenesis consisting of genetic, immunological, and environmental components." | ( Arenas-Guzmán, R; Carnero-Gregorio, M; Cordeiro-Rodríguez, M; Fabbrocini, G; González-Cespón, JL; López-Barcenas, A; Martínez-Herrera, E; Rodríguez-Cerdeira, C; Sinani, A, 2019) |
| "Psoriasis is a systemic disease associated with metabolic syndrome and cardiometabolic diseases." | ( Baran, A; Flisiak, I; Kiluk, P; Maciaszek, M; Myśliwiec, H; Świderska, M, 2019) |
| "Psoriasis is a severe disfiguring skin disease affecting approximately 3% of people worldwide and negatively affecting their daily lives." | ( Lin, Z; Liu, Z; Meng, S; Sun, L; Wang, L; Wang, Z; Xi, L; Zheng, Y, 2019) |
| "Psoriasis is a multifactorial systemic disease with predominantly cutaneous manifestations." | ( Giácaman-von der Weth, M; Hernández-Bel, P; Partarrieu-Mejías, F; Pérez-Ferriols, A, 2019) |
| "Psoriasis is an immune system meditated disease, especially T cells." | ( Chen, Y; Fang, W; He, S; Huang, L; Leng, Y; Li, B; Li, Y; Liu, D; Liu, G; Liu, R; Liu, X; Wang, R; Yang, Z; Ye, C; Yin, H, 2019) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Fukaya, S; Fukuyasu, A; Hayashi, K; Ishikawa, T; Kamata, M; Ohnishi, T; Shimizu, T; Tada, Y; Tanaka, T, 2019) |
| "Psoriasis is a chronic inflammatory systemic disease caused by deregulation of the interleukin-23/-17 axis that allows the activation of Th17 lymphocytes and the reprogramming of keratinocytes proliferative response, thereby inducing the secretion of cyto-/chemokines and antimicrobial peptides." | ( Bernardini, N; Calogero, A; Carlomagno, S; Chiantore, MV; Iuliano, M; Mangino, G; Potenza, C; Romeo, G; Rosa, P; Skroza, N, 2019) |
| "Psoriasis is a chronic inflammatory skin disease characterized by IL-17-mediated immune responses." | ( Dainichi, T; Egawa, G; Garcet, S; Ghosh, S; Grinberg-Bleyer, Y; Guttman-Yassky, E; Honda, T; Iwakura, Y; Kabashima, K; Kitoh, A; Krueger, JG; Matsumoto, R; Nakajima, S; Nakano, Y; Nomura, T; Otsuka, A; Otsuka, M; Sakurai, K; Sugimoto, Y; Tsuchiya, S; Yamamoto, Y, 2019) |
| "Psoriasis is a common inflammatory skin disorder with complex pathomechanisms." | ( Abdelshafey, AS; Attwa, EM; Elkot, RA; Hafez, AR, 2019) |
| "Psoriasis is a skin chronic inflammatory disease with a complex aetiology." | ( Cannavò, SP; Casciaro, M; Di Salvo, E; Gangemi, S; Riso, G, 2019) |
| "Psoriasis is an immune-mediated inflammatory skin disease that mainly affects the skin barrier." | ( Chen, H; Dai, Z; Deng, J; Han, L; Liang, CL; Liu, C; Liu, H; Lu, C; Wang, Y; Wei, J; Yan, Y, 2019) |
| "Psoriasis is commonly treated with topical corticosteroids, oral cytotoxic drugs and biologic agents, which can be associated with significant adverse effects (AEs), high cost and response attenuation." | ( Alex, P; Centola, M; Sutton, C; Sutton, L; Thomas, S; Williams, S; Yesudas, T, 2020) |
| "BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression." | ( , 2019) |
| "Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment." | ( Falques, M; Loewe, R; Mrowietz, U; Pau-Charles, I; Szepietowski, JC; van de Kerkhof, PCM, 2020) |
| "Psoriasis is a frequent systemic inflammatory autoimmune disease characterized primarily by skin lesions with massive infiltration of leukocytes, but frequently also presents with cardiovascular comorbidities." | ( Archer, NK; Bittner, Z; Businger, R; Codrea, MC; Ghoreschi, K; Grabbe, S; Heister, M; Herster, F; Heumos, S; Löffler, MW; Miller, LS; Schäkel, K; Schindler, M; Stegner, D; Weber, ANR; Wegner, J, 2019) |
| "Psoriasis is hallmarked by vascular dysfunction, arterial hypertension, and an increased risk for cardiovascular diseases." | ( Daiber, A; Karbach, SH; Knopp, T; Kossmann, S; Molitor, M; Münzel, T; Schüler, R; Waisman, A; Wenzel, P; Wild, J, 2019) |
| "Psoriasis is a common and intractable skin disease affecting the physical and mental health of patients." | ( Wang, H; Wang, W, 2019) |
| "Psoriasis is a chronic, systemic, hyper-proliferative immune-mediated inflammatory skin disease." | ( Kong, Y; Peng, D; Su, X; Su, Y; Wu, R; Zhang, S; Zhao, M, 2019) |
| "Psoriasis is a chronic dermatologic disease affecting 2% of the general population." | ( Bulut, H; Engin, B; Gökalp, E; Kutlubay, Z; Özkoca, D; Serdaroğlu, S; Songür, A; Tanakol, A; Tüzün, Y; Vehid, HE, 2020) |
| "Psoriasis is a common dermatosis causing considerable inconvenience to 4% of the general population." | ( Bao, YL; Jiang, BW; Jing, QQ; Li, WJ; Li, YX; Liu, L; Liu, YC; Song, ZB; Tan, LP; Yang, XG; Yu, CL, 2019) |
| "Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression." | ( Bhatia, ND; Green, LG; Lin, T; Martin, G; Vlahovic, TC, 2019) |
| "Psoriasis is a chronic inflammatory skin disease with a genetic and autoimmune background." | ( Allam, JP; Brendes, K; Bunzek, C; Haidl, G; Heltzel, M; Novak, N; Schnell, L; Weckbecker, L; Wilsmann-Theis, D, 2019) |
| "Psoriasis is a chronic inflammatory skin disease with numerous involved factors." | ( Abram, K; Kaldvee, B; Kingo, K; Kivihall, A; Maslovskaja, J; Mrowietz, U; Prans, E; Raam, L; Rebane, A; Runnel, T; Vaher, H; Weidinger, S, 2020) |
| "Psoriasis is an inflammatory skin disease that affects 1%-3% of Caucasian populations and may be persistent, disfiguring and stigmatising." | ( Bafutto, M; Oliveira, EC; Zaterka, S, 2019) |
| "Psoriasis is a chronic, multifactorial, inflammatory disorder, with an estimated prevalence of 0." | ( AlMutairi, N; Nour, T, 2020) |
| "Psoriasis is a multifactorial skin disease involving abnormal cell proliferation and inflammation; an efficacious topical treatment is yet to be identified." | ( Banov, D; Bassani, AS; Ip, K; Song, G; Valdez, BC, 2020) |
| "Psoriasis is caused by a complex interplay among the immune system, genetic background, autoantigens, and environmental factors." | ( Lin, X; Meng, X; Song, Z, 2019) |
| "Psoriasis is an autoregulated immune and inflammation-based skin disease affecting approximately 3-4% of the worldwide population." | ( Ai, D; Feng, S; Liu, Y; Ma, J; Yang, X, 2019) |
| "Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence." | ( Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ, 2020) |
| "Although psoriasis is a proven testing ground for treatment-response prediction using transcriptomic data from clinically accessible skin biopsies, these biopsies are expensive, invasive, and challenging to obtain from certain body areas." | ( Berstein, G; Correa da Rosa, J; Fitz, LJ; Kim, J; Krueger, JG; Lee, J; Suárez-Fariñas, M; Tomalin, LE; Valdez, H; Wolk, R, 2020) |
| "Psoriasis is considered an immune-mediated inflammatory skin disorder that affects the quality of life of nearly four percent of the world population." | ( Bao, YL; Jiang, BW; Li, YX; Liu, L; Song, ZB; Tan, LP; Wang, SY; Wang, Y; Yu, CL; Zhang, WJ, 2020) |
| "Psoriasis is a disease that commonly manifests in adolescence." | ( Eichenfield, LF; Kurvits, M; Liljedahl, M; Marcoux, D, 2020) |
| "Psoriasis is a chronic, recurrent inflammatory autoimmune skin disease." | ( Feng, H; Kong, Y; Liu, Z; Lu, Q; Su, Y; Wang, H; Wu, H; Wu, R; Zhang, S; Zhao, M, 2020) |
| "Psoriasis is a cutaneous disease mainly characterized by keratinocyte hyperproliferation, abnormal epidermal differentiation, inflammation and angiogenesis." | ( Huang, C; Le, K; Sun, Y; Wu, S; Xie, M; Xu, M; Zhao, M, 2020) |
| "Psoriasis is a chronic, immune-mediated disorder with chronic plaque psoriasis being the primary manifestation during the remission stage." | ( Chen, Z; Di, T; Duan, X; Feng, S; Guo, X; Lan, H; Li, B; Li, P; Li, W; Liu, Z; Wang, Y; Zhang, J; Zhao, J; Zhou, D, 2019) |
| "Psoriasis is a widespread chronic disease affecting 1-3 % of total population." | ( Gupta, AR; Joshi, SV; Maulvi, FA; Pandey, SS; Patel, PS; Shah, DO; Shah, KM; Shukla, MR, 2020) |
| "Psoriasis is an autoimmune skin disease caused by interactions between keratinocytes and immune cells, such as macrophages." | ( Hu, J; Jin, X; Li, D; Tang, L; Wang, Y; Xia, C; Xu, H, 2020) |
| "Psoriasis is an autoimmune skin disease, where hyperproliferation of keratinocytes and exaggerated immune responses are the important hallmarks of the disease." | ( Godugu, C; Pooladanda, V; Thatikonda, S, 2020) |
| "Psoriasis is a chronic, inflammatory skin disease with high incidence and high rates of relapse, for which no satisfactory treatments are currently available." | ( Chen, D; Jia, J; Li, H; Lin, Y; Liu, J; Mo, X; Wang, N; Yan, F; Zheng, Y, 2020) |
| "Psoriasis is a common inflammatory skin disorder that is characterized by keratinocyte hyperproliferation and abnormal differentiation, resulting in the thickening of the epidermis and stratum corneum." | ( Hiebert, P; Kim, TG; Kim, YS; Lee, J; Song, K; Werner, S, 2020) |
| "Psoriasis is a T cells mediated chronic skin inflammation in which helper T (Th) cells play in critical roles in its pathogenesis." | ( Du, Z; Li, N; Lu, C; Wu, D; Yuan, X; Zhang, M; Zhu, W, 2020) |
| "Psoriasis is a refractory skin disease characterized by macrophage cell infiltrated in the dermal layer." | ( Chen, H; Han, L; Li, L; Lu, C; Lu, Y; Wei, J; Zhang, HY; Zhong, XQ, 2020) |
| "Psoriasis is a skin disorder characterized by epidermal hyperplasia, hyperkeratosis, and inflammation." | ( Bélanger, A; Gendreau, I; Grenier, A; Legault, J; Pichette, A; Pouliot, R; Simard, F, 2019) |
| "Psoriasis is an autoimmune skin disease, where chronic immune responses due to exaggerated cytokine signaling, abnormal differentiation, and evasion of keratinocytes apoptosis plays a crucial role in mediating abnormal keratinocytes hyperproliferation." | ( Godugu, C; Pooladanda, V; Sigalapalli, DK; Thatikonda, S, 2020) |
| "Palmoplantar psoriasis is a localised variant of psoriasis." | ( Andanooru Chandrappa, NK; Channakeshavaiah Ravikumar, B; Rangegowda, SM, 2020) |
| "Psoriasis is an autoinflammatory/autoimmune skin disease and the epitome of an exaggerated primary inflammatory response in the surface barrier tissue." | ( Fujimoto, M; Fujisawa, Y; Furuta, J; Inoue, S; Ishitsuka, Y; Nakamura, Y; Ogawa, T; Okiyama, N; Saito, A; Watanabe, R, 2020) |
| "Psoriasis is an unchecked chronic inflammation characterized by thick, erythematous, and scaly plaques on the skin." | ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A, 2020) |
| "Many patients with psoriasis are bothered by symptoms in highly visible, pruritic areas, such as the scalp." | ( Cauthen, A; Lebwohl, M; Lynde, C; Paris, M; Sofen, H; Stein Gold, L; Strober, B; Tyring, S; Van Voorhees, AS; Wang, Y; Zhang, Z, 2020) |
| "Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment." | ( Bentley, MVLB; Caron, AL; Del Ciampo, JO; Kravicz, M; Medina, WSG; Praça, FG; Silvestrini, AVP; Suzuki, I; Viegas, JSR, 2020) |
| "Psoriasis is a chronic immune-mediated skin disease, with a pathogenesis resulting from a combination of genetic and environmental factors." | ( Ascenso, A; Martins, AM; Marto, J; Ribeiro, HM, 2020) |
| "Psoriasis is a common autoimmune and chronic inflammatory skin disorder globally affecting 0." | ( Chen, H; Duan, X; Huang, Y; Jin, Z; Liu, N; Liu, X; Ming, Z; Zhang, S, 2020) |
| "Psoriasis is a common non-contagious chronic inflammatory skin lesion, with frequent recurrence." | ( Chang, DC; Hsiao, CY; Hung, CF; Li, HJ; Pu, CM; Wu, NL, 2020) |
| "Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population." | ( Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ, 2020) |
| "Psoriasis is a chronic inflammatory skin disease characterized by dysregulated keratinocyte differentiation, but oxidative stress also plays an important role in the pathogenesis of this disease." | ( Biernacki, M; Gęgotek, A; Jarocka-Karpowicz, I; Skrzydlewska, E; Wroński, A, 2020) |
| "Psoriasis is a skin inflammatory disorder that affects 3% of the human population." | ( Cayuela, ML; Corbalán-Vélez, R; García-Moreno, D; López-Muñoz, A; Martínez-Menchón, T; Martínez-Morcillo, FJ; Martínez-Navarro, FJ; Mulero, V; Pardo-Sánchez, I; Pérez-Oliva, AB, 2020) |
| "Psoriasis is a chronic immune-mediated inflammatory dermatosis." | ( Cheng, H; Cheng, Q; Ding, S; Dou, J; Gao, L; Guo, A; Lei, L; Lu, J; Luo, Z; Tan, L; Yang, C; Zeng, J; Zeng, Q; Zhang, B, 2020) |
| "Psoriasis is a common non-communicable chronic immune-mediated skin disease, affecting approximately 125 million people in the world." | ( Ascenso, A; Martins, AM; Marto, J; Ribeiro, HM, 2020) |
| "Psoriasis is clinically characterized by well-demarcated silvery plaques which may appear on the extremities, scalp, and sacral area." | ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; Alqahtani, F; Alzahrani, KS; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Mahmood, HM; Nadeem, A, 2020) |
| "Psoriasis is a common inflammatory skin condition, affecting 2-4% of the worldwide population." | ( Bianchi, L; Campione, E; Cesaroni, GM; Chiaramonte, C; Chimenti, MS; Cosio, T; Dattola, A; Galluzzo, M; Gaziano, R; Gisondi, P; Lanna, C; Mazzilli, S; Palumbo, V; Zangrilli, A, 2020) |
| "Psoriasis is a skin disease characterized by abnormal keratinocyte proliferation and inflammation." | ( Civelli, M; Facchinetti, F; Pambianchi, E; Sticozzi, C; Valacchi, G; Villetti, G; Woodby, B, 2020) |
| "Psoriasis is an inflammatory skin disease associated with itch, which is a troublesome symptom with a few therapeutic options." | ( Berta, T; Choi, Y; Jung, SJ; Lee, SH; Tonello, R, 2020) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disease and highly depends on inflammation and angiogenesis as well as other pathways." | ( Cheng, Y; Guan, W; Jiang, P; Kuang, H; Liu, Y; Sun, Y; Tan, J; Yang, B, 2020) |
| "Psoriasis is a chronic recurrent inflammatory disease." | ( Chang, W; Hou, R; Jiao, J; Li, J; Li, X; Liang, N; Liang, Y; Wang, Y; Xing, J; Zhang, K, 2020) |
| "Psoriasis is a chronic inflammatory skin disease with unclear pathogenesis." | ( Chen, J; Chen, R; Chen, Y; Chen, Z; Cui, L; Diao, H; Gong, Y; Hu, Y; Shi, Y; Wang, Y; Yu, Q; Yu, Y; Zhang, X, 2020) |
| "Psoriasis is a persistent and recurrent chronic inflammatory skin disease that is characterized by inflammation and increased proliferation of keratinocytes." | ( Deng, X; Li, Q; Wang, J; Wu, X, 2020) |
| "Psoriasis is a chronic autoinflammatory disorder characterized by patches of abnormal skin." | ( Aydın, A; Erol, İ; Orak, D; Özer, Ö; Sipahi, H; Üstündağ Okur, N, 2020) |
| "Chronic plaque psoriasis is an immune-mediated, chronic, inflammatory skin disease, which can impair quality of life and social interaction." | ( Chan, D; Chan, T; Gambichler, T; Harari, M; Labeit, AM; Peinemann, F; Peternel, S, 2020) |
| "Psoriasis is a systemic immune-mediated disease for which MSCs could have therapeutic potential." | ( Benassi, L; Kaleci, S; Magnoni, C; Paganelli, A; Tarentini, E, 2020) |
| "Psoriasis is a chronic inflammatory autoimmune skin condition that affects millions of people worldwide." | ( Angelatos, AS; King, NJC; Macia, L; Mazur, E; Niewold, P; Pinget, GV; Tan, J, 2020) |
| "Psoriasis is one of the common chronic inflammatory skin diseases in which inflammatory cytokines such as IL-17 and TNF-α play critical roles." | ( Matsushima, Y; Mizutani, K; Okada, K; Yamanaka, K, 2020) |
| "Scalp psoriasis is common in psoriasis patients, difficult to treat and manifests a significant burden on quality of life." | ( Alsenaid, A; Ezmerli, M; Heppt, M; Illigens, BM; Prinz, JC; Srour, J, 2022) |
| "Psoriasis is a chronic disease and often requires long-term treatment, especially in patients with moderate-to-severe psoriasis." | ( Chen, M; Lian, N; Liu, L; Shi, L, 2020) |
| "Psoriasis is characterized by excessive growth and aberrant differentiation of epidermal keratinocytes due to persistent inflammation." | ( Hara, T; Ishido, Y; Ishii, N; Kambara, T; Kawashima, A; Luo, Y; Suzuki, K; Suzuki, S, 2020) |
| "Psoriasis is a common chronic inflammatory skin disorder that is associated with excess cardiovascular risk." | ( Blankstein, R; Brown, JM; Di Carli, M; Divakaran, S; Dorbala, S; Liao, K; Merola, JF; Perez-Chada, LM; Taqueti, V; Weber, B, 2022) |
| "Psoriasis is a common, chronic multifactorial inflammatory skin disease with both genetic and environmental components." | ( Di, T; Fu, J; Guo, J; Li, N; Li, P; Meng, Y; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "Psoriasis is a common chronic skin disease characterized by epidermal proliferation and inflammation." | ( Ding, Y; Li, Y; Lu, J; Shi, Y; Xu, X; Yu, N, 2020) |
| "Psoriasis is a chronic relapsing inflammatory and hyperproliferative skin disease affecting quality of life." | ( Awasthi, R; Jindal, S; Kulkarni, GT; Singhare, D, 2020) |
| "Psoriasis is a chronic immune-mediated inflammatory skin disease without effective treatment." | ( Du, YZ; Huang, QL; Lu, KJ; Qi, J; Shu, GF; Sun, MC; Tan, WQ; Wang, W; Xu, XL, 2020) |
| "Psoriasis is a chronic inflammatory skin condition known to affect about 1%-3% of the global population." | ( D, S; Dogra, S; Rajagopalan, M, 2020) |
| "Psoriasis is a common chronic inflammatory skin disease." | ( Cao, M; Chen, CY; Li, B; Li, H; Li, X; Ma, T; Peng, S; Sun, X; Zhou, Y; Zhu, B, 2020) |
| "Psoriasis is a recrudescent chronic immune-mediated inflammatory dermatosis; the production and release of proinflammatory cytokines/chemokines such as TNF-α has been regarded as critical issues during psoriasis pathogenesis." | ( Huang, P; Luomei, J; Peng, Y; Wang, H; Zhang, Y; Zhou, R, 2020) |
| "Psoriasis is a very common chronic inflammatory skin disease affecting up to 3% of the general population with 75% of the psoriasis subjects being affected by a mild form of disease." | ( Camela, E; Cinelli, E; Fabbrocini, G; Megna, M, 2020) |
| "Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population worldwide." | ( Fang, H; Gao, J; Guo, J; Mi, J; Mo, W; Nong, Y; Qi, Q; Yang, M, 2020) |
| "Psoriasis is a chronic immune-mediated inflammatory cutaneous disorder with Th17 cells and Th17-related cytokines playing an important role in its development." | ( Lane, JA; Lei, K; Li, Y; Lin, L; Sun, L; Wang, D; Zeng, J; Zhang, L; Zuo, D, 2020) |
| "Psoriasis is a chronic, systemic disease with features suggestive of autoimmune dysregulation." | ( Abramovits, W; Schlessinger, J, 2020) |
| "Psoriasis is a chronic inflammatory disease whose etiology is multifactorial." | ( Bai, J; Cai, X; Chen, X; Deng, S; Ginhoux, F; Gu, J; Li, Q; Liu, Z; Lou, F; Niu, L; Shi, YL; Sun, L; Sun, Y; Tao, W; Wang, H; Wang, Z; Wu, Z; Xu, Z; Yin, Q; Zhou, H, 2020) |
| "Psoriasis is a chronic relapsing inflammatory skin disease, affecting up to 3% of the global population." | ( Gao, WW; Li, GQ; Liang, SJ; Sun, DD; Wang, T; Wu, S; Xu, F; Xu, GL; Yang, Y; Zheng, QY; Zhong, Y, 2020) |
| "Psoriasis is a common inflammatory skin disease characterized by hyperproliferation of epidermal keratinocytes, however, there is still no curative therapy for psoriasis." | ( Bai, X; Dang, E; Luo, Y; Wang, G; Yang, L; Yu, C; Zhi, D, 2020) |
| "Psoriasis is an autoimmune disease of the skin with lapsing episodes of hyperkeratosis, irritation, and inflammation." | ( Dadwal, A; Mishra, N; Narang, RK, 2021) |
| "Psoriasis is a chronic inflammatory skin disease that is thought to affect ∼2% of the global population." | ( Brain, SD; Caton, PW; Evans, EA; Frame, J; Hannen, RF; Kodji, X; Philpott, MP; Rizvi, A; Sayers, SR; Shaikh, M; Xia, Y, 2020) |
| "Psoriasis is a chronic inflammatory disease that can be effectively treated using topical cyclosporine." | ( Chen, H; Li, F; Li, Q; Qi, X; Wang, T; Wei, F, 2020) |
| "Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation and abnormal differentiation of epidermal keratinocytes accompanied by increased infiltration of immune cells." | ( Choi, YA; Jang, YH; Kang, J; Kim, N; Kim, SH; Kwon, TK; Lee, B; Lee, S, 2020) |
| "Psoriasis is a prevalent chronic inflammatory skin disease characterized by thickening of the epidermis accompanied by lesional erythema, scaling, and induration as a result of abnormal proliferation of keratinocytes." | ( Jon, S; Jung, W; Keum, H; Kim, D; Kim, J; Kim, TW; Kim, Y; Seo, C; Son, Y; Whang, CH, 2020) |
| "Psoriasis is a common immune-mediated, chronic inflammatory genetic-related disease that affects patients' quality of life." | ( Chen, C; Chen, X; Kuang, Y; Lei, L; Li, J; Liu, P; Peng, C; Tan, L; Zhu, W, 2020) |
| "Psoriasis is an inflamed skin disorder associated with the activation of phosphorylation signals in keratinocytes, which leads to proliferation." | ( Anbardar, MH; Chavoshy, F; Tamaddon, AM; Zadeh, BSM, 2020) |
| "Psoriasis is a chronic inflammatory skin disease characterized by well‑defined scaly papules and plaques." | ( Gao, XH; Geng, L; Guo, H; Lan, XO; Qi, RQ; Wang, HX; Xu, YY; Yang, Y; Yu, YJ, 2020) |
| "Nail psoriasis is also considered a risk factor for the development of psoriatic arthritis (PsA)." | ( Azad, J; Takwale, A; Thomas, L, 2021) |
| "Psoriasis is a pathological condition characterized by immune system dysfunction and inflammation." | ( Andrys, C; Beranek, M; Borska, L; Borsky, P; Fiala, Z; Hamakova, K; Holmannova, D; Krejsek, J; Malkova, A; Palicka, V; Rehacek, V; Svadlakova, T, 2020) |
| "Psoriasis is a lifelong disease and its prevalence in older adults continues to increase as the population ages." | ( Kalb, RE; Shary, N, 2020) |
| "Psoriasis is an immune-mediated inflammatory disease in which the Th17 pathway is mainly involved." | ( Castex-Rizzi, N; Cousy, A; Lestienne, F; Mengeaud, V; Nguyen, T, 2020) |
| "Psoriasis is a common inflammatory skin disease." | ( Chen, YF; Liu, SG; Luo, GP; Qu, YB, 2020) |
| "Psoriasis is a severe disease associated with the disturbance of metabolism and inflammation, but the molecular mechanisms underlying these aspects of psoriasis pathology are poorly understood." | ( Cao, G; Deng, L; Gao, Y; Guo, C; Hao, J; Li, P; Li, Z; Song, Y; Sun, G; Tian, Y; Wang, X; Xia, X; Yin, Z; Zhang, H; Zhong, J; Zhou, W; Zhu, L, 2020) |
| "Introduction: Psoriasis is a chronic, immune-mediated skin disease that is associated with sex-related differences." | ( Cook-Bolden, FE; Guenthner, ST; Hebert, AA; Jacobson, A; Kang, R; Martin, G, 2020) |
| "Psoriasis is a common skin inflammatory disease." | ( Cai, S; Chen, H; Chen, L; Dong, L; Gong, F; Li, B; Li, J; Mao, J; Qian, Y; Shi, J; Tan, Z; Xiao, Y; Xu, Y; Zeng, F; Zheng, F, 2021) |
| "Psoriasis is a chronic, recurrent skin disease requiring long-term management." | ( Chen, K; Gu, H; Guo, Z; He, C; Jin, H; Li, X; Song, Y; Xiong, L; Xu, AE; Xu, J; Yang, Q; Yu, W; Zhang, J; Zhang, L; Zheng, J, 2020) |
| "Psoriasis is a chronic inflammatory disease affecting ~2-3% of the Australasian population." | ( Baker, C; Cains, GD; Dolianitis, C; Doolan, BJ; Foley, P; Koye, D; Ling, J, 2021) |
| "Psoriasis is linked to systemic inflammation and cardiovascular comorbidities, but studies of the underlying cellular mechanisms are lacking." | ( Bivik Eding, C; Enerbäck, C; Fekri, SZ; Sandin, C; Sigurdardottir, G; Verma, D, 2021) |
| "Psoriasis is considered as a common chronic immune-mediated skin disorder characterized by abnormal keratinocyte proliferation." | ( Du, J; Du, Z; Hu, J; Hu, M; Liu, Q; Xiang, Z; Zang, X; Zhang, L; Zhou, W, 2020) |
| "Psoriasis is associated with increased production of reactive oxygen species which leads to oxidative stress." | ( Garley, M; Jabłońska, E; Skrzydlewska, E; Wójcik, P; Wroński, A, 2020) |
| "The pathogenesis of psoriasis is still not fully understood." | ( Geng, Y; Li, J; Weng, Z; Wu, H; Xu, X; Zhou, X; Zhu, X, 2020) |
| "Psoriasis is a highly prevalent chronic dermatitis, characterized by widespread skin inflammation and spontaneous itch." | ( Huang, X; Mei, Z; Wang, H; Wang, W; Xiong, H; Zhao, Z, 2020) |
| "Psoriasis is a common chronic inflammatory skin condition manifested by T cell responses and characterized by preferential recurrence at previously inflamed sites upon withdrawal of treatment." | ( Cowin, AJ; Fenix, K; Grubor-Bauk, B; Kopecki, Z; Wijesundara, DK, 2020) |
| "Psoriasis is characterized by keratinocyte hyperproliferation." | ( Dang, E; Ke, Y; Lei, J; Shao, S; Shen, S; Wang, G; Yang, L; Zhang, C; Zhang, T; Zhu, Z, 2020) |
| "Psoriasis is a chronic, inflammatory, and multifactorial dermatosis that impairs quality of life (QoL)." | ( Andrianarison, M; Raharolahy, O; Rakotoarisaona, MF; Rakotonaivo, NA; Ramarozatovo, LS; Ranaivo, IM; Rapelanoro, RF; Ratovonjanahary, V; Razanakoto, NH; Sata, M; Sendrasoa, FA, 2020) |
| "Psoriasis is a skin disease that is accompanied by oxidative stress resulting in modification of cell components, including proteins." | ( Karabowicz, P; Ostrowska, H; Skrzydlewska, E; Waeg, G; Wroński, A; Zarkovic, N, 2020) |
| "Psoriasis is a highly prevalent inflammatory skin disease." | ( Chen, B; Jing, H; Kuang, Z; Li, L; Liu, J; Liu, Y; Qiu, X; Sun, T; Wang, L; Wu, D; Wu, M; Wu, W; Wu, Y; Wu, Z; Yi, S; Zhou, S, 2020) |
| "Psoriasis is mainly caused because of inappropriate immune responses in the epidermis." | ( Ampawong, S; Aramwit, P; Buaban, T; Kanjanapruthipong, T; Kengkoom, K; Muangkaew, W; Sukphopetch, P, 2020) |
| "Psoriasis is a common chronic inflammatory skin disease." | ( Chen, F; Fang, H; Gao, J; Mi, J; Qi, Q; Yang, M, 2020) |
| "Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferative keratinocytes and immune cell infiltration into the skin, often accompanied by itch." | ( Bäumer, W; Brehm, R; Bruer, G; Gutzmer, R; Kietzmann, M; Langeheine, M; Rode, K; Rossbach, K; Schaper-Gerhardt, K; Wahle, K; Werfel, T, 2020) |
| "Psoriasis is a chronic immune-mediated inflammatory skin disease that easily recurs and is difficult to cure." | ( Bian, G; Chen, Z; Deng, S; Feng, H; Li, Y; Wang, L; Wang, Y; Xie, Q; Yu, Y, 2021) |
| "Psoriasis is a chronic inflammatory skin disorder in humans, and the inflammatory reaction plays an important role in development and onset of psoriasis." | ( Fu, J; Li, P; Wang, Y; Zeng, Z; Zhang, L, 2020) |
| "Psoriasis is a common chronic inflammatory skin disease with 2% to 3% prevalence worldwide and a heavy social-psychological burden for patients and their families." | ( Dang, EL; Fu, M; Qiao, HJ; Wang, G; Xiao, CY; Zhang, C; Zhu, ZL, 2020) |
| "Psoriasis is a common inflammatory skin disease that starts before the age of 40 years in 3/4 cases." | ( Brenaut, É, 2020) |
| "Psoriasis is not only a chronic inflammatory skin disease but also a psychosomatic disorder." | ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "The diagnosis of psoriasis is mainly made by clinical examination but on some occasions according to the localization or duration of the lesions when spongiosis is more prominent, it can be challenging and may be considered as overlapping eczema." | ( Karadag, AS; Topaloglu Demir, F; Uzunçakmak, TK; Zemheri, E, 2021) |
| "Psoriasis is a chronic inflammation resulting from interactions between immunological and genetic factors." | ( Bieniek-Kobuszewska, M; Maciejewska-Radomska, A; Owczarczyk-Saczonek, A; Placek, W; Wojtacha, P, 2022) |
| "Psoriasis is a common inflammatory skin disease characterized by aberrant inflammation and epidermal hyperplasia." | ( Atwood, S; Chen, Z; Dai, X; Dragan, M; Greenberg, E; Gutierrez, G; Haensel, D; Han, W; Kessenbrock, K; Nguyen, Q; Pearlman, E; Shi, Y; Sun, P; Vu, R; Wu, J, 2021) |
| "Psoriasis is an incurable chronic inflammatory skin disorder." | ( Lou, F; Sun, Y; Wang, H, 2020) |
| "Psoriasis is an immune-mediated chronic inflammatory disease." | ( Chen, C; Chen, X; Hou, G; Peng, C; Ren, Y; Zeng, C, 2021) |
| "Psoriasis is the most prevalent inflammatory skin disorders, affecting 1-3% of the worldwide population." | ( Cao, S; Chen, L; He, S; Huang, Y; Lin, Z; Liu, Y; Tang, W; Yang, X; Zhu, F; Zuo, J, 2021) |
| "Psoriasis is a chronic inflammatory skin disease characterized by a skewed interleukin-17 immune response and dysregulated epidermal hyperproliferation and differentiation." | ( Hoashi, T; Kanda, N; Saeki, H; Serizawa, N, 2020) |
| "Psoriasis is a challenging skin disorder due to its chronicity, high rate of prevalence, disability, comorbidity and disfiguration." | ( Easwari, TS; Singh, A, 2021) |
| "Psoriasis is an immune disorder-related inflammatory skin disease." | ( Hayashi, M; Murayama, T; Otake, S; Otsubaki, T; Ueda, Y; Uesato, N, 2021) |
| "As psoriasis is an inflammatory disorder, we analyzed tissue infiltrating immune cells and cytokine production." | ( Chao, T; Gu, Y; He, L; Huang, R; Jia, T; Kong, E; Li, W; Liang, Y; Liu, Q; Liu, Z; Lu, L; Maeda, T; Pierre, P; Tian, S; Wang, Y; Yang, W; Zhang, L; Zhou, B, 2020) |
| "Psoriasis is a refractory inflammatory skin disease affecting 2 %-3 % of the world population, characterized by the infiltration and hyper-proliferation of inflammatory cells and aberrant differentiation of keratinocytes." | ( Bai, C; Chen, H; He, X; Huang, Z; Lei, Y; Li, Y; Liu, Z; Sheng, L; Tang, L; Tian, X; Wei, F; Xu, X; Yang, Y; Yu, B; Zhang, B; Zhou, X, 2021) |
| "Psoriasis is an autoimmune, inflammatory disease that needs a reliable animal model." | ( Badanthadka, M; D'Souza, L; Salwa, F, 2021) |
| "Plaque psoriasis is a chronic disease requiring long-term therapy." | ( Feldman, SR; Lopez-Gonzalez, L; Marchlewicz, EH; Martinez, DJ; Mendelsohn, AM; Shrady, G; Zhang, J; Zhao, Y, 2021) |
| "Psoriasis is a disease with a proinflammatory base, in which an increased expression of leptin, tumor necrosis factor alpha (TNF-α), interleukin (IL) IL-12/23, IL-6, is observed." | ( Adwent, I; Brus, R; Grabarek, BO; Kasela, T; Zawidlak-Węgrzyńska, B, 2021) |
| "Psoriasis is a chronic skin disease associated with T helper (Th)17-mediated inflammation." | ( Arima, Y; Hara, Y; Ito, M; Iwama, A; Kaibori, Y; Kamiyama, F; Kawada, A; Kitahata, K; Matsuo, K; Nagakubo, D; Nakayama, T; Oiso, N; Quan, YS; Yoshie, O, 2021) |
| "Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups." | ( Del Rosso, JQ; Desai, SR; Glick, B; Harris, S; Jacobson, A, 2021) |
| "Psoriasis is a chronic inflammatory disease associated with obesity and metabolic syndrome." | ( Akaslan, TÇ; Bulut, H; Gülcan, AS; Onsun, N; Sallahoglu, K; Yabacı, A, 2022) |
| "Psoriasis is a chronic inflammatory skin disease mediated by immunity." | ( Ji, WL; Kuai, L; Li, B; Luo, Y; Qu, KS; Ru, Y; Song, JK; Xing, M; Yan, XN, 2021) |
| "Nail psoriasis is a common and potentially debilitating condition for which no effective and safe nonsystemic therapy is currently available." | ( Artzi, O; Ellenbogen, E; Matz, H; Shehadeh, W; Sprecher, E, 2021) |
| "Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and expression of pro-inflammatory cytokines in the epidermis." | ( Gendrisch, F; Haarhaus, B; Krieger, N; Quirin, KW; Schempp, CM; Wölfle, U, 2021) |
| "Psoriasis is a chronic and relapsing disorder with considerable negative effects on patients' quality of life." | ( Jin, M; Li, H; Li, S; Wang, H; Xu, Y, 2021) |
| "Psoriasis is an immune-mediated skin disease for which the crosstalk between genetic and environmental factors is responsible." | ( Arase, N; Fujimoto, M; Hirata, J; Inohara, H; Kishikawa, T; Kumanogoh, A; Maeda, Y; Masuda, T; Nii, T; Ogawa, K; Ohshima, S; Okada, Y; Suzuki, K; Tsuji, S; Yamamoto, K, 2021) |
| "Psoriasis is a chronic autoimmune skin disease characterized by hyperproliferation of keratinocytes." | ( Devabattula, G; Gangadevi, V; Godugu, C; Pooladanda, V; Thatikonda, S, 2021) |
| "Psoriasis is a chronic disease requiring long-term treatment strategies." | ( Gold, M; Gooderham, M; Kircik, LH; Lacour, JP; Laws, P; Liljedahl, M; Lynde, C; Mørch, MH; Sondermann, W; Thaçi, D; Warren, RB, 2021) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Asano, Y; Kamata, M; Mitsui, A; Okura, I; Sato, S; Shimizu, T; Tada, Y, 2021) |
| "Psoriasis is a chronic inflammatory skin disease, in which the key features are epidermis hyperplasia, hyper-keratinization, leading to low drug absorption." | ( Cui, Y; Fei, WM; Guo, XD; Hao, YY; Liang, L; Zhang, C; Zhao, ZQ, 2021) |
| "Psoriasis is a chronic, immune-mediated skin disease." | ( Bortoletto, MC; da Costa, AC; Oyafuso, LKM; Rocha, ACL; Sanudo, A; Tomita, LY, 2022) |
| "Psoriasis is a long-lasting inflammatory skin disease lacking proper cure." | ( Chang, SH; Chen, YL; Hsieh, PS; Hsieh, PW; Hwang, TL; Korinek, M; Wu, YH, 2021) |
| "Scalp psoriasis is often undiagnosed or inadequately treated." | ( Alessandrini, A; Bruni, F; Orlando, G; Piraccini, BM; Starace, M, 2021) |
| "Psoriasis is a chronic inflammatory skin disease without cure." | ( Gago-López, N; Lagunas Arnal, C; Perez, JJ; Wagner, EF, 2021) |
| "Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pustular or erythrodermic." | ( Barker, JN; Mahil, SK; Raharja, A, 2021) |
| "Psoriasis is a life-threatening autoimmune inflammatory skin disease, triggered by T lymphocyte." | ( Biswasroy, P; Ghosh, G; Kar, B; Pradhan, D; Rath, G, 2021) |
| "Psoriasis is a chronic inflammatory disorder of the skin and is characterized by hyper-dividing keratinocytes." | ( Evan Prince, S; Hiraganahalli Bhaskarmurthy, D, 2021) |
| "Psoriasis is one of the most influential and fastest-growing inflammatory diseases of the skin." | ( Ding, W; Li, F; Qiu, B; Yang, C; Yu, F; Zhang, Y, 2021) |
| "Psoriasis is a chronic, inflammatory skin disease." | ( Chang, L; Fujita, Y; Hashimoto, K; Hashimoto, Y; Ishima, T; Matsue, H; Shinno-Hashimoto, H; Wei, Y, 2021) |
| "Psoriasis is chronic incurable skin inflammation." | ( Cai, MH; Chen, LL; Chen, XJ; Guo, LC; Shi, F; Wu, J; Wu, L; Zhu, HY; Zhu, WD, 2022) |
| "Psoriasis is a chronic inflammatory skin disease with abnormal epidermal proliferation." | ( Cui, Q; Dang, E; Lai, B; Li, F; Luo, W; Wang, G; Wang, N; Xiao, L; Xie, X; Zheng, Y, 2021) |
| "Psoriasis is a chronic and relapsing inflammatory skin disease lacking a cure that affects approximately 2% of the population." | ( Cabré, G; Ciruela, F; Filgaira, I; Hernando, J; Jacobson, KA; López-Cano, M; Nolen, EG; Soler, C; Tosh, DK, 2021) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disease, affecting approximately 2% of the general population, which can be accompanied by psoriatic arthritis (PsA)." | ( Pretorius, E; Roberts, TJ; Tarr, G; Venter, C; Visser, MJE, 2021) |
| "Psoriasis is a most common chronic autoimmune-arbitrated cutaneous inflammatory skin disorder by unclear pathogenesis." | ( Alavala, S; Jerald, MK; Nalban, N; Sangaraju, R; Sistla, R, 2021) |
| "Psoriasis is an immune-mediated skin disorder that affects populations worldwide." | ( Pang, M; Tang, Y; Wang, M; Wang, W; Wang, Y; Xu, Y; Yang, X, 2021) |
| "Psoriasis is a chronic inflammatory skin disease that is characterized by well-demarcated erythematous plaques with a silver scale." | ( Aylı, M; Caliskan, E; Coban, SN; Esme, P; Ugur, B, 2021) |
| "Psoriasis is a skin disease with autoimmune tendency, and taxifolin is an effective flavonoid with anti-inflammatory activity." | ( Chen, Z; Di, T; Li, P; Wang, Y; Zhai, C; Zhao, J, 2021) |
| "Psoriasis is a chronic inflammatory skin disease in which IL-17‒producing T helper 17 cells play a crucial role." | ( Bartolomaeus, T; Birukov, A; Boschmann, M; Brand, A; Clausen, BE; Dechend, R; Forslund, SK; Gimenez-Rivera, VA; Jung, R; Karbach, S; Karlsen, TV; Kelm, M; Kleinewietfeld, M; Kokolakis, G; Krause, A; Kuehne, T; Kurschus, FC; Linz, P; Luft, FC; Maifeld, A; Markó, L; Müller, DN; Philipp, S; Rakova, N; Schultheis, M; Waisman, A; Wegner, J; Wiig, H; Wilck, N; Wild, J; Wistorf, E, 2022) |
| "psoriasis is a chronic inflammatory skin disease." | ( Chen, Z; Di, T; Guo, X; Han, L; Han, X; Li, P; Lu, C; Wang, Y; Zhao, J, 2021) |
| "Psoriasis is a systemic immune‑mediated inflammatory disease characterized by uncontrolled keratinocyte proliferation and poor differentiation." | ( Ding, Z; Liu, J; Lv, M; Qian, H; Wu, L, 2021) |
| "Psoriasis is a chronic inflammatory skin disease prevalent in patients with chronic disease." | ( Han, KD; Kim, M; Lee, JH; Lee, SH, 2021) |
| "Psoriasis is a chronic immune-mediated disease characterized by excessive proliferation of epidermal keratinocytes and increased immune cell infiltration to the skin." | ( Bian, L; Blevins, M; Deng, H; Fan, B; Fujita, M; Han, G; High, W; Huang, M; Li, H; Norris, D; Wang, XJ; Yang, C; Zhang, C; Zhao, R, 2022) |
| "Psoriasis is a chronic inflammatory skin disease characterized by abnormal proliferation and differentiation of keratinocytes." | ( Jiang, F; Liu, J; Lv, M; Shao, J, 2021) |
| "Psoriasis is an autoimmune, inflammatory and chronic skin disease in which cell growth and proliferation are increased, causing erythema, lesions and skin's peeling." | ( Agostini, SBN; Bernardes, MTCP; Bruschi, ML; Carvalho, FC; da Silva, JB; da Silva, LP; Novaes, RD; Pereira, GR, 2021) |
| "Psoriasis is a common chronic skin condition, which is an immune-related hyperproliferative disorder." | ( Al Salman, M; Azizpour, A; Farid, AS; Ghiasi, M; Mahmoudi, H; Taraz, M, 2021) |
| "Psoriasis is one of the most common chronic inflammatory diseases that is characterized by well-defined erythematous plaques, with typical histopathological findings of lymphocytic infiltration and epidermal hyperplasia." | ( Chan, TC; Chang, WY; Huang, WC; Krueger, JG; Lee, MS; Tsai, TF, 2021) |
| "While psoriasis is a Th17-mediated disease, how immune cells are affected by the modulation of cellular metabolism is not fully evaluated, either." | ( Fujimoto, M; Fujisawa, Y; Furuta, J; Inoue, S; Ishitsuka, Y; Koguchi-Yoshioka, H; Matsumura, Y; Matsuzaka, T; Nakamura, Y; Okiyama, N; Shimano, H; Watanabe, R, 2021) |
| "Psoriasis is a common autoimmune inflammatory skin disease, with no clear cause, treated with topical agents and phototherapy, conventional immunosuppressant drugs and biologic agents." | ( Abdel Hamid, HF; Amin, MA; Attia, SS; El-Nefiawy, NE; Fetouh, MA; Rafla, M, 2022) |
| "Psoriasis is a common, inflammatory autoimmune skin disease." | ( Estadt, SN; Gharaee-Kermani, M; Gruszka, D; Gudjonsson, JE; Kahlenberg, JM; Liu, J; Lowe, L; Reed, TJ; Theros, J; Tsoi, LC; Ward, NL; Wolf-Fortune, SJ; Xing, X, 2022) |
| "Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines." | ( Ivanic, MG; Liao, W; Thatiparthi, A; Walia, S; Wu, JJ, 2021) |
| "Psoriasis is a common chronic inflammatory skin disorder that causes patches of thick red skin and silvery scales and affects 1-3% of the population, which reduces patient's quality of life." | ( Jia, HY; Lv, SC; Tang, ZL; Xu, GW; Zhang, JF; Zhang, K, 2021) |
| "Psoriasis is a chronic inflammatory skin disease that presents increased expression of tumor necrosis factor α (TNFα), a proinflammatory cytokine." | ( Bagnato, VS; Bentley, MVLB; de Araujo, MM; Suzuki, IL, 2021) |
| "Psoriasis is a chronic inflammatory skin disease associated with both innate and adaptive immune responses." | ( Chen, C; Dai, L; Liu, J; Liu, L; Pan, Y; Sui, Q; Sun, H; Sun, L; Wen, X; You, Y; Yuan, H, 2021) |
| "Psoriasis is a chronic skin disease characterized by thickening and disorganization of the skin's protective barrier." | ( Cheah, TY; Chowdhury, SR; Goh, BH; Kong, CK; Kwan, Z; Ng, MH; Yap, WH; Yong, LC, 2021) |
| "Psoriasis is an inflammatory skin disease, where keratinocytes play pivotal roles in its pathogenesis." | ( Chen, S; Qiu, F; Wang, Z; Xi, L; Zhao, Y; Zheng, Y, 2021) |
| "Psoriasis is an immune cell‒mediated inflammatory disease of the skin with a mixed T helper type 1/T helper type17 cytokine environment combined with an innate immune response engaging toll-like receptors." | ( Amento, E; Kang, GJ; Kaur, M; Mechanic, J; Ravikumar, P; Welihinda, A; Yadav, S, 2022) |
| "Psoriasis is a chronic inflammatory skin disease characterized by an active dynamic interplay between immune cells and keratinocytes (KCs)." | ( Su, L; Tang, W; Xue, X; Yu, Y; Zhang, L; Zhang, Y, 2022) |
| "Psoriasis is a common chronic skin disorder characterized by keratinocyte hyperproliferation with altered differentiation accompanied by increased inflammation and angiogenesis." | ( Gao, J; Li, X; Ma, X; Miao, Y; Wei, W; Xi, B; Yang, C; Zhang, J; Zhou, H, 2021) |
| "Psoriasis is an autoimmune, chronic proliferative, inflammatory skin disease with high comorbidity." | ( Gupta, A; Pandey, S; Tripathi, P; Yadav, JS, 2022) |
| "Psoriasis is a chronic immune-mediated skin disorder." | ( Gao, YM; Jin, HZ; Li, F; Wang, WM; Wu, C; Yu, XL, 2021) |
| "Psoriasis is a chronic autoimmune-mediated skin disease manifested by patches of hyperproliferative keratinocytes that do not undergo apoptosis." | ( Gęgotek, A; Skrzydlewska, E; Wójcik, P; Žarković, N, 2021) |
| "Psoriasis is a chronic inflammatory skin disease characterized by massive keratinocyte proliferation and immune cell infiltration into the epidermis." | ( Chen, S; Chen, X; Cheng, H; Hua, C; Lai, L; Song, Y; Wu, X; Xu, Y; Zhu, J, 2021) |
| "Psoriasis is a chronic skin condition associated with interleukin-23/interleukin-17 (IL-23/IL-17) pathway." | ( Abdollahifar, MA; Dehpour, AR; Haddadi, NS; Hedayatyanfard, K; Kazemi, K; Shayan, M; Shokrian Zeini, M; Solaimanian, S, 2021) |
| "Psoriasis is a severe skin disease with significant physical and psychological health consequences." | ( Hu, Z; Huang, N; Li, J; Liu, X; Ma, T; Wang, Z; Wei, X; Wu, W; Zhang, J; Zhen, H; Zhou, H, 2021) |
| "Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperplasia and cellular infiltration." | ( Cai, Z; Ichii, O; Inaba, M; Kozai, M; Masum, MA; Mita, H; Takada, K; Wang, S, 2021) |
| "Plaque psoriasis is a common, chronic and relapsing inflammatory skin disease clinically characterized by erythema and scaling desquamation." | ( Augustin, M; Gold, LS; Green, LJ; Pinter, A; Praestegaard, M; Selmer, J, 2022) |
| "Psoriasis is related to thyroid dysfunction, especially in patients with atypical psoriasis types." | ( Chen, S; Du, J; Gao, L; Lin, L; Lu, X; Ma, C; Wang, R, 2021) |
| "While psoriasis is known as a T cell- and dendritic cell-driven skin inflammation disease, macrophages are also reported to play some roles in its development." | ( Alalaiwe, A; Chang, ZY; Chen, CY; Chuang, SY; Fang, JY; Sung, JT, 2021) |
| "Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and a pro-inflammatory milieu in the skin." | ( Gendrisch, F; Haarhaus, B; Schempp, CM; Wölfle, U, 2021) |
| "Treatment of nail psoriasis is disappointing; due to poor penetrability of topical therapies and variable efficacy of systemic therapies." | ( Essa Abd Elazim, N; Mahmoud Abdelsalam, A; Mohamed Awad, S, 2022) |
| "Psoriasis is a chronic inflammatory skin disease that affects approximately 125 million people worldwide." | ( Guo, X; Li, Y; Zhou, J, 2021) |
| "Psoriasis is an auto-inflammatory skin disease characterized by abnormal activation of epidermal keratinocytes, aberrant neovascularization, and dysregulation of immune cells." | ( Chen, C; Chen, X; Chen, Z; Dou, X; Huang, C; Huang, H; Huang, X; Jian, X; Jiang, B; Li, Z; Liu, X; Ren, X; Shen, C; Yang, L; Yu, B; Zhong, W, 2021) |
| "Psoriasis is a chronic inflammatory skin disease affecting about 2-3% of the worldwide population." | ( Vinardell, MP, 2022) |
| "Psoriasis is a systemic disease that is associated with metabolic disorders, which may contribute to abnormal adipokine levels." | ( Fang, H; Li, C; Lu, Z; Ma, L; Shao, S; Wang, G; Xue, K, 2022) |
| "Psoriasis is a chronic immune-mediated skin disease with a significant impact on patients' quality of life." | ( Lé, AM; Torres, T, 2022) |
| "Psoriasis is a chronic immune-mediated inflammatory skin condition that commonly presents with red, thickened, and scaling plaques." | ( Fortenbach, C; Maibach, HI; Modjtahedi, BS; Motlagh, M, 2022) |
| "Psoriasis is a chronic multifactorial inflammatory disease that affects 3% of people worldwide." | ( Abdellatif, AAH; Abdulmonem, WA; Al Rugaie, O; Alhumaydhi, FA; Aljasir, M; Aljohani, ASM; AlKhowailed, MS; Alnuqaydan, AM; Alsagaby, SA; Alsuhaibani, SA; Alwashmi, ASS; Babiker, AY; Elsheikh, SY; Hegazy, AMS; Mousa, AM; Seleem, HS; Soliman, KEA; Yosof, MYR, 2022) |
| "Psoriasis is a chronic relapsing inflammatory skin disease that may markedly influence the patients' physical health and mental condition." | ( Jiang, J; Kuai, L; Li, B; Li, X; Liu, T; Luo, Y; Ru, Y; Song, J; Sun, X; Xing, M; Zhang, H, 2022) |
| "Psoriasis is characterized by aberrant activation of several pro-inflammatory circuits as well as abnormal hyperproliferation and dysregulated apoptosis of keratinocytes (KCs)." | ( Bochner, R; Fuchs-Telem, D; Gilhar, A; Keren, A; Magal, L; Malovitski, K; Nousbeck, J; Sagiv, N; Samuelov, L; Sarig, O; Sprecher, E, 2022) |
| "Psoriasis is a chronic inflammatory disease characterized by keratinocyte hyperproliferation and aberrant differentiation with great negative impact on patients' quality of life (QoL)." | ( Kumsa, SM; Tadesse, TA; Woldu, MA, 2021) |
| "Psoriasis is a dermatological condition often associated with systemic comorbidities such as arthritis." | ( Abdshah, A; Ghiasi, M; Nasimi, M; Parsaeian, M, 2022) |
| "Psoriasis is an immune-mediated inflammatory disease with increased risk of myocardial infarction." | ( Chen, M; Kapoor, P; Keel, A; Manyak, G; Mehta, NN; Osborne, MT; Pantoja, C; Parel, P; Patel, NH; Playford, MP; Rodante, JA; Scott, C; Sorokin, AV; Svirydava, M; Tawakol, A; Teague, H; Teklu, M; Zhou, W, 2021) |
| "Psoriasis is a psychosomatic immune skin disease with psychological factors contributing to the disease." | ( Di, T; Fu, J; Guo, J; Guo, X; Li, P; Liu, Q; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2022) |
| "Psoriasis is a chronic inflammatory and proliferative skin disease characterized by pathological skin lesions which significantly impact the quality of life." | ( Abubakar, M; Challa, VS; Gangasani, JK; Naidu, VGM; Np, S; Puppala, ER; Saha, P; Sudha Yalamarthi, S; Usn, M, 2022) |
| "Psoriasis is a chronic, complicated, and recurrent inflammatory skin disease." | ( Cai, Y; Dai, Y; Li, J; Long, X; Peng, X; Shang, M; Wang, Q; Xia, C; Xian, J, 2022) |
| "Psoriasis is a chronic inflammatory skin disease with multiple genetic backgrounds, whose etiology and pathogenesis are still unclear." | ( Deng, M; Li, S; Li, X; Luo, S; Su, Y; Tan, S; Tang, G; Wu, R; Zhang, P; Zhang, Q; Zhang, S; Zhang, X; Zhao, M; Zhu, Y, 2022) |
| "Psoriasis is a complex chronic inflammatory skin disease with unclear molecular mechanisms." | ( Chen, D; Gao, J; Guo, W; Jiang, X; Ke, B; Lai, Y; Ma, H; Shao, F; Sun, Y; Wu, Z; Xu, Q; Yan, W; Zhu, Y, 2022) |
| "Patients with psoriasis are commonly treated with methotrexate or biologics." | ( Loft, N; Møller, DL; Nielsen, SD; Ostrowski, SR; Skov, L; Todberg, T, 2022) |
| "Psoriasis is a chronic inflammatory skin disease characterized by accelerated tumor necrosis factor-α (TNF-α) /interleukin (IL) -23/IL-17 axis, epidermal hyperproliferation, and dysregulated differentiation." | ( Hoashi, T; Kanda, N; Okazaki, S; Saeki, H, 2021) |
| "Psoriasis is an autoimmune skin disease associated with lipid metabolism." | ( Chen, ST; Jin, MZ; Li, B; Li, HJ; Li, X; Liu, L; Lu, Y; Luo, Y; Ru, Y; Sun, XY; Wang, J; Yang, D; Zhang, S; Zhou, YQ, 2021) |
| "Psoriasis is a common chronic inflammatory hypertrophic skin disease characterized by abnormal proliferation and differentiation of keratinocyte and immune T cell." | ( Chen, Z; Di, T; Li, P; Lv, J; Wang, Y; Xu, J; Yang, H; Zhou, T, 2022) |
| "Psoriasis is a common chronic immune-mediated disease that often has a serious negative impact on the physical and mental health of patients." | ( Chang, G; Chen, B; Li, C; Wang, H, 2022) |
| "Psoriasis is a chronic immune-mediated skin disorder with the nervous system contributing to its pathology." | ( Bai, J; Bao, L; Cai, X; Jiang, B; Li, Q; Li, X; Lou, F; Song, N; Sun, L; Sun, Y; Tang, S; Wang, B; Wang, H; Wang, Z; Wu, Y; Yin, Q; Yu, B; Zhou, H, 2022) |
| "Psoriasis is an autoimmune disease mediated by T cells." | ( Chen, X; Li, B; Li, HJ; Li, W; Li, X; Liu, L; Lu, Y; Sun, XY; Ze, K; Zhou, YQ, 2022) |
| "Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits." | ( Bernardini, N; Maddalena, P; Mambrin, A; Marchesiello, A; Marraffa, F; Potenza, C; Proietti, I; Rossi, G; Skroza, N; Tolino, E; Volpe, S, 2022) |
| "Psoriasis is a common chronic and recurrent disease in dermatology, which has a great impact on the physical and mental health of patients." | ( Ou, J; Zhang, J, 2022) |
| "Mild to moderate psoriasis is most often treated with topical therapy." | ( Frątczak, A; Lis-Święty, A, 2022) |
| "Psoriasis is a complex autoimmune disease that is closely associated with the disorganized pro-inflammatory polarization of macrophages and the activation of inflammatory signalling pathways." | ( Cui, J; Li, W; Sun, H; Zhai, S; Zhang, P; Zhao, Y, 2022) |
| "Psoriasis is a chronic inflammatory skin disease whose pathogenesis involves skin microbiota dysbiosis." | ( Chen, J; Dang, E; Fang, H; Fu, M; Li, Q; Luo, Y; Ma, J; Qiao, P; Shao, S; Wang, G; Yin, W; Yu, J; Zhang, C; Zhang, J; Zhi, D, 2022) |
| "Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and phosphodiesterase 4 (PDE4) is an effective target for the treatment of inflammatory diseases such as psoriasis." | ( Hou, KQ; Huang, Y; Huang, YY; Liu, L; Luo, HB; Song, Z; Wan, G; Xiong, XF; Zhou, F, 2022) |
| "Psoriasis is a systemic inflammatory disease that is associated with increased risk of several diseases, such as psoriatic arthritis (PsA), inflammatory bowel disease, and cardiovascular diseases." | ( Ci, X; Du, X; Li, L; Lu, X; Luo, M; Wu, L; Xue, H, 2022) |
| "Psoriasis is a common inflammatory skin disorder, which can be associated with psychological disorders, such as anxiety and depression." | ( Choi, MJ; Nguyen, LTH; Shin, HM; Yang, IJ, 2022) |
| "Psoriasis is a complex chronic skin inflammatory disease characterized by abnormal proliferation, differentiation of keratinocytes and infiltration of lymphocytes and neutrophils." | ( Lin, X; Liu, Q; Qian, J; Tang, J; Xie, Q; Xiong, S; Zhou, Z, 2022) |
| "Psoriasis is an autoimmune inflammatory skin disorder consists of hyperkeratosis, abnormal keratinization, acanthosis, and infiltration of inflammatory cells in the dermis." | ( Jenabikordi, K; Rezaie, A; Zadeh, BSM, 2021) |
| "Psoriasis is a chronic skin disorder associated with multiple sequelae, such as psoriatic arthritis and cardiovascular diseases." | ( Cheng, H; Du, X; Li, M; Mei, X; Pan, Y; Tian, D; Yang, L; Zhang, D, 2022) |
| "Psoriasis is a recurrent inflammatory skin disorder characterized by epidermal hyperplasia, which is primarily driven by IL-17A." | ( Chen, Y; Cui, L; Dai, X; Gu, J; Guo, C; Shi, Y; Xu, H; Yu, Q; Yu, Y; Yu, Z; Zhang, X, 2022) |
| "Psoriasis is a skin disorder which mostly affects adults, beginning in childhood in almost one-third of patients." | ( Bardazzi, F; Chessa, MA; Dormi, A; Fabi, M; Filice, E; Gazzano, A; Lanari, M; Neri, I; Panizza, D; Patrizi, A; Rocca, A, 2022) |
| "Psoriasis is a chronic relapsing immunological skin disease characterized by multiple cross-talk inflammatory circuits which are relevantly associated with abnormal cross-reactivity between immune cells and keratinocytes (KCs)." | ( Chen, B; Chen, H; Chu, Z; He, Y; Lai, W; Li, Z; Ma, Y; Qian, H; Sun, J; Wang, F; Xu, J; Xu, Y, 2022) |
| "Psoriasis is a common immunologic chronic skin disease that affects at least 100 million individuals worldwide." | ( Chung, JH; Jo, SJ; Kim, EJ; Kim, SJ; Kim, TG; Lee, Y; Ohn, J; Suh, JH, 2022) |
| "Psoriasis is a condition of the skin which involves scales, dry patches, and inflammation." | ( Banga, AK; Garimella, HT; German, CL; Vora, D, 2022) |
| "Psoriasis is a chronic and remitting immune-related disease." | ( Chen, Y; Chen, Z; Guo, C; Hu, Y; Shi, Y; Wang, Y; Xu, P; Yu, Q; Yu, Z; Zhang, X; Zhao, Z; Zhou, X, 2022) |
| "Psoriasis is a chronic inflammatory skin disorder." | ( Agostini, SBN; Alves, CO; Bernardes, MTCP; Carvalho, FC; da Silva, LP; Gonçalves, RV; Novaes, RD; Pereira, GR, 2022) |
| "Patients with psoriasis are frequently complicated with metabolic syndrome; however, it is not fully understood how obesity and dyslipidemia contribute to the pathogenesis of psoriasis." | ( Akagi, T; Hiramatsu-Asano, S; Ikeda, K; Iseki, M; Ishihara, K; Kaneto, H; Morita, Y; Morizane, S; Mukai, T; Tachibana, K; Wada, J; Yahagi, A, 2022) |
| "Psoriasis is associated with an increased risk for cardiovascular disease (CVD)." | ( Deng, H; Fang, X; Guo, M; Han, L; Huang, Q; Meng, Q; Wang, B; Wu, S; Yan, K; Yang, K; Yawalkar, N; Zhang, Z; Zheng, Z; Zhu, J, 2022) |
| "Psoriasis is characterized by chronic skin inflammation and an aberrant pattern of keratinocyte differentiation." | ( Chiu, LY; Hsiao, PF; Huang, YT; Hung, CF; Lu, PH; Weng, TH; Wu, NL, 2022) |
| "Psoriasis is a common, chronic inflammatory skin disease associated with a large number of comorbidities." | ( Egeberg, A; Gyldenløve, M, 2022) |
| "Psoriasis is a highly inflammatory autoimmune-mediated skin disease." | ( Rasool, M; Srikanth, M, 2022) |
| "Psoriasis is a common chronic inflammatory skin disease that is prone to recurrence, and the proinflammatory factor, cysteine-rich protein 61 (Cyr61), is important in its pathophysiology." | ( Cheng, LY; Deng, Y; Feng, XY; Guo, DJ; Guo, WJ; Hua, L; Li, FL; Liu, X; Wang, Y; Xi, RF; Ze, K; Zhu, JY; Zhu, SJ, 2022) |
| "Psoriasis is a chronic, inflammatory, immune-mediated disease of the skin and joints." | ( Alahmadi, RA; Alamri, AM; Aljefri, YE; Alkhamisi, TA; Alkhunani, TA; Alraddadi, AA; Ghaddaf, AA, 2022) |
| "Psoriasis is a chronic inflammatory disease distinguished by an excessive proliferation and abnormal differentiation of keratinocytes." | ( Bonifaz, LC; Cancino-Diaz, JC; Cancino-Diaz, ME; Castro-Escamilla, O; Martínez-Torres, I; Perez-Tapia, SM; Rodríguez-Martínez, S; Tepale-Segura, A, 2022) |
| "Psoriasis is an autoimmune skin disease with an increased number of leukocytes infiltrating the dermal and epidermal compartments compared with normal skin." | ( Julien, P; Morin, S; Pouliot, R; Rioux, G; Simard, M, 2022) |
| "Psoriasis is a chronic dermal inflammatory disease with a world-wide prevalence in which different immune/non-immune cells, e." | ( Ahmad, SF; Al-Harbi, NO; Alanazi, AZ; Alasmari, F; Alharbi, M; Alhazzani, K; Almutairi, M; Alqahtani, F; Alqarni, SA; Ibrahim, KE; Nadeem, A, 2022) |
| "Psoriasis is a chronic inflammatory skin disease, which does not have effective treatment options." | ( Correa Atella, G; Donato-Trancoso, A; Romana-Souza, B, 2022) |
| "Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life." | ( Afach, S; Chaimani, A; Doney, L; Dressler, C; Garcia-Doval, I; Hua, C; Hughes, C; Le Cleach, L; Naldi, L; Sbidian, E, 2022) |
| "Psoriasis is associated with multiple comorbidities, including cardiovascular disease." | ( Burlando, M; Capurro, N; Carmisciano, L; Cozzani, E; Herzum, A; Oddenino, G; Parodi, A, 2022) |
| "(1) Background: Psoriasis is a T helper 1/T helper 17 cells-involved immune-mediated genetic disease." | ( Chen, LC; Cheng, YP; Guo, JW; Liu, CY, 2022) |
| "Psoriasis is linked to atherosclerosis." | ( Baloghova, J; Feketeova, E; Kolarcik, P, 2022) |
| "Psoriasis is a chronic skin inflammation caused by a dysfunctional immune system, which causes systemic inflammation in various organs and tissues." | ( Cho, H; Hwang, ES; Je, JH; Jeon, Y; Jeong, MG; Kang, J; Lee, K; Song, J, 2022) |
| "Psoriasis is an immune-mediated skin disease dominated by the cutaneous immune system." | ( Chen, XY; Landeck, L; Man, XY; Wang, P; Wang, ZY; Xu, F; Yan, BX; Zheng, M; Zhou, Y, 2022) |
| "Psoriasis is an immune-mediated, chronic inflammatory disease, and genetic, immune, oxidative stress (OS), and environmental factors are all thought to contribute to its occurrence." | ( Guo, M; Lai, R; Lei, Q; Xian, D; Xian, L; Xu, J; Yang, Y; Zhao, Y; Zhong, J, 2022) |
| "Psoriasis is a chronic inflammatory disease, with lesions mainly manifesting as scaly erythematous plaques." | ( Chen, X; Kuang, Y; Li, J; Liu, N; Liu, P; Peng, C; Yan, B; Yi, X; Zhu, W, 2022) |
| "Psoriasis is an autoimmune disease characterized by erythematous, scaly patches on the skin." | ( Kushwaha, P; Pandey, S; Shaif, M; Usmani, S, 2022) |
| "Psoriasis is a common skin disease with complex pathogenesis that lacks diagnostic methods." | ( Guo, Y; Liu, L; Wei, P; Yi, T; Zhou, X, 2022) |
| "Psoriasis is a chronic inflammatory autoimmune disease that is considered linked to genetic and environmental factors such as stress." | ( Ahangari, F; Ahangari, G; Makvand, M; Mohamadian, M; Mortazavi, H, 2022) |
| "Psoriasis is a chronic systemic inflammatory disease, and hyperuricemia is a common comorbidity in patients with psoriasis." | ( Cai, L; Li, C; Liu, X; Zhang, H; Zhang, J; Zhang, S; Zhao, Y; Zhao, Z, 2022) |
| "Psoriasis is a medical condition in which the skin of the body is affected at a multisytemic level." | ( Al-Ameedee, AA; Al-Hattab, MK; Al-Oudah, GA; Sahib, AS, 2022) |
| "Psoriasis is a chronic skin auto-inflammatory and systemic disorder." | ( Gupta, RC; Kyriakopoulos, AM; Marcinkiewicz, J; Nagl, M, 2022) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Chen, Z; Gao, WQ; Hao, W; Lin, J; Tang, J; Wang, L; Xu, H; Yang, M; You, Q; Zhao, X, 2022) |
| "Psoriasis is a chronic noncommunicable dermatological condition, and psoriasis vulgaris is the most common phenotype." | ( Geng, A; Jia, B; Pei, T; Zhao, X, 2022) |
| "Management of scalp psoriasis is difficult, in part due to the difficulty of applying topical agents and its refractory nature." | ( Ghafoor, R; Goldust, M; Grabbe, S; Kircik, L; Patil, A; Weinberg, J; Yamauchi, P, 2022) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Wu, X; Xiang, S; Xiang, Y, 2022) |
| "Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently considered its main pathogenic pathway." | ( Lé, AM; Puig, L; Torres, T, 2022) |
| "Psoriasis is a prevalent chronic inflammatory skin condition marked by immune cell infiltration and keratinocyte abnormal proliferation." | ( Di, T; Feng, F; Hu, X; Li, P; Meng, Y; Qi, C; Wang, Y; Zhang, X; Zhao, J; Zhao, N, 2022) |
| "Psoriasis is a chronic skin disease with 2-4% of prevalence worldwide conferring a major burden on health systems." | ( Aftab, U; Akhtar, T; Muhammad, H; Rafi, A; Salahuddin, Z; Shahzad, M; Zafar, MS, 2022) |
| "Psoriasis is a chronic inflammatory skin disorder related to dyslipidemia, with decreased high-density lipoprotein (HDL)." | ( Chen, J; He, L; Liu, L; Niu, Y; Qi, H; Qin, S; Yu, S, 2022) |
| "Psoriasis is a common chronic autoinflammatory/autoimmune skin disease associated with elevated pro-inflammatory cytokines." | ( Cai, H; Chen, X; Chen, Y; Hu, W; Hua, L; Liang, S; Lin, G; Liu, Z; Ou, Y; Sun, P; Wu, X; Yang, Z; Zhou, Y, 2022) |
| "Psoriasis is a chronic skin inflammatory auto-immune disorder." | ( Bhardwaj, P; Gupta, R; Pandey, S; Ramchandra Patil, P; Tripathi, P, 2022) |
| "Psoriasis is a papulosquamous disorder that causes significant social and psychological trauma to the patient." | ( Attwa, E; Essam, R; Khater, MH; Selim, HM, 2022) |
| "Psoriasis is a chronic inflammatory disease whereby long-term disease control remains a challenge for the patients." | ( Cardot-Leccia, N; Duteil, L; Heim, M; Irondelle, M; Passeron, T; Rocchi, S; Tulic, MK, 2022) |
| "Psoriasis is characterized by increased dermal vascularity, indicating that aberrant angiogenesis is associated with the pathogenesis of psoriasis." | ( Egawa, S; Fukaya, S; Fukuyasu, A; Hayashi, K; Ishikawa, T; Ito, M; Kamata, M; Nagata, M; Nakajima, H; Niimura, Y; Sakurai, E; Shimizu, T; Suzuki, S; Tada, Y; Tanaka, T; Uchida, H; Watanabe, A, 2023) |
| "Psoriasis is an inflammatory condition associated with metabolic and cardiovascular disease." | ( Alavi, A; Armstrong, AW; Blauvelt, A; Fitzsimmons, R; Gelfand, JM; Gottlieb, S; Kalb, RE; Lockshin, BN; Manyak, GA; Mehta, NN; Mendelsohn, L; Noe, MH; Papadopoulos, M; Parel, P; Playford, MP; Rodante, J; Shin, DB; Syed, MN; Tyring, SK; Wan, J; Werner, TJ, 2022) |
| "Psoriasis is characterized by hyperproliferative keratinocytes, dilated capillaries and leukocyte infiltration." | ( Li, M; Liu, C; Liu, S; Lu, J; Tang, J; Zhou, X; Zhu, L, 2022) |
| "Psoriasis is a chronic relapsing dermatological disorder that significantly affects the patients' psychosocial well-being and quality of life (QOL)." | ( Ahmad Fuat, MS; Mat Yudin, Z; Mohd Zin, F; Muhammad, J, 2022) |
| "Psoriasis is a common inflammatory skin disease that has a great impact on patients' physical and mental health." | ( Chen, YJ; Dong, RJ; Kuang, YQ; Li, YY; Lu, YW; Shi, N; Wang, HM; Yang, LH, 2022) |
| "Psoriasis is strongly associated with insulin resistance (IR)." | ( Calvo-Anguiano, G; Cerda-Flores, R; Chavez-Alvarez, S; Gomez-Flores, M; Gonzalez-Gonzalez, JG; Martinez-de-Villarreal, LE; Ocampo-Candiani, J; Rodriguez-Rivera, MR; Ruiz-Herrera, C; Villarreal-Martinez, A; Villarreal-Perez, JZ, 2023) |
| "Nail psoriasis is a chronic nail disorder that commonly affects psoriatic patients causing severe distress despite the limited body surface area." | ( Barilà, D; Cattel, F; Dapavo, P; Gallo, G; Mastorino, L; Panzone, M; Quaglino, P; Ribero, S, 2022) |
| "Psoriasis is a serious non-communicable, chronic immune-inflammatory mediated disease affecting about 125 million people worldwide." | ( Liu, JL; Msafiri Makene, A, 2022) |
| "Psoriasis is a chronic inflammatory skin disorder accompanied by excessive keratinocyte proliferation." | ( Chen, W; Liu, Y; Wei, K; Yu, H; Zheng, F, 2022) |
| "Psoriasis is a type of chronic autoimmune-mediated inflammatory skin condition in which clinical manifestations are characterized by erythema and scaly changes, with complex pathogenesis and ease of relapse, and it is difficult to cure." | ( Hou, JJ; Jia, HY; Qiu, HY; Wu, Y; Zhang, MD; Zhou, ML, 2022) |
| "Psoriasis is a chronic inflammatory skin disease that is currently incurable and causes long-term distress to patients." | ( Bai, D; Cheng, X; Hao, J; Li, Q; Lu, F; Sun, T; Zhang, B; Zhang, Y, 2023) |
| "Psoriasis is a prevalent chronic inflammatory dermatosis, which can significantly impact life quality of patients." | ( Cai, R; Chen, C; Chen, L; Ye, Z; Zhang, D; Zhou, J, 2023) |
| "Psoriasis is considered as an inflammatory skin disease accompanied by dyslipidemia comorbidity." | ( Li, W; Yang, C; Yang, W, 2022) |
| "Psoriasis is an inflammatory skin disease of chronic recurrence mediated by the interaction between IL-17 and keratinocytes, which sustains a vicious circle of inflammation." | ( Duan, J; Duan, R; Gao, S; Li, J; Li, X; Ma, X; Qin, Y; Shi, R; Zhang, L; Zhao, R, 2023) |
| "Psoriasis is a chronic skin disorder characterized by epidermal keratinocyte hyperproliferation and inflammatory infiltration." | ( Huo, R; Li, H; Shen, B; Sheng, H; Shu, J; Sun, H; Sun, Y; Zhai, T; Zhang, J, 2023) |
| "Psoriasis is a disease of immunological origin that damages the skin and mucous membranes." | ( Benites, E; Carrillo, E; Heras, M, 2022) |
| "Psoriasis is a disease of immunological origin that damages the skin and mucous membranes." | ( Benites, E; Carrillo, E; Heras, M, 2022) |
| "Psoriasis is a disease of immunological origin that damages the skin and mucous membranes." | ( Benites, E; Carrillo, E; Heras, M, 2022) |
| "Psoriasis is a chronic inflammatory skin disease and lysophosphatidic acid (LPA) has recently been reported to contribute to its pathogenesis through keratinocyte proliferation." | ( Jun, HS; Khin, PP; Kim, D; Lim, OK, 2022) |
| "Psoriasis is a chronic inflammatory skin disease and lysophosphatidic acid (LPA) has recently been reported to contribute to its pathogenesis through keratinocyte proliferation." | ( Jun, HS; Khin, PP; Kim, D; Lim, OK, 2022) |
| "Psoriasis is a chronic inflammatory skin disease and lysophosphatidic acid (LPA) has recently been reported to contribute to its pathogenesis through keratinocyte proliferation." | ( Jun, HS; Khin, PP; Kim, D; Lim, OK, 2022) |
| "Psoriasis is a chronic, immune-mediated, skin disease with a significantly negative impact on patients' quality of life." | ( Estevinho, T; Lé, AM; Torres, T, 2023) |
| "Psoriasis is a chronic, immune-mediated, skin disease with a significantly negative impact on patients' quality of life." | ( Estevinho, T; Lé, AM; Torres, T, 2023) |
| "Psoriasis is a chronic skin disease associated with deregulated interplays between immune cells and keratinocytes." | ( Abram, CL; Bevilacqua, D; Cassatella, MA; Caveggion, E; Cestari, T; Constantin, G; Costa, S; De Sanctis, F; Donini, M; Dusi, S; Gasperini, S; Girolomoni, G; Lonardi, S; Lowell, CA; Pettinella, F; Rodegher, P; Scapini, P; Tagliaro, F; Ugel, S; Vermi, W; Zenaro, E, 2022) |
| "Psoriasis is a chronic skin disease associated with deregulated interplays between immune cells and keratinocytes." | ( Abram, CL; Bevilacqua, D; Cassatella, MA; Caveggion, E; Cestari, T; Constantin, G; Costa, S; De Sanctis, F; Donini, M; Dusi, S; Gasperini, S; Girolomoni, G; Lonardi, S; Lowell, CA; Pettinella, F; Rodegher, P; Scapini, P; Tagliaro, F; Ugel, S; Vermi, W; Zenaro, E, 2022) |
| "Psoriasis is a chronic inflammatory disease that affects over 125 million people worldwide." | ( Aguiar, ALR; da Silva, BN; de Aguiar Cordeiro, R; de Andrade, ARC; de Lima-Neto, RG; Lima, XTV; Maia, DCSC; Moura, SGB; Pereira, LMG; Portela, FVM; Reis, AT; Rocha, MFG; Sidrim, JJC, 2023) |
| "Psoriasis is a chronic inflammatory disease that affects over 125 million people worldwide." | ( Aguiar, ALR; da Silva, BN; de Aguiar Cordeiro, R; de Andrade, ARC; de Lima-Neto, RG; Lima, XTV; Maia, DCSC; Moura, SGB; Pereira, LMG; Portela, FVM; Reis, AT; Rocha, MFG; Sidrim, JJC, 2023) |
| "Psoriasis is a chronic, recurrent, and often severe skin disease which is frequently associated with metabolic disorders and increased risk of cardiovascular complications." | ( Damasiewicz-Bodzek, A; Nowak, A, 2022) |
| "Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease." | ( Asaji, M; Chang, J; Hattori, H; Higo, T; Hikoso, S; Ichi, I; Inui, H; Ito, K; Kamada, Y; Kanno, K; Koseki, M; Nishida, M; Nishihara, S; Ohama, T; Okada, T; Okuzaki, D; Omatsu, T; Ono, M; Saga, A; Saibara, T; Sakata, Y; Tanaka, K; Yamashita, S; Zhu, Y, 2022) |
| "Psoriasis is a chronic, immune-mediated inflammatory skin disorder." | ( Ahn, SH; Nguyen, LTH; Shin, HM; Yang, IJ, 2022) |
| "Psoriasis is a chronic immune-mediated inflammatory disease." | ( Chen, C; Chen, M; Chen, X; Hou, G; Kuang, Y; Li, J; Li, L; Lin, L; Liu, P; Peng, C; Su, J; Yan, B; Zhu, W, 2023) |
| "Psoriasis is a recurring, immune-mediated dermatological disorder." | ( Contri, RV; Frank, LA; Gomes, GS; Guterres, SS; Longhi, MS; Pohlmann, AR, 2023) |
| "Psoriasis is a chronic, inflammatory cutaneous disease." | ( Chenyang, W; Fushida, N; Hamaguchi, Y; Horii, M; Ikawa, Y; Kitano, T; Komuro, A; Matsushita, T; Nakabori, I; Sawada, K; Xibei, J, 2022) |
| "Psoriasis is a systemic immune-mediated disease associated with an increased risk of comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, inflammatory bowel disease, psychiatric disorders, and malignancy." | ( Chen, Y; Jiang, Y; Shi, Y; Yu, Q, 2023) |
| "Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells." | ( Issa, N; Kircik, L, 2023) |
| "Psoriasis is a chronic recurrent inflammatory skin disease with a high risk of diabetes based on disease severity." | ( Cai, X; Li, B; Li, H; Li, X; Liu, L; Luo, Y; Su, Y; Sun, X; Zhou, Y, 2023) |
| "Plaque psoriasis is a chronic skin disease characterised by periods of remission and relapse and associated with considerable burden to patients and healthcare systems." | ( Beveridge, AJ; Perry, R; Rasmussen, ER; Sears, AJ, 2023) |
| "Psoriasis is a genetically determined, environmentally triggered, immune system-mediated autoimmune disease." | ( Li, K; Nandakumar, KS; Ou, J; Wang, T; Wu, H, 2023) |
| "Psoriasis is a chronic inflammatory disease with a multifactorial genesis." | ( Fabbrocini, G; Genco, L; Megna, M; Noto, M; Potestio, L, 2022) |
| "Psoriasis is an immune-mediated chronic inflammatory skin disorder characterized by epidermal hyperplasia and infiltration of inflammatory cells." | ( Cai, W; Chen, L; Chen, R; Huang, S; Jiang, X; Jiang, Y; Jiang, Z; Kou, L; Mao, P; Sun, T; Wang, M; Wang, P; Wang, R; Yao, Q; Zhang, L, 2023) |
| "Psoriasis is a common inflammatory skin disease recognized by the World Health Organization as "an incurable chronic, noninfectious, painful, disfiguring and disabling disease." | ( Chen, H; Huang, Y; Jiang, J; Jin, Z; Kong, Y; Li, L; Liu, X; Tong, Q; Wei, F; Yin, J; Zhang, Y, 2022) |
| "Psoriasis is a chronic inflammatory skin disease with an autoimmune component and associated with joint inflammation in up to 30% of cases." | ( Banfi, G; Casciano, F; Gornati, L; Granucci, F; Guerrini, R; Marzola, E; Mingozzi, F; Montico, G; Protti, G; Reali, E; Secchiero, P; Volinia, S, 2023) |
| "Copy: Palmoplantar psoriasis is a chronic, difficult-to-treat localized variant of psoriasis that affects the palms and soles, significantly affecting patient's quality of life." | ( Babalola, F; Campbell, C; Gottlieb, A; Mitchell, K; Vargas, J; Yousif, J, 2023) |
| "Psoriasis is a complex and chronic disease with treatment needs that may change over time, influencing patient treatment goals and expectations of efficacy." | ( Armstrong, A; Del Rosso, J; Han, G; Jacobson, A; Lewitt, GM, 2023) |
| "Psoriasis is an inflammation of the skin mediated via the IL-23/Thl17/IL-17 pathway." | ( Apostolopoulou, K; Bogdanos, DP; Dardiotis, E; Grammatikopoulou, MG; Mavropoulos, A; Tsiogkas, SG; Zafiriou, E, 2023) |
| "Psoriasis is an autoimmune disorder disease with abnormally activated T lymphocytes and thickening of the epidermis." | ( Cheng, G; Jin, S; Liu, W; Mi, R; Pan, W; Piao, H; Zou, M, 2023) |
| "Psoriasis is a chronic inflammatory skin disease characterized by epidermal gene abnormalities, epidermal barrier defects and inflammation." | ( Ardizzone, A; Campolo, M; Capra, AP; Casili, G; Cuzzocrea, S; Esposito, E; Filippone, A; Lanza, M; Paterniti, I; Scuderi, SA, 2023) |
| "Psoriasis is an inflammatory skin disease." | ( Bi, D; Du, H; Liu, H; Liu, P; Liu, Y; Qu, F; Tao, J; Wu, J; Xiao, W; Xie, Y; Zhang, L; Zhu, J, 2023) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Árvai, K; Bender, T; Illés, A; Kósa, J; Kulisch, Á; Lakatos, P; Lengyel, Z; Mándó, Z; Papp, M; Sándor, E; Tóbiás, B, 2023) |
| "Psoriasis is a chronic disease; thus, topical treatment options are needed that address these barriers to use and promote long-term adherence, making satisfactory improvement of psoriasis more attainable." | ( Bhatia, N; Jacobson, A; Kircik, L; Lain, E, 2023) |
| "Psoriasis is a chronic inflammatory dermatological condition characterized by well-demarcated erythematous scaly plaques." | ( Galande, T; Kumar, R; Pawar, S; Sangtani, R; Sarasambi, A, 2023) |
| "Psoriasis is a chronic inflammatory dermatosis with an unclear pathogenesis." | ( Chen, H; Chen, K; Hu, Y; Huang, D; Ju, M; Liu, L; Luan, C; Zhang, J; Zhou, X, 2023) |
| "Psoriasis is a prevalent inflammatory skin disease characterized by excessive proliferation and abnormal differentiation of keratinocytes, and infiltration of inflammatory cells into the epidermis." | ( Li, J; Ren, F; Sang, H; Yan, W, 2023) |
| "Psoriasis is a chronic inflammatory skin disease mediated by immune and complex genetic factors." | ( Li, H; Li, X; Lin, N; Liu, L; Lu, Y; Luo, D; Sun, X; Wang, J; Yin, C; Zhang, M; Zhou, Y, 2023) |
| "Psoriasis is a chronic skin disorder characterized by a skin rash with scaly patches." | ( Egusa, C; Harada, K; Hayakawa, K; Maeda, T; Okubo, Y, 2023) |
| "Nail psoriasis is a significant challenge because of the difficulties in its diagnosis." | ( Yorulmaz, A, 2023) |
| "Although psoriasis is classified as a T cell-mediated inflammatory disease, the contribution of myeloid cells to the pathogenesis of psoriasis is not fully understood." | ( Cheng, D; Dong, G; Li, C; Liu, C; Shi, D; Wang, C; Wei, L; Xiong, H; Yan, F; Yang, Z; Zhang, H; Zhang, J; Zhang, Y, 2023) |
| "Psoriasis is a chronic inflammatory skin disease." | ( Chen, X; He, Y; Huang, X; Jia, H; Liu, T; Shan, W; Sun, R; Yang, Q, 2023) |
| "Psoriasis is an autoimmune chronic inflammatory skin disease with an unclear pathogenesis that is difficult to cure, causing serious physical and mental burdens for patients." | ( Jiang, Q; Wei, B; You, M; Zhou, X, 2023) |
| "Psoriasis is often combined with metabolic abnormalities, such as obesity and diabetes." | ( Cao, YC; Cui, WY; Kong, SM; Sun, XY, 2023) |
| "Psoriasis is a chronic inflammatory disease in which hyperproliferation of keratinocytes occurs." | ( Buda, P; Dąbala, M; Grabarek, BO; Kasela, T; Świder, M, 2023) |
| "Psoriasis is a chronic and immune-mediated skin condition characterized by pro-inflammatory cytokines and keratinocyte hyperproliferation." | ( Bakinowska, E; Dec, P; Gromowska, E; Gurazda, K; Kiełbowski, K; Modrzejewski, A; Ostrowski, P; Pala, B; Pawlik, A, 2023) |
| "Psoriasis is a systemic inflammatory disease associated with poor cholesterol efflux capacity and accelerated noncalcified coronary burden (NCB) as measured by coronary computed tomographic angiography." | ( Berg, AR; Florida, EM; Gelfand, JM; Gonzalez-Cantero, A; Hong, C; Joshi, A; Kapoor, P; Keel, A; Li, H; Mehta, NN; O'Hagan, R; Patel, N; Petrole, RF; Playford, MP; Rodante, J; Sorokin, AV; Teague, HL, 2023) |
| "Psoriasis is a common chronic inflammatory skin disease that is easy to relapse and difficult to cure." | ( Cai, X; Du, J; Gao, W; Gong, H; Lu, H; Xiao, H; Xu, J; Yang, Y, 2023) |
| "Psoriasis is an autoimmune, persistent, inflammatory skin illness that is influenced by a variety of circumstances." | ( Agop, AK; Ali Abd, S; Alsaffar, JMJ; Kadhem, EJ, 2022) |
| "Psoriasis is one of the chronic and autoimmune skin diseases." | ( Liu, Q; Ren, C; Wang, D; Wang, Q; Zhang, H, 2023) |
| "Psoriasis is a complex disease triggered by genetic, immunological, and environmental stimuli." | ( Liu, Q; Ren, C; Wang, D; Wang, Q; Zhang, H, 2023) |
| "Psoriasis is a disease that causes keratinocytes to proliferate ten times faster than normal, resulting in chronic inflammation and immune cell infiltration in the skin." | ( Carvalho, BG; Carvalho, FA; de Barros, NR; de Mendonça, RJ; Dokmeci, MR; Dos Santos, AG; Dos Santos, TO; Farhadi, N; Floriano, JF; Gomez, A; Guerra, NB; Herculano, RD; Jucaud, V; Kawakita, S; Khorsandi, D; Li, B; Mandal, K; Mecwan, M; Mussagy, CU; Nguyen, HT; Pegorin Brasil, GS; Peirsman, A; Perego, CH; Scontri, M; Tirpáková, Z, 2023) |
| "Psoriasis is an immune-mediated, chronic inflammatory disease affecting mainly the skin." | ( Menon, V; Mohan Raj, PS; Munisamy, M; Priyadarshini, G; Rajappa, M; Rajasekharan, A, 2023) |
| "Psoriasis is one of the most common dermatological disorders, characterized by increased epidermal hyperplasia and immune cell infiltration." | ( Al Rudaisat, M; Amanullah, M; Chen, S; Chen, X; Cheng, H; Hua, C; Liang, Q; Song, Y; van der Veen, S; Wang, X; Zhou, C, 2023) |
| "Psoriasis is a chronic autoinflammatory skin disease associated with multiple comorbidities, with a prevalence ranging from 2 to 3% in the general population." | ( Chen, L; Guo, Y; Li, C; Luo, L; Zhu, J, 2023) |
| "Psoriasis is a chronic inflammatory skin disorder, affecting the trunk and extensor surfaces of the limbs and scalp predominantly." | ( Ambrose, MM; Balamurugan, D; Chattopadhyay, A; Karuppusamy, A; Koley, M; Kumar, A; Nayak, C; Saha, S; Singh, NK, 2023) |
| "Psoriasis is a recurrent, life-threatening anti-inflammatory condition that affects nearly 1-3% of the global population." | ( Kumar, B; Sahoo, PK, 2023) |
| "Psoriasis is a chronic inflammatory skin disease that is characterized by clearly delineated erythema and squamous skin lesions." | ( Lin, J; Lin, P; Lu, YY; Shi, HY, 2023) |
| "Psoriasis is a chronic inflammatory skin disorder characterized by abnormal keratinocytes proliferation and multiple immune cells infiltration in the dermis and epidermis." | ( Chen, Y; Dai, Z; Feng, B; Han, W; Huang, H; Li, G; Li, H; Li, Q; Liu, H; Lu, Y; Su, Z; Tang, L; Wang, M; Wu, D; Yang, L; Ye, Z; Zhang, B; Zheng, G; Zhu, Y, 2023) |
| "Psoriasis is a common inflammatory skin disease characterized by the excessive proliferation and abnormal differentiation of keratinocytes." | ( Luo, F; Luo, M; Pan, Y; Peng, Y; Ran, C; Wang, B; Wang, H; Wang, L; Yan, YN; Yi, T; Zhang, Y; Zhou, R, 2023) |
| "Psoriasis is a chronic inflammatory disease with an established genetic background." | ( Abbad-Jaime de Aragon, C; Berna-Rico, E; Gonzalez-Cantero, A; Perez-Bootello, J, 2023) |
| "Psoriasis is a chronic inflammatory disease affecting the skin and the joints." | ( Campbell, JDM; Cuesta-Gomez, N; Graham, GJ; Medina-Ruiz, L, 2023) |
| "Psoriasis is an immune-mediated skin disease characterized by keratinocytes hyperproliferation, abnormal differentiation and inflammation." | ( Agrahari, K; Chanda, D; Khan, A; Mukhopadhyay, P; Sahoo, D; Singh, VK; Yadav, NP, 2023) |
| "Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life." | ( Afach, S; Chaimani, A; Garcia-Doval, I; Guelimi, R; Hua, C; Hughes, C; Kinberger, M; Le Cleach, L; Naldi, L; Sbidian, E, 2023) |
| "Psoriasis is a chronic inflammatory disease due to immune dysregulation that cannot be cured." | ( Chu, MY; Lee, CL; Liu, CT; Song, YC; Wang, CM; Yen, HR, 2024) |
| "Psoriasis is an autoimmune skin disease characterized by immunocyte activation, excessive proliferation, and abnormal differentiation of keratinocytes." | ( Li, P; Lin, Y; Liu, X; Wang, N; Xie, X; Zhang, L, 2023) |
| "Psoriasis is an inflammatory skin disease that is characterized by keratinocyte hyperproliferation, abnormal epidermal differentiation and dysregulated lipid metabolism." | ( Flamand, N; Morin, S; Pouliot, R; Rioux, G; Simard, M; Tremblay, A, 2023) |
| "Psoriasis is a complex chronic immunologically mediated disease that may involve skin, nails, and joints." | ( Chabowski, A; Dadan, J; Flisiak, I; Lewoc, M; Lukaszuk, B; Malla, H; Matwiejuk, M; Mysliwiec, H; Mysliwiec, P, 2023) |
| "Psoriasis is a chronic and incurable skin disorder that causes inflammation." | ( Chen, X; He, X; Hou, Y; Jiang, W; Li, W; Liu, M; Shen, F; Su, L; Xu, Z; Zhang, H; Zhu, Y; Zou, C, 2023) |
| "Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing." | ( Frey, K; Kalabalik-Hoganson, J; Nogid, A, 2023) |
| "Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies." | ( Alexis, AF; Andriessen, A; Blattner, C; Glick, BP; Gold, LS; Kircik, L; Lynde, CW, 2023) |
| "Psoriasis is a chronic inflammatory skin condition." | ( Becker, M; Bezdek, S; Bieber, K; Gross, N; Gullberg, D; Gupta, Y; Hdnah, A; Ibrahim, SM; Künzel, S; Ludwig, RJ; Mousavi, S; Prüssmann, J; Sadik, CD; Sayegh, JP; Sezin, T; Vorobyev, A, 2023) |
| "The chronic disease psoriasis is associated with severe inflammation and abnormal keratinocyte propagation in the skin." | ( Chan, CI; Chen, SJ; Hseu, JH; Hseu, YC; Vadivalagan, C; Wu, PY; Yang, HL; Yen, HR, 2023) |
| "Psoriasis is a chronic inflammatory skin disease that is difficult to treat." | ( Chen, R; Gao, N; Gong, S; Huang, Y; Liu, E; Liu, L; Pan, L; Shen, H; Zhang, Y, 2023) |
| "Psoriasis is a skin disease presenting as erythematous lesions with accentuated proliferation of epidermal keratinocytes, infiltration of leukocytes, and dysregulated lipid metabolism." | ( Bélanger, S; Cortez Ghio, S; Morin, S; Pouliot, R, 2023) |
| "Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment." | ( Cui, J; Deng, H; Deng, J; Han, L; Lu, C; Yan, Y; Yao, D; Ye, S; Yu, J; Yu, X; Zhang, X, 2023) |
| "Psoriasis is an autoimmune skin disease that often co-occurs with psychological morbidities such as anxiety and depression, and psychosocial issues also lead psoriasis patients to avoid other people." | ( Aji, A; Chen, T; Chu, YX; Li, FL; Wang, H; Wang, YQ; Xu, S; Zhang, C; Zhu, SJ, 2023) |
| "Psoriasis is a chronic inflammatory skin disease in which growth activity is more prominent than inflammatory activity at the centre of lesional skin (CE skin)." | ( Boonpethkaew, S; Chakkavittumrong, P; Jumlongpim, O; Juntongjin, P; Komine, M; Meephansan, J; Morita, A; Ponnikorn, S; Wongpiyabovorn, J, 2023) |
| "Psoriasis is an inflammatory skin disease accompanied with chronic papulosquamous lesions and multiple comorbidities that considerably affect patients' quality of life." | ( Chen, X; Fan, G; He, F; Li, S; Wang, Y; Yang, G; Yang, Z; Zhan, J; Zhang, L; Zhang, Y, 2023) |
| "Psoriasis is a deleterious auto-immune disorder which seriously harms the patients physical and mental health." | ( Alshehri, SA; Hazari, SA; Kesharwani, P; Molugulu, N; Sahebkar, A; Sheikh, A; Wahab, S, 2023) |
| "Psoriasis is a chronic autoimmune skin disease with a significant impact on quality of life and potential for severe comorbidities." | ( Chen, YC; Chou, TY; Li, CL; Liao, EC; Lu, LY; Shih, MC; Wang, KC; Yen, CY; Yen, LJ; Yu, SJ, 2023) |
| "Psoriasis is a chronic inflammatory skin disease that affects both localized and systemic regions of the body." | ( Bhuvarahamurthy, S; Kalaiyazhagan, A; Meganathan, J; Ramamoorthy, R; Venugopal, B; Vijayapoopathi, S, 2023) |
| "Psoriasis is a common and recurrent inflammatory skin disease characterized by inflammatory cells infiltration of the dermis and excessive proliferation, reduced apoptosis, and abnormal keratosis of the epidermis." | ( Chen, X; Fang, Z; Huang, B; Jiang, R; Wang, Y; Yin, M, 2023) |
| "Psoriasis is an immune-mediated inflammatory disorder of the skin, characterised by uncontrolled proliferation and dysfunctional differentiation of keratinocytes." | ( Karampitsakos, T; Katsaras, M; Sotiropoulou, V; Tzouvelekis, A, 2023) |
| "Psoriasis is a skin disease characterized by epidermal hyperplasia and an inappropriate activation of the adaptive immunity." | ( Dumais, E; Flamand, N; Julien, P; Morin, S; Pouliot, R; Tremblay, A, 2023) |
| "Psoriasis is a chronic skin disease with interleukin (IL)-17-dominated inflammation and hyperproliferation of epidermis." | ( Funasaka, Y; Kanda, N; Saeki, H; Yamamoto, M; Yoshida, M, 2023) |
| "Psoriasis is an inflammatory disease mediated by helper T (Th)17 and Th1 cells." | ( Han, L; Huang, Q; Ren, J; Yan, K; Yawalkar, N; Zhang, F, 2023) |
| "Psoriasis is a common systemic inflammatory skin disorder affecting over 60 million people globally." | ( An, Q; Du, G; Hao, Y; Li, W; Lu, Y; Ren, L; Wang, J; Yang, D; Yang, H; Yang, Y; Yu, M; Zhang, S; Zhang, Y, 2023) |
| "Psoriasis is a long-lasting skin condition characterized by redness and thick silver scales on the skin's surface." | ( Alimohammadi, S; Di Nardo, A; Masuda-Kuroki, K, 2023) |
| "Psoriasis is a chronic, complex, immunological disorder, which may lead to many different systemic complications." | ( Chabowski, A; Dadan, J; Flisiak, I; Lewoc, M; Lukaszuk, B; Malla, H; Matwiejuk, M; Myśliwiec, H; Myśliwiec, P, 2023) |
| "Psoriasis is a prevalent laborious inflammation in skin with alternate phases of remission and relapses." | ( El-Kayal, M; Hatem, S, 2023) |
| "Psoriasis is a chronic inflammatory disease characterized by skin redness, scaliness, and itching." | ( Goddard, WA; Han, JH; Jang, Y; Kim, JH; Kim, SK; Kim, YC; Ko, B; Kwak, SH; Lee, JE; Park, HD; You, H, 2023) |
| "Psoriasis is a complex disease that nowadays is considered not only a dermatosis but a kind of systemic disorder associated with many accompanying diseases." | ( Baran, A; Flisiak, I; Hermanowicz, JM; Nowowiejska, J; Pawlak, D; Sieklucka, B, 2023) |
| "Psoriasis is an auto-immune condition with high keratinocyte hyperproliferation due to lower p53 and p22 levels." | ( Dadwal, N; Singh, A; Singh, D, 2023) |
| "Psoriasis is a chronic inflammatory skin disease characterized by thickening the epidermis with erythema, scaling, and proliferation." | ( Askari, VR; Baradaran Rahimi, V; Golmohammadzadeh, S; Jaafari, MR; Kamali, H; Rahmanian-Devin, P; Sanei-Far, Z, 2023) |
| "Psoriasis is a chronic inflammatory skin disease with metabolic abnormalities serving as important contributors for pathogenesis and progression." | ( Chen, W; Ding, Y; Ma, R; Peng, C; Qin, H; Shi, R; Shi, Y; Wang, X; Yu, Z, 2023) |
| "Psoriasis is one of the common chronic inflammatory skin diseases worldwide." | ( Bai, J; Fu, D; Guo, Y; Hu, H; Li, J; Li, M; Qu, Z; Si, W; Song, G; Song, X; Tian, Z; Wang, K; Wu, M; Wu, X; Xu, M; Yan, D; Yang, Z; Zhou, X, 2023) |
| "Psoriasis is a chronic inflammatory skin disease that affects millions of people worldwide." | ( Gu, C; Huang, Z; Li, L; Lian, P; Lu, R; Lu, Y; Ma, C; Peng, Z; Pu, W; Ruan, B; Su, Z; Wang, H; Wang, W; Wazir, J; Wei, L; Zong, Y, 2023) |
| Excerpt | Reference |
|---|
| "Photochemotherapeutic treatment of psoriasis with trioxsalen baths (0." | ( Alsins, J; Fischer, T, 1976) |
| "Patients treated for psoriasis with 8-MOP show concentrations of 10(-6)-10(-7) M." | ( Wettermark, G; Wulf, HC, 1977) |
| "The present study indicates, that PUVA treatment of psoriasis is not only an alternative to the use of systemic corticosteroids and cytotoxic agents but is superior to these treatment modalities due to its lack of side effects and its higher effectiveness." | ( Gschnait, F; Hönigsmann, H; Konrad, K; Wolff, K, 1977) |
| "The results of the first six months of treatment of psoriasis with photochemotherapy in the Skin and Cancer Foundation's clinic resulted in 30 out of 53 patients being completely clear of psoriasis lesions, 14 showing progressive improvement (and subsequently clearing), four failures, and five withdrawals." | ( King, R; O'Brien, H; Paver, K; Poyzer, K, 1979) |
| "The successful treatment of psoriasis with folic acid antagonists during the past 25 years has led to extensive research in the areas of cytokinetics and chemotherapy." | ( McCullough, JL; Weinstein, GD, 1976) |
| "A total of 60 patients was treated for psoriasis in a double-blind, paired comparison study of 0." | ( Blau, S; Kanof, NB, 1976) |
| "Results of treatment of psoriasis and various keratinizing dermatoses with an orally effective, aromatic retinoid are presented." | ( Ott, F, 1977) |
| "The possible methods of treating psoriasis and results obtained are reviewed and the superior effectiveness of an approach reported in recent literature, an association of methoxalene per os and broad ultraviolet rays, is pointed out." | ( Ormea, F, 1976) |
| "Azaribine is an effective agent in the treatment of psoriasis." | ( Cornell, RC; Fox, RM; Milstein, HG; Stoughton, RB, 1976) |
| "vitamin A by mouth for 38 days as a treatment for psoriasis." | ( Ehlers, B; Földi, E; Moeller, J, 1976) |
| "We report here the treatment of psoriasis, a chronic inflammatory skin disease characterized by uncontrolled keratinocyte proliferation, with BB14, a CD4 murine IgG1 antibody." | ( Morel, P; Nicolas, JF; Revillard, JP; Rizova, H; Thivolet, J; Wijdenes, J, 1992) |
| "Cyclosporine is effective in the treatment of psoriasis; however, potentially serious side effects limit its long-term use." | ( Goodman, MM; McCormick, A; McCullough, J; Weinstein, G; White, GM, 1992) |
| "During a therapeutic trial to treat psoriasis with either etretinate or cyclosporin A (CyA) we measured the respiratory burst activity of polymorphonuclear leukocytes (PMN)." | ( Färber, L; Höcher, J; Morsches, B; Rehder, M; Schopf, RE, 1992) |
| "The efficacy of home treatment of psoriasis with a new dithranol formulation, Micanol, was investigated in three studies." | ( Agren, S; Arlés, UB; Björnberg, A; Brolund, L; Pedersen, NB; Tegner, E; Volden, G, 1992) |
| "Throughout the study, untreated psoriasis plaques did not improve." | ( Annesley, TM; Birnbaum, JE; Burns, MK; Duell, E; Eisen, D; Ellis, CN; Griffiths, CE; Hamilton, TA; Voorhees, JJ, 1992) |
| "The efficacy of this treatment in psoriasis is well recognized, and the relative safety of up to 2 years of therapy is also established, provided that the guidelines are observed." | ( Mihatsch, MJ; Wolff, K, 1992) |
| "Cyclosporine A is efficacious in the treatment of psoriasis when taken orally or injected intralesionally but not topically." | ( Astrom, A; Duell, E; Fischer, V; Fisher, G; Voorhees, J, 1991) |
| "Methotrexate is effective in the treatment of severe psoriasis." | ( Bournerias, I, 1991) |
| "UVB radiation is beneficial for the treatment of psoriasis vulgaris." | ( Armstrong, R; Bourget, T; Edelstein, J; Lowe, NJ; Nychay, S; Prystowsky, JH, 1991) |
| "At the end of treatment, the psoriasis severity index decrease was 79% in the acitretin and UV-B group and 35% in the placebo and UV-B group." | ( Braun-Falco, O; Köster, W; Lengen, W; Lensing, W; Letzel, H; Meigel, WN; Paul, E; Przybilla, B; Ruzicka, T; Sommerburg, C, 1990) |
| "The present findings reveal that a pretreatment of psoriasis with topical glucocorticoids reduces the response to dithranol and the duration of remission." | ( Mahrle, G; Schulze, HJ, 1990) |
| "Dithranol is highly effective in the treatment of psoriasis." | ( Braun-Falco, O; Kemény, L; Ruzicka, T, 1990) |
| "Combined treatment of psoriasis with methotrexate and etretinate may be associated with hepatoxicity." | ( Jakobsen, P; Kragballe, K; Larsen, FG; Nielsen-Kudsk, F; Schrøder, H, 1990) |
| "The goal of therapy in the treatment of psoriasis is to decrease the rate of epidermal proliferation and the underlying inflammation." | ( Maibach, HI; Tung, JP, 1990) |
| "24 days after starting treatment of psoriasis with fumaric acid derivatives (0." | ( Arnholdt, H; Dalhoff, K; Faerber, P; Sack, K; Strubelt, O, 1990) |
| "Recently the treatment of psoriasis with vitamin D3, its metabolites or analogues, has been reported to be clinically effective and free from side effects." | ( Cunliffe, WJ; Holland, DB; Roberts, SG; West, MR; Wood, EJ, 1989) |
| "5% is an alternative in the treatment of psoriasis vulgaris on the face region as shown by bilateral comparison studies with fluocinolone acetonide 0." | ( Heller, G, 1989) |
| "In the treatment of psoriasis, which requires a stronger water-binding substance, a combination of sodium chloride and urea in equal concentrations is optimal." | ( Swanbeck, G, 1989) |
| "In the treatment of psoriasis with urea and urea-combined preparations, the individual sequence should be so clearly prescribed such that acceptance is assured." | ( Rohde, BT, 1989) |
| "Drugs used for treatment of psoriasis will sometimes cause a flare because of irritation, phototoxicity, or hypersensitivity reaction resulting in a Koebner phenomenon." | ( Abel, EA; DiCicco, LM; Farber, EM; Fraki, JE; Orenberg, EK, 1986) |
| "Oral treatment of psoriasis on an outpatient basis, using a preparation containing fumaric acid derivatives, was evaluated as initial monotherapy (3 months) and as long-term basic therapy (12-14 months) in 13 and 11 patients, respectively." | ( Bayard, W; Hunziker, T; Joshi, R; Krebs, A; Speiser, P, 1987) |
| "Like in the treatment of Psoriasis a strict correlation between the weekly administered dose and the cellular MTX could be established, the total cumulative dose, however, had no influence on the cellular MTX-level." | ( Dunky, A; Eberl, R; Fischer, M; Leeb, B; Ogris, E; Schenk, G; Tausch, G; Wohanka, A, 1988) |
| "Patients with untreated, active psoriasis had increased chemotactic response of their monocytes and neutrophils to N-formyl-methionyl-leucyl-phenylalanine." | ( Ternowitz, T, 1987) |
| "Methotrexate is frequently used in the treatment of severe psoriasis, and its hepatotoxicity has long been recognized by dermatologists." | ( Baker, H; Jones, DH; Phillips, TJ, 1987) |
| "Hydroxyurea is an effective treatment for psoriasis but consistently produces macrocytosis in peripheral blood with a fall in haemoglobin levels and white cell counts." | ( Comaish, JS; Dahl, MG, 1972) |
| "Sera from patients with untreated psoriasis were found to induce increased superoxide anion (O-2) generation when incubated with normal granulocytes (PMNs) and zymosan." | ( Bergstresser, PR; Hurd, ER; Sedgwick, JB, 1981) |
| "Current concepts in the treatment of psoriasis are reviewed, including: traditional modalities of dithranol (anthralin), tar, and corticosteroids alone or in combination with other agents; phototherapy and photochemotherapy; experimental studies with the aromatic retinoid etretinate and related analogues; dialysis; and the potential use of hyperthermia." | ( Farber, EM; Nall, L, 1984) |
| "A new preparation for treatment of psoriasis of the scalp, containing desoxymethasone 0." | ( Hillström, L, 1984) |
| "Report on the treatment of psoriasis in saturated sodium chloride water from a natural source followed by irradiation with ultraviolet UV-A- and UV-B-lights, similar to the treatment at the Dead Sea." | ( Ständer, M, 1983) |
| "In the treatment of psoriasis with topically applied methoxsalen, the patient is exposed to long-wave UV (UV-A) energy two hours after the application of methoxsalen." | ( Danno, K; Horio, T; Ishida, H; Toda, K, 1982) |
| "All patients taking methotrexate for treatment of psoriasis over the past 5 yr have been reviewed." | ( Ashton, RE; Millward-Sadler, GH; White, JE, 1982) |
| "The following treatments for psoriasis are compared with each other: PUVA, UVB, retinoid 10-9359 alone and in combination with 4 mg triamcinolone or UVB." | ( Schuppli, R, 1980) |
| "Advances in the treatment of psoriasis with anthralin are presented, including the suitability and acceptability of the base, the use of varying strengths of anthralin to suit the prevailing circumstances, and the need for showers or baths to control the treatment response." | ( Seville, RH, 1981) |
| "Patients with untreated psoriasis were less responsive than healthy controls; responses were less still in patients treated with dithranol/UV-B/tar and they were least of all in patients treated with photochemotherapy with 8-methoxypsoralen and UV-A (PUVA), particularly in those who pigmented least." | ( Friedmann, PS; Moss, C; Shuster, S, 1981) |
| "Three conventional treatments of scalp psoriasis were compared in a randomized, blind, uncontrolled clinical trial in 30 patients at a psoriasis day-care centre." | ( Ross, SD; Schachter, RK, 1981) |
| "In comparison to cyclosporine treatment of psoriasis, PUVA therapy leads to more complete reversal of pathological epidermal and lymphocytic activation, changes which we propose to be the cellular basis for a more sustained remission of disease after PUVA treatment." | ( Battat, L; Gilleaudeau, P; Gottlieb, AB; Heftler, N; Hodak, E; Krueger, JG; Nabeya, R; Vallat, VP; Wolfe, J, 1994) |
| "She had been treated for psoriasis vulgaris for 17 years without systemic immunosuppressive therapy." | ( Mizutani, H; Okada, H; Shimizu, M; Tanaka, H, 1995) |
| "Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro." | ( Federman, D; Kirsner, RS, 1995) |
| "Topically applied capsaicin effectively treats pruritic psoriasis, a finding that supports a role for substance P in this disorder." | ( Berberian, B; Dodd, WA; Ellis, CN; Jarratt, MT; Katz, HI; Krueger, G; Prawer, S; Rex, IH; Sulica, VI; Wolf, JE, 1993) |
| "Etretinate is effective for treating psoriasis and other keratinizing disorders." | ( Goh, CL; Shahidullah, M; Tham, SN, 1993) |
| "Our studies on the treatment of psoriasis with cyclosporine A (CSA) have demonstrated efficacy at doses < 5 mg/kg/day." | ( Johnson, KJ; Messana, JM; Mihatsch, MJ, 1995) |
| "Coal tar treated psoriasis patients were used as a model population to evaluate a panel of immunoassays for monitoring exposure to benzo[a]pyrene (BP) and related polycyclic aromatic hydrocarbons (PAH)." | ( Beachman, A; Chiamprasert, S; DeLeo, VA; Lin, JH; Perera, FP; Santella, RM; Tang, D; Wang, LW; Young, TL; Zhang, YJ, 1995) |
| "Fish oil may be beneficial in the treatment of psoriasis and in RA." | ( Belch, JJ; Fitzsimons, C; O'Dowd, A; Richards, IM; Sturrock, RD; Torley, HI; Veale, DJ, 1994) |
| "Topical treatment of psoriasis with calcipotriol has been proven effective." | ( Berardesca, E; Distante, F; Farinelli, N; Rabbiosi, G; Vignini, M; Vignoli, GP, 1994) |
| "Recent advances in the treatment of psoriasis include both the topical vitamin D analogue calcipotriol and cyclosporine." | ( Amblard, P; Belaich, S; Claudy, A; de Belilovsky, C; de la Brassinne, M; Grossman, RM; Guilhou, JJ; Souteyrand, P; Thivolet, J; Thomas, P, 1994) |
| "Coal tar-treated psoriasis patients were used as a model population to test a newly developed enzyme-linked immunosorbent assay (ELISA) for urinary excretion of benzo(a)pyrene and related polycyclic aromatic hydrocarbons (PAHs)." | ( Beachman, A; Blaskovic, R; DeLeo, VA; Lin, JH; Nunes, MG; Perera, FP; Santella, RM; Tang, D, 1994) |
| "Dithranol is highly effective in the treatment of psoriasis, but the exact mechanism of action is not known." | ( Arenberger, P; Kemény, L; Michel, G; Ruzicka, T, 1993) |
| "A new topical treatment for psoriasis was introduced in 1992 when the vitamin D analogue calcipotriol was registered in Norway." | ( Austad, J, 1993) |
| "In considering specific treatment for psoriasis, cost analyses, including appropriate laboratory and other specialized evaluations, must be taken into account." | ( Harrison, PE; Menter, A; Morris, LF; Phillips, CM; Sander, HM, 1993) |
| "Therefore, in the treatment of psoriasis, therapeutic effects may be expected with liarozole which are similar to those observed with synthetic retinoids." | ( Decree, J; Degreef, H; Dockx, P, 1995) |
| "UVB phototherapy is an effective treatment for psoriasis in patients infected with HIV." | ( Fotiades, J; Jiang, SB; Lim, HW; Moy, J; Sanchez, M; Soter, NA, 1995) |
| "Topical treatment of scalp psoriasis (with corticosteroids, dithranol or tar) results in decreased scaling, induration and erythema of the plaques." | ( Kuijpers, AL; van Baar, HM; van de Kerkhof, PC; van Gasselt, MW, 1995) |
| "Its use in the treatment of psoriasis has been attempted only quite recently and some modest success achieved." | ( Fergin, P, 1996) |
| "Our findings suggest that dithranol treatment of a psoriasis plaque is associated with a decrease in oxygen radical generating capacity in vivo." | ( Burton, JL; Donnell, VO; Kavanagh, GM, 1996) |
| "The histologic response to vitamin D treatment of psoriasis includes suppression of both immune and keratinocyte activation in situ." | ( Gilleaudeau, P; Gottlieb, AB; Gottlieb, S; Heftler, N; Kamber, M; Krueger, JG; Lu, I; McLane, JA, 1996) |
| "PUVA treatment of psoriasis is usually given with broad-band fluorescent UVA lamps." | ( de Berker, DA; Diffey, BL; Farr, PM; Matthews, JN; Sakuntabhai, A, 1997) |
| "Psoralen-UVB treatment of psoriasis is as effective as conventional PUVA." | ( de Berker, DA; Diffey, BL; Farr, PM; Matthews, JN; Sakuntabhai, A, 1997) |
| "Although many other topical treatments for psoriasis (occlusive therapy and vitamin D3 analogues) result in a prominent reduction in the amount of transglutaminase and involucrin positive cell layers, the effect of dithranol on these markers is minimal." | ( de Jong, EM; van de Kerkhof, PC; van der Vleuten, CJ, 1996) |
| "It was more effective in the treatment of palmar psoriasis, whereas its greater pigmentogenic activity appeared to have an adverse effect on therapeutic effectiveness in the treatment of plaque-type psoriasis." | ( Calzavara-Pinton, PG; Carlino, A; De Panfilis, G; Zane, C, 1997) |
| "Oral retinoids are effective in the treatment of psoriasis, but their use is limited by concerns for teratogenic potential and systemic side effects." | ( Marks, R, 1997) |
| "Once daily topical treatment of psoriasis with tacalcitol ointment (4 micrograms/g) was compared with twice daily treatment with calcipotriol ointment (50 micrograms/g) in a double-blind, randomized study over a treatment period of 8 weeks." | ( Bjerke, JR; Jakobsen, HB; Rossmann-Ringdahl, I; Veien, NK, 1997) |
| "After 4 weeks out-patient treatment, the psoriasis in all patients had improved by > or = 90%." | ( Muchenberger, S; Schöpf, E; Simon, JC, 1997) |
| "Systemic treatment of psoriasis with fumaric acid esters (FAE) has been found effective by empirical means." | ( Altmeyer, P; Christophers, E; Mrowietz, U, 1998) |
| "An optimal treatment of psoriasis requires a spectrum of topical drugs and their formulations in different vehicles." | ( Kuipers, MV; Steegers-Theunissen, RP; van de Kerkhof, PC, 1998) |
| "Cyclosporine for the treatment of psoriasis constitutes a new approach." | ( Bos, JD; Dobozy, A; Dubertret, L; Jablonska, S; Kind, P; Rubins, A; Ruzicka, T; Zonneveld, IM, 1998) |
| "Systemic treatment of psoriasis with fumaric acid derivatives (FAEs) has been reported to be effective in the treatment of psoriasis, but the mode of action is still unknown." | ( Funk, R; Goos, M; Ockenfels, G; Ockenfels, HM; Schultewolter, T, 1998) |
| "Methotrexate is widely used in the treatment of severe psoriasis." | ( Assaraf, YG; Bergman, R; Drori, S; Friedman-Birnbaum, R; Krivoy, N; Maor, G; Reiter, I; Sprecher, E; Sprecher, H, 1998) |
| "We conclude that treatment of psoriasis with CyA leads to a rapid drop of blood eosinophils and that the activation state of eosinophils does not decrease after antipsoriatic treatment." | ( Bräutigam, M; Hultsch, T; Lotz, J; Schopf, RE, 1998) |
| "Thioguanine has been used to treat psoriasis, but experience is limited." | ( Levine, N; Silvis, NG, 1999) |
| "The aim of treatment in psoriasis is to reduce the degree of extension to a point compatible with the patients social, occupational and personal lifestyle." | ( Chiaverini, C; Desruelles, F; Lacour, JP; Ortonne, JP, 1999) |
| "Tazarotene shows promise as a treatment for psoriasis in special localisations, such as the scalp, face and skin folds, although clinical studies are required." | ( Barker, JN; Finzi, AF; Gollnick, HP; Jansen, C; Marks, R; Revuz, J; Saurat, J, 1999) |
| "In each case, combination treatment for psoriasis resulted in good control of both skin and joint problems using lower doses of each agent than would have been used for monotherapy." | ( Allen, BR; Barker, JN; Chalmers, RJ; Clark, CM; Davison, S; Emerson, R; Griffiths, CE; Kirby, B; Morris, AD; Saihan, EM; Zaki, I, 1999) |
| "Anthralin is a safe, effective treatment for psoriasis, but its efficacy is hampered by the side-effects of irritation and staining of the uninvolved skin." | ( Friedmann, PS; Parslew, R, 1999) |
| "Cyclosporin is an effective treatment for psoriasis but its efficacy is only palliative." | ( Barthélemy, H; Bressieux, JM; Jan, V; Legoux, A; Reigneau, O; Steiner, HG; Vaillant, L, 1999) |
| "However, oral treatment of psoriasis for 4 weeks did not result in a decrease in disease severity." | ( Kooijmans-Otero, ME; Mommers, JM; Parker, GL; van de Kerkhof, PC; Van Rossum, MM, 2000) |
| "In the treatment of psoriasis with topical vitamin D3 analogues, lesional and perilesional irritation is the main side-effect." | ( Lehmann, P; Neumann, NJ; Ortland, C; Ruzicka, T; Schlotmann, K, 2000) |
| "In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects." | ( Lebwohl, M, 2000) |
| "As with treatment of psoriasis affecting skin, relapse is common and therapies may need to be maintained or repeated." | ( de Berker, D, 2000) |
| "betamethasone valerate 1% lotion in the treatment of psoriasis of the scalp." | ( Abdulla, SA; Abuzariba, O; al-Taweel, M; Duweb, GA; Rahim, M, 2000) |
| "The effectiveness of systemic treatment of psoriasis with fumaric acid esters has been proven, but their mode of action at the cellular and molecular level has not yet been fully elucidated." | ( Boorsma, DM; Flier, J; Nieboer, C; Sampat, S; Stoof, TJ; Tensen, CP, 2001) |
| "Out patient treatment of psoriasis is less expensive than in patient treatment." | ( Warin, AP, 2001) |
| "In the treatment of scalp psoriasis, cream formulations are used." | ( Franssen, ME; van de Kerkhof, PC, 2001) |
| "We assessed cost-effectiveness for treating psoriasis using two strategies: one consisted principally of methotrexate and the other was principally a rotational schedule of modified cyclosporine (Neoral) with methotrexate." | ( Bandekar, RR; Ellis, CN; Fendrick, AM; Reiter, KL, 2002) |
| "A method of treating psoriasis without the use of corticosteroids or antimitotic agents is described." | ( Comaish, S, 1965) |
| "It has been an established treatment for psoriasis since 1991 in Europe and 1994 in the USA." | ( Holm, EA; Jemec, GB, 2002) |
| "As we are treating selected psoriasis patients with low dose hydroxyurea we attempted to define the spectrum and chronology of dermatological adverse effects in this group of patients prospectively." | ( Kaur, I; Kumar, B; Saraswat, A, 2002) |
| "The use of cyclosporin A (CSA) for the treatment of severe psoriasis is well established." | ( Markham, T; Rogers, S; Watson, A, 2002) |
| "At the end of treatment, the psoriasis area and severity index had decreased by 57." | ( Green, C; Hamberg, KJ; Hutchinson, PE; Jensen, JK; Kidson, P; Kragballe, K; Larsen, FG; Munro, CS; Tillman, DM; Van de Kerkhof, PC, 2002) |
| "Psoralen + ultraviolet A-treated psoriasis patients are at increased risk for squamous cell carcinomas and basal cell carcinomas; however, the incidence and risk factors associated with second squamous cell carcinomas and basal cell carcinomas in this population are not well qualified." | ( Katz, KA; Marcil, I; Stern, RS, 2002) |
| "PTU may be considered as treatment model in psoriasis, in particular for resistant cases, because of its antioxidant potential, and also antiproliferative and immunomodulatory effects." | ( Akdaş, A; Keleştimur, F; Köse, K; Utaş, S; Yazici, C, 2002) |
| "Data on the efficacy of 308nm laser treatment of psoriasis were obtained from a previously published case series, supplemented by reanalysis of the data to estimate the median time to success using Kaplan-Meier methods." | ( Feldman, SR; Housman, TS; Mellen, BG; Rodewald, EJ, 2001) |
| "Body-weight-dependent (BWD) treatment of psoriasis with cyclosporine A (CsA is well established." | ( Bräutigam, M; Christophers, E; Kaufmann, R; Paul, C; Thaçi, D; Weidinger, G, 2002) |
| "In conclusion, treatment of psoriasis with cyclosporine is associated with an increased risk of nonmelanoma skin cancer." | ( Christophers, E; Dubertret, L; Guillaume, JC; Ho, VC; Lamarque, V; McGeown, C; Paul, CF; Schmidtmann, B, 2003) |
| "2 (ZHG2) in treating psoriasis with Liver-Qi stagnancy." | ( Luo, WH; Ouyang, H; Yang, Z, 2001) |
| "The effect of ZHG2 in treating psoriasis patients with Liver-Qi stagnancy is satisfactory, and worth further studying." | ( Luo, WH; Ouyang, H; Yang, Z, 2001) |
| "Many systemic agents are used in the treatment of psoriasis." | ( Kormeili, T; Lowe, NJ; Patnaik, R; Rizk, D; Yamauchi, PS, 2003) |
| "Oral retinoids are used to treat psoriasis." | ( Nijsten, TE; Stern, RS, 2003) |
| "The majority of patients treated had psoriasis that was refractory to treatment with broadband ultraviolet B, monotherapy with narrowband UVB, monotherapy with acitretin, or the combination of acitretin and broadband UVB." | ( Lebwohl, M; Rozenblit, M; Spuls, PI, 2003) |
| "Originally used to treat psoriasis nearly three decades ago, mycophenolic acid, reformulated as mycophenolate mofetil (MMF), has been rediscovered by the world of dermatology." | ( Liu, V; Mackool, BT, 2003) |
| "Vitamin D has been used for topical treatment of psoriasis, and 22-oxacalcitriol (OCT), shown to be less calcemic, was developed for the topical treatment of psoriasis in Japan." | ( Hashimoto, N; Higurashi, M; Hoshimoto, S; Ohigashi, S; Saito, Y; Seki, N; Tatsuno, I; Uchida, D, 2003) |
| "Methotrexate treatment for psoriasis is known to cause hepatic fibrosis in some patients, which might progress to cirrhosis." | ( Abramidou, M; Hytiroglou, P; Papadimitriou, CS; Saxena, R; Theise, ND; Tobias, H, 2004) |
| "Compared with other systemic treatments of psoriasis, the low cost, efficiency and well known adverse effects, are still favorable to methotrexate." | ( Bournerias, I, 2004) |
| "The efficacy of ciclosporin in the treatment of psoriasis is well established." | ( Ho, VC, 2004) |
| "To document and compare the costs of treatment of psoriasis with 2 established systemic agents that differ substantially in their unit costs: methotrexate vs cyclosporine." | ( Bos, JD; Bossuyt, PM; De Borgie, CA; De Rie, MA; Heydendael, VM; Opmeer, BC; Spuls, PI, 2004) |
| "Rational decision making for the treatment of psoriasis may include costs only within a long-term horizon and may consider the societal and patient benefits of different alternatives." | ( Bos, JD; Bossuyt, PM; De Borgie, CA; De Rie, MA; Heydendael, VM; Opmeer, BC; Spuls, PI, 2004) |
| "We aimed to develop a mechanism-based treatment for psoriasis with cyclopamine." | ( Avci, O; Taş, S, 2004) |
| "An effective treatment for psoriasis is described, consistent with intervention in a proximal/key pathogenic event." | ( Avci, O; Taş, S, 2004) |
| "Topical corticosteroids are the primary treatment for psoriasis; however, the side effects of corticosteroids are magnified on intertriginous and facial skin." | ( Chapman, MS; Feldman, SR; Freeman, AK; Hartle, JE; Henning, A; Lebwohl, M, 2004) |
| "In those patients receiving systemic treatment for psoriasis, methotrexate was the most widely used drug (4." | ( Boffa, MJ, 2005) |
| "We tried to clarify whether the treatment of plaque psoriasis as an inpatient with dithranol and narrow band UV-B 311 nm is still appropriate and economical when compared to biologics such as efalizumab." | ( Hahn, M; Schulz, T, 2005) |
| "Advances in topical treatments for psoriasis have kept pace with a rapidly evolving comprehension of its pathogenesis, making a review of current therapies useful for those who treat psoriasis." | ( Afifi, T; de Gannes, G; Huang, C; Zhou, Y, 2005) |
| "Approval for its use for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis is expected in the near future." | ( Scheinfeld, N, 2005) |
| "Daivobet is a once-daily treatment of psoriasis vulgaris containing betamethasone dipropionate and calcipotriol in a new ointment vehicle." | ( Guignard, E; Ortonne, JP; Peeters, P; Sitbon, R, 2005) |
| "Triptolide tablet is effective for the treatment of psoriasis vulgaris during the one-year follow-up." | ( Guo, NR; Wu, SX, 2005) |
| "It is widely used for the topical treatment of psoriasis showing good tolerability and effectiveness." | ( Bergamin, A; Carboni, I; Chimenti, S; de Felice, C, 2005) |
| "Topical agents for the treatment of psoriasis are indicated for patients whose affected area is less then 10% of their skin." | ( Koo, JY, 2005) |
| "Cyslosporin A (CyA) treatment of psoriasis is warranted in severe cases where other, conventional antipsoriatic approaches have failed." | ( V'lckova-Laskoska, MT, 2005) |
| "One-month acitretin treatment reduced psoriasis activity, insulin sensitivity, evaluated as QUICKI values (0." | ( Angioni, R; Beck-Peccoz, P; Cattaneo, A; Corbetta, S; Spada, A, 2006) |
| "The topical treatment of psoriasis benefits from the alternate use of dermocorticosteroids and vitamin D3 analogues." | ( Delvoye, P; Flagothier, C; Henry, F; Piérard, GE; Piérard-Franchimont, C, 2005) |
| "There are few reports regarding the treatment of nail psoriasis with topical calcipotriol." | ( Barzegari, M; Mortazavi, H; Valikhani, M; Zakeri, M, 2005) |
| "Since treatment of psoriasis is generally long-term, the objective of this study was to investigate the efficacy and safety of transferring patients to maintenance treatment with calcipotriene cream (Dovonex cream) following a 4-week treatment period with the two-compound product." | ( Bibby, A; Cambazard, F; Foster, R; Haverkamp, C; Martinez Escribano, JA; Naeyaert, JM; Thaçi, D; Vender, R; White, S, 2006) |
| "Numerous therapies exist for the treatment of psoriasis." | ( Hodulik, SG; Zeichner, JA, 2006) |
| "The efficacy of ciclosporin in the treatment of psoriasis and atopic dermatitis has been established and clinical data also demonstrate its efficacy in treating less common but equally challenging conditions such as pyoderma gangrenosum, lichen planus, autoimmune bullous disease, recalcitrant chronic idiopathic urticaria and chronic dermatitis of the hands and feet." | ( Dijkmans, BA; Finlay, AY; Griffiths, CE; Ho, VC; Johnston, A; Katsambas, A; Luger, TA; Mrowietz, U; Thestrup-Pedersen, K, 2006) |
| "Calcipotriol has become a first-line treatment for psoriasis." | ( Damstra, R; de Rie, MA; de Vries, HJ; de Waard-van der Spek, FB; Haertlein, NG; Hol, CW; Kucharekova, M; Kunkeler, AC; Lijnen, RL; Oranje, AP; Swinkels, OQ; van de Kerkhof, PC; van der Valk, PG; van Hees, C; van Neer, P, 2006) |
| "Dithranol has been used to treat psoriasis for decades." | ( Dobo, E; Gulya, K; Orojan, I; Szigeti, C; Varszegi, S, 2006) |
| "Patients with methotrexate treated psoriasis and risk factors for liver disease, especially diabetes type 2 or overweight, are at higher risk of developing severe liver fibrosis compared to those without such risk factors, even when lower cumulative methotrexate doses are given." | ( Hultcrantz, R; Johannesson, A; Kinnman, N; Lindholm, J; Ros, AM; Rosenberg, P; Urwitz, H, 2007) |
| "Biologics in the treatment of nail psoriasis have been the subject of recent research, but their cost-effectiveness is questionable." | ( Berth-Jones, J; Vlachou, C, 2007) |
| "Conventional treatments of psoriasis include topical and systemic drugs." | ( Rebora, A, 2007) |
| "Alefacept is a biologic treatment for psoriasis, with a selective effect on memory effector T cells." | ( De Jong, EM; Langewouters, AM; Van De Kerkhof, PC; Van Erp, PE, 2006) |
| "Furthermore, she had suffered from an untreated psoriasis since the age of 20." | ( Albert, A; Darsow, U; Eberlein, B; Eyerich, K; Hein, R; Jakob, T; Kerzl, R; Ring, J; Rombold, S; Traidl-Hoffmann, C, 2008) |
| "A case of a patient who was being treated for plaque psoriasis with acitretin, who subsequently developed erythrodermic psoriasis is reported." | ( Ahdout, J; Chiu, M; Mandel, H, 2008) |
| "In the treatment of psoriasis, patient adherence to oral medications is poor and even worse for topical therapy." | ( Balkrishnan, R; Boles, A; Camacho, FT; Clark, A; Feldman, SR; Fleischer, AB; Makhzoumi, Z; Pearce, DJ; Yelverton, CB; Yentzer, BA, 2008) |
| "The choice of treatment for psoriasis in children, as in adults, is determined by disease acuity, morphology, distribution, severity, and the presence of comorbidities, such as psoriatic arthropathy." | ( Cordoro, KM, 2008) |
| "New topical treatments in scalp psoriasis are needed because many current topical treatments are disliked by patients and associated with poor compliance." | ( Austad, J; Berne, B; Burden, AD; de Unamuno, P; Figueiredo, A; Ganslandt, C; Jemec, GB; Ortonne, JP; Poulin, Y, 2008) |
| "Excimer is a useful and effective treatment for psoriasis that may be used as a compliment to topical medications as well as NB-UVB." | ( Gattu, S; Rashid, RM; Wu, JJ, 2009) |
| "Before and after treatment, psoriasis area and severity index was calculated, and serum levels of interleukin (IL)-17, IL-22, and IL-23 were investigated." | ( Antiga, E; Caproni, M; Del Bianco, E; Fabbri, P; Melani, L; Volpi, W, 2009) |
| "After treatment, psoriasis area and severity index was significantly lower for both groups." | ( Antiga, E; Caproni, M; Del Bianco, E; Fabbri, P; Melani, L; Volpi, W, 2009) |
| "Because systemic treatment of psoriasis is associated with several adverse effects, methotrexate (MTX), either topically or as targeted delivery, has become a more-interesting alternative." | ( Ali, MF; Rafea, M; Salah, M; Saleh, N, 2008) |
| "Visits to dermatologists for treatment of psoriasis were identified using National Ambulatory Medical Care Survey data, a representative survey of visits to physician offices in the United States." | ( Feldman, SR; Fleischer, AB; Strowd, LC; Yentzer, BA, 2009) |
| "The primary treatment for psoriasis in the late 1980s and early 1990s was mid-potency corticosteroids." | ( Feldman, SR; Fleischer, AB; Strowd, LC; Yentzer, BA, 2009) |
| "These indicated treatments for psoriasis and psoriatic arthritis result in suppression of the immune system." | ( Forman, SB; Garrett, AB; Higginson, R, 2008) |
| "Indigo naturalis has shown efficacy in treating psoriasis in our previous clinical studies." | ( Chen, HW; Leu, YL; Lin, YK; Pang, JH; Wang, CT; Yang, SH, 2009) |
| "Topical corticosteroids are the primary treatment for psoriasis." | ( Feldman, SR; Kosari, P, 2009) |
| "PDL seems to be effective in the treatment of nail psoriasis and improves nail matrix and nail bed involvement." | ( Fernández-Guarino, M; García-Morales, I; Harto, A; Jaén, P; Sánchez-Ronco, M, 2009) |
| "The patient has been treated for psoriasis for the past seven years, and two years ago, had to undergo surgery due to bladder carcinoma, followed by a radiotherapy course." | ( Dadić-Hero, E; Graovac, M; Medved, P; Ruzić, K; Torić, I, 2009) |
| "The use of fumaric acid esters in the treatment of psoriasis was first proposed in 1959." | ( Avian, A; Kokelj, F; Plozzer, C; Trevisan, G, 2009) |
| "TNF inhibitors have revolutionized the treatment of psoriasis vulgaris as well as psoriatic and rheumatoid arthritis and Crohn disease." | ( Cardinale, I; Fuentes-Duculan, J; Guttman-Yassky, E; Krueger, JG; Lowes, MA; Nograles, KE; Suárez-Fariñas, M; Zaba, LC, 2009) |
| "This suggests that optimal treatment of psoriasis needs to target pathogenic pathways in both leukocytes and keratinocytes." | ( Prens, EP; Rácz, E, 2009) |
| "The Goeckerman regimen (GR) for the treatment of psoriasis comprises dermal application of crude coal tar (polycyclic aromatic hydrocarbons, PAHs) and exposure to ultraviolet radiation (UVR)." | ( Borska, L; Cerna, M; Fiala, Z; Hamakova, K; Kremlacek, J; Kucera, I; Pelikanova, D; Smejkalova, J, 2010) |
| "It has been used successfully for the treatment of psoriasis and psoriatic arthritis, rheumatoid arthritis, Crohn's disease and ankylosing spondylitis either as monotherapy or in combination with drugs such as methotrexate." | ( Kamili, Qu; Menter, A, 2010) |
| "Established treatments for psoriasis are generally based on antiproliferative, anti-inflammatory, or differentiation-modifying activity, or a combination of these effects." | ( Anderson, RJ; Cunningham, A; Donaldson, M; George, SE; Groundwater, PW, 2010) |
| "Calcipotriene has limited efficacy in treating psoriasis." | ( Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010) |
| "Acitretin is a time-honored treatment for psoriasis." | ( Booij, MT; Van De Kerkhof, PC, 2011) |
| "Finally, we treated psoriasis patients with STA-21-containing ointment in a nonrandomized study." | ( Asao, N; DiGiovanni, J; Iiyama, T; Ikeda, M; Kanda, T; Miyoshi, K; Nakajima, K; Sano, S; Takaishi, M; Tarutani, M, 2011) |
| "Tacrolimus is effective in treatment of psoriasis vulgaris." | ( Chen, L; Hao, F; Shen, Z; Song, Q; Tang, S; Zhong, B, 2011) |
| "Biological treatment of psoriasis, a chronic inflammatory immune-mediated pathology of huge social impact, has become a recent revolutionizing breakthrough in the management of the disease." | ( de Luca, C; Gubinelli, E; Korkina, LG; Kostyuk, VA; Lulli, D; Mariani, S; Mariani, V; Pastore, S; Pecorelli, A; Potapovich, AI; Raskovic, D; Stancato, A; Valacchi, G, 2011) |
| "Dimethylfumarate (DMF) is used in the treatment of psoriasis." | ( Gesser, B; Iversen, L; Johansen, C; Kjellerup, RB; Kragballe, K; Raaby, L; Rasmussen, MK; Rosada, C, 2011) |
| "Two therapies commonly used to treat psoriasis-phototherapy and tumor necrosis factor-alpha antagonists-must be used with caution in patients with both JDM and psoriasis owing to their potential to exacerbate clinical manifestations of JDM." | ( Jarvis, JN; Kim, NN; Lio, PA; Morgan, GA; Pachman, LM, 2011) |
| "Phototherapy is a mainstay in the treatment of psoriasis and is available as psoralen plus UVA (PUVA), broadband UVB (BB-UVB), and narrowband UVB (NB-UVB)." | ( Bagel, J; Feldman, SR; Halvorson, CR; Lapolla, W; Yentzer, BA, 2011) |
| "Acitretin, which is widely used in the treatment of psoriasis is part of this controversy secondary to its chemical relation to isotretinoin, a drug which has been associated with a large number of anecdotal case reports of depression and suicidal ideation." | ( Hayes, J; Koo, J, 2011) |
| "The medical records of 120 infliximab-treated psoriasis patients at our referral psoriasis clinic in Dallas between 2002-2008 were reviewed for response rates, side effects and concomitant therapies." | ( Hapa, A; Kamili, QU; Menter, A; Miner, A, 2011) |
| "Acitretin is a beneficial treatment for psoriasis, and should be considered when not contraindicated." | ( Dunn, LK; Feldman, SR; Gaar, LR; O'Neill, JL; Yentzer, BA, 2011) |
| "Etanercept is approved for the treatment of plaque psoriasis at a subcutaneous (SC) dosage of 50 mg twice-weekly for three months, followed by 50 mg SC once-weekly thereafter." | ( Kircik, LH, 2011) |
| "Methotrexate (MTX) treatment for psoriasis is most often administered weekly, because the drug has been considered more hepatotoxic when taken daily." | ( Moosavi, ZB; Radmanesh, M; Rafiei, B; Sina, N, 2011) |
| "There are few evidence-based studies on treating psoriasis in pregnant and lactating women." | ( Bae, YS; Bebo, B; Hsu, S; Kimball, AB; Korman, NJ; Lebwohl, MG; Van Voorhees, AS; Young, M, 2012) |
| "Some of these medications used to treat psoriasis are known abortifacients, mutagens, or teratogens and must be clearly avoided but others can be used with relative confidence in select patients with appropriate counseling of risks and benefits." | ( Bae, YS; Bebo, B; Hsu, S; Kimball, AB; Korman, NJ; Lebwohl, MG; Van Voorhees, AS; Young, M, 2012) |
| "Activated vitamin D3 is the first-line treatment for psoriasis." | ( Morimoto, S; Okuro, M, 2011) |
| "In the treatment of nail psoriasis, standardized therapeutic regimens are currently lacking." | ( Chang, YC; Chen, JL; Huang, YH; Leu, YL; Lin, YK; See, LC; Shen, YM; Tsou, TC, 2011) |
| "The only agent licensed for the treatment of psoriasis in patients above the age of 8 years is etanercept if classical treatment has failed." | ( Sticherling, M, 2012) |
| "An herbal drug for the treatment of psoriasis showed severe clinical adverse reactions." | ( He, Y; Lin, R; Lu, J; Zhang, Y, 2012) |
| "Methotrexate (MTX) has been used in the treatment of psoriasis." | ( Dayalan, H; Elango, T; Gnanaraj, P; Malligarjunan, H; Subramanian, S, 2012) |
| "Options for treatment of facial psoriasis, including hairline involvement, are the use of low potency topical steroids, calcineurin inhibitors, and vitamin D analogues." | ( Kamangar, F; Koo, JY; Nguyen, TV; Wong, JW, 2012) |
| "Despite recent advances in the treatment of psoriasis, the therapeutic options for nail psoriasis are very limited, particularly when this is the only manifestation of the disease." | ( Caldarola, G; D'Agostino, M; De Simone, C; Maiorino, A; Tassone, F, 2013) |
| "Only dermatologists with interest in treating psoriasis were surveyed and general perceptions were elicited via survey format." | ( Abuabara, K; Bebo, BF; Callis Duffin, K; Gelfand, JM; Krueger, GG; Shin, DB; Troxel, AB; Van Voorhees, AS; Wan, J, 2013) |
| "Photo(chemo)therapy is widely used to treat psoriasis, the pathogenesis of which might be caused by an imbalance of Th17 cells/regulatory T cells (Treg)." | ( Furuhashi, T; Morita, A; Nishida, E; Saito, C; Torii, K; Yamazaki, S, 2013) |
| "A clinical trial study in the treatment of psoriasis was conducted in twenty three patients." | ( Hazra, SC; Khan, SI; Khondker, L; Mahbub, MS, 2013) |
| "Hence, PUVAsol may be recommended as treatment for psoriasis in a developing economy such as India." | ( Aggarwal, K; Khandpur, S; Khanna, N; Pandav, CS; Sharma, VK, 2013) |
| "The successful treatment of psoriasis depends not only on the efficacy of the medication but also on patientsí acceptance and adherence to the prescribed regimen." | ( Anger, T; Eicke, C; Sticherling, M, 2013) |
| "Whether systemic treatments for psoriasis or psoriatic arthritis affect cardiovascular comorbidities is a clinically significant question." | ( Armstrong, AW; Armstrong, EJ; Brezinski, EA; Follansbee, MR, 2014) |
| "Methotrexate (MTX) is an effective treatment for psoriasis but its use is limited by its toxicity." | ( Al-Dabagh, A; Davis, SA; Feldman, SR; Huang, K; Kinney, MA, 2013) |
| "Methotrexate (MTX) is a drug used to treat psoriasis due to inducing immune cell apoptosis." | ( Chen, C; Chen, X; Kuang, Y; Li, Q; Liu, S; Luo, Z; Su, J; Wu, L; Zeng, W; Zhang, J; Zhao, S; Zhou, S, 2013) |
| "The unsatisfactory outcome in the treatment of psoriasis is partially due to the poor compliance to the present therapies with more or less side-effects." | ( Hu, J; Li, H; Wen, C; Yang, R; Zhao, H; Zhao, M; Zhou, Q, 2013) |
| "Ciclosporin (Cs)A is an effective treatment for psoriasis." | ( Asano, Y; Kadono, T; Kamata, M; Kanda, N; Kawashima, T; Mitsui, H; Sato, S; Shibata, S; Sugaya, M; Tada, Y; Tatsuta, A; Watanabe, S, 2013) |
| "As part of a Cochrane review of topical treatments for psoriasis, we systematically searched electronic databases for randomized controlled trials." | ( Cork, MJ; Dooley, G; Hancock, H; Mason, AR; Mason, JM, 2013) |
| "Biological therapies for the treatment of psoriasis include targeted therapies (alefacept) and anti-cytokine therapies (anti-tumour necrosis factor [TNF] therapies [adalimumab, etanercept, infliximab] and a monoclonal antibody against interleukin [IL]-12 and IL-23 [ustekinumab])." | ( Costanzo, A; Papoutsaki, M, 2013) |
| "Methotrexate (MTX) is an effective treatment for psoriasis but concerns regarding the development of liver fibrosis prevent optimal use." | ( Barker, JN; Dhillon, AP; Jabbar-Lopez, ZK; Maybury, CM; Smith, CH; Wong, T, 2014) |
| "The upcoming systemic agents for the treatment of psoriasis are presented in this article, encompassing novel biologics and small-molecule medicines (eg, IL-17 receptor blockers, Janus kinase [Jak] inhibitors)." | ( Han, G, 2014) |
| "Topical therapy is a conventional treatment for psoriasis vulgaris." | ( Guo, XF; Li, G; Li, XY; Lu, CJ; Ou, AH; Wen, ZH; Xuan, ML; Yan, YH; Yao, DN, 2014) |
| "The frequency of systemic treatments to treat psoriasis has not significantly increased from 1993 to 2010." | ( Davis, SA; Feldman, SR; Fleischer, AB; Shaw, MK, 2014) |
| "Dermatologists and other clinicians who treat psoriasis continue to benefit from insights gained in the field of rheumatology." | ( Mandell, BF; Sobell, JM, 2014) |
| "Topical therapies are the mainstream treatment of psoriasis because most patients have mild disease." | ( van de Kerkhof, PC, 2015) |
| "Chinese herbal medicine is effective in treating psoriasis vulgaris." | ( Goodman, G; Lu, C; Parker, S; Wen, Z; Xue, CC; Zhang, AL; Zhang, CS, 2014) |
| "Current available treatments for psoriasis and melanoma are inefficient due to systemic side effects, poor transcutaneous permeation and thus present a challenge for development of novel colloidal carriers." | ( Divate, D; Gangurde, S; Pawar, S; Pund, S, 2015) |
| "MTX remains the mainstay in the treatment of psoriasis in developing countries and its combination with NBUVB offers a cheap and a beneficial therapeutic option." | ( Asal, M; El Desouky, F; Nofal, A; Nofal, E; Soliman, A, 2015) |
| "Imiquimod treatment induced a psoriasis-like skin inflammation." | ( Jessen, N; Kjær, TN; Pedersen, SB; Stenderup, K; Thorsen, K, 2015) |
| "Many biological agents, used in the treatment of psoriasis, include TFN-α inhibitors, such as etanercept, adalimumab, and anti IL-12/IL-23 p40 antibody, such as ustekinumab." | ( D'Amico, F; Gangemi, P; Granata, M; Longo, V; Mazzarino, MC; Mosca, A; Pettinato, M; Rossi, GA; Skarmoutsou, E; Trovato, C, 2015) |
| "Topical therapies are the mainstay of treatment for psoriasis vulgaris." | ( Hol, CW; Lambert, J; Vink, J, 2015) |
| "cinnamomea in the treatment of psoriasis and other Th17 cell-mediated inflammatory diseases." | ( Li, MH; Lin, CC; Pan, IH; Wen, SF; Wu, HC; Yao, HJ, 2015) |
| "Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments." | ( Griffiths, CE; Tan, KW, 2016) |
| "Four trials were identified on the treatment of psoriasis." | ( Bank, M; Haber, SL; Hamilton, S; Leong, SY; Pierce, E, 2016) |
| "Oral CHM itself appeared safe for treating psoriasis vulgaris and possibly could reduce the common adverse events seen with acitretin." | ( Guo, X; Lu, C; May, BH; Xue, CC; Yang, L; Yu, JJ; Zhang, AL; Zhang, CS, 2016) |
| "Food and Drug Administration for the treatment of psoriasis, cyclosporine has been used with great efficacy in the treatment of not only psoriasis but also a wide consortium of dermatological diseases." | ( Soleymani, T; Vassantachart, JM; Wu, JJ, 2016) |
| "Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life." | ( Bissonnette, R; Chen, R; Day, RM; Goncalves, J; Pariser, DM; Sebastian, M; Wasel, NR, 2016) |
| "Topical treatments for psoriasis include corticosteroids, vitamin D derivatives, tazarotene, anthralin, tacrolimus, pimecrolimus, and newer formulations of tar." | ( Stein Gold, LF, 2016) |
| "Attempts to use topical cyclosporine in treatment of psoriasis have failed because of unfavorable physicochemical properties and inappropriate formulation design of the conventional dosage forms." | ( Amarji, B; Dogra, S; Katare, OP; Kumar, R; Kumar, S; Mahajan, R; Singh, B; Vinay, K, 2016) |
| "Methotrexate (MTX) has been used to treat psoriasis for over half a century." | ( Foerster, J; Ogston, S; West, J, 2016) |
| "In 2 identical, phase III studies (Oral treatment for Psoriasis Trial Pivotal 1 [NCT01276639], n = 901, and Pivotal 2 [NCT01309737], n = 960), patients were randomized 2:2:1 to receive 5 or 10 mg of tofacitinib or placebo, twice daily." | ( Augustin, M; Buonanno, M; de la Cruz, C; Feldman, SR; Gooderham, M; Kaur, M; Lan, S; Mallbris, L; Mamolo, C; Tatulych, S; Thaçi, D; Valdez, H, 2016) |
| "Difficult to treat areas of psoriasis (nail or scalp) also responded to ixekizumab." | ( Aoki, T; Cameron, GS; Ishii, T; Morisaki, Y; Nakagawa, H; Nakajo, K; Osuntokun, OO; Saeki, H, 2017) |
| "Undertreatment of psoriasis remains a problem in Belgium and more effective educational strategies are needed to ensure the best treatment outcome for these patients." | ( Cauwe, B; Ghislain, PD; Lambert, J; Van den Enden, M, 2017) |
| "Methotrexate is extensively used in the treatment of psoriasis." | ( Gönül, M; Hacınecipoğlu, F; Keseroglu, H, 2016) |
| "Psoriasis patients not taking any treatment, 3." | ( Ahmed, AS; Al-Najjar, AH; El-Gharabawy, RM, 2017) |
| "After treatment of psoriasis patients with a traditional anti-psoriatic drug in combination with metformin and peroxisome proliferator-activated receptor gamma (PPARɤ) agonist (pioglitazone), the CD4+ T cells, IL-2, CRP, CP, ALT and AST levels were statistically significantly decreased compared to psoriasis patients without treatment." | ( Ahmed, AS; Al-Najjar, AH; El-Gharabawy, RM, 2017) |
| "Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years." | ( Funding, AT; Grønbæk, H; Heickendorff, L; Heidenheim, M; Iversen, L; Kyvsgaard, N; Lindberg, R; Madsen, JT; Raaby, L; Skov, L; Strauss, G; Thielsen, P; Zachariae, C; Østensen, M, 2017) |
| "As methotrexate (MTX) is a widely used treatment for psoriasis, it is important to gain insight into the reasons for the discontinuation of MTX and to understand the determinants for drug survival." | ( de Jong, EM; Kievit, W; Otero, ME; Seyger, MM; van de Kerkhof, PC; van den Reek, JM, 2017) |
| "Drugs that are currently used in the treatment of psoriasis are associated with drawbacks such as rapid recrudescence, high costs and unwanted side-effects." | ( Bo, KP; Chen, WG; Ma, W; Shi, HJ; Song, HB; Xia, L; Yang, J; Zhou, H, 2017) |
| "Approaches currently available to treat psoriasis are not satisfactory due to undesirable side-effects or expense." | ( Chen, Q; Chi, M; Deng, X; Leavesley, D; Shi, H; Xie, N; Xie, Y; Yang, Y; Zhang, H; Zhou, H, 2017) |
| "Our study suggests that untreated psoriasis may impair male fertility." | ( Baroni, S; Caldarola, G; De Simone, C; Grande, G; Marana, R; Milardi, D; Morelli, R; Peris, K; Pontecorvi, A; Quercia, A, 2017) |
| "In spite of significant advances in the treatment of psoriasis, more effective and safer therapeutic strategies are still needed." | ( Chen, T; Fu, LX; Guo, ZP; Liu, XY; Wu, YB; Zhang, LW, 2017) |
| "To assess the efficacy of short-term treatment of scalp psoriasis with topical clobetasol lotion." | ( Feldman, SR; Firooz, A; Hasanzadeh, H; Rajabi-Estarabadi, A; Taheri, A, 2018) |
| "To elucidate the effect of FAE treatment on human psoriasis and healthy donor NET formation." | ( Enk, AH; Hadaschik, EN; Hartl, D; Hoffmann, JHO; Schaekel, K, 2018) |
| "Biologic and systemic drugs used to treat psoriasis can result in an increase in infections or malignancies." | ( Armstrong, AW; Prussick, R; Siegel, MP; Van Voorhees, AS; Wu, JJ, 2018) |
| "The variety of available systemic treatments for psoriasis is increasing rapidly." | ( Barnetche, T; Brenaut, E; Misery, L; Théréné, C, 2018) |
| "Most methotrexate-treated psoriasis patients do not achieve a long-term PASI75 (75% reduction from baseline Psoriasis Area and Severity Index score) response." | ( Betts, KA; Gordon, KB; Li, J; Okun, MM; Signorovitch, JE; Sundaram, M; Wu, EQ; Xie, M, 2017) |
| "Still, there are unmet needs in the treatment of psoriasis regarding long-term efficacy, tolerability, safety, route of administration, and cost." | ( Azevedo, A; Torres, T, 2018) |
| "The effectiveness of icotinib in treating psoriasis was tested in three psoriasis models, including diethylstilbestrol-treated mouse vaginal epithelial cells, mouse tail granular cell layer formation, and propranolol-induced psoriasis-like features in guinea pig ear skin." | ( Chen, H; Deng, Y; Ding, L; Guo, J; Huang, X; Li, H; Tan, F; Wang, Y; Yang, G; Yu, B; Yu, P, 2018) |
| "Many treatments for psoriasis and psoriatic arthritis are also used for IBD." | ( Armstrong, AW; Enos, CW; Gottlieb, A; Langley, RG; Lebwohl, M; Merola, JF; Ryan, C; Siegel, MP; Van Voorhees, AS; Weinberg, JM; Whitlock, SM; Wu, JJ, 2018) |
| "Apremilast is a safe and efficacious treatment for psoriasis patients as it produces ΔPASI75 and ΔPASI50 responses combined with DLQI ≤ 5 in 16 weeks in 70." | ( Kokkalis, G; Papadavid, E; Rigopoulos, D; Rompoti, N; Theodoropoulos, K, 2018) |
| "There is no evidence that treatment for psoriasis modifies leptin and adiponectin concentrations." | ( Goulis, DG; Kyriakou, A; Patsatsi, A; Sotiriadis, D, 2018) |
| "Systemic treatment of psoriasis is associated with several adverse effects, therefore the development of a customized topical treatment modality for psoriasis would be an interesting alternative to systemic delivery." | ( Aboel-Fadl, DM; Fadel, M; Nasr, M; Nour El-Deen, F; Ramez, SA; Soliman, MM; Youness, ER, 2018) |
| "The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown." | ( Egeberg, A; Goldblum, O; Korman, N; Mallbris, L; Solomon, JA; Wu, JJ; Zhao, F, 2018) |
| "Methotrexate (MTX) is used to treat psoriasis, a chronic inflammatory skin disease." | ( Han, L; Huang, Q; Huang, Y; Ma, Y; Xin, KZ; Xu, W; Yan, K; Zhang, Z, 2018) |
| "Thus, DMF as monotherapy for the treatment of psoriasis is as efficacious as in combination with MEF, making the addition of such fumarate derivatives unnecessary." | ( Amasuno, A; Asadullah, K; Landeck, L; Mrowietz, U; Pau-Charles, I, 2018) |
| "Nonadherence to systemic treatments for psoriasis leads to treatment failure and increased health care utilization." | ( Dommasch, ED; Gagne, JJ; Garry, EM; Joyce, CJ; Lee, MP, 2018) |
| "The available treatments for psoriasis are not curative and may have numerous side effects, and topical administration is preferred over systemic therapy due to the reduced systemic burden of the drug." | ( Andreola, F; Calcaterra, A; Camponeschi, C; De Angelis, C; Giovannini, D; Nicotera, G; Pierimarchi, P; Serafino, A; Sferrazza, G; Zonfrillo, M, 2018) |
| "Acitretin is widely used to treat psoriasis, but the efficacy varies significantly among individuals." | ( Chen, W; Chen, X; Peng, C; Zhang, W; Zhang, X; Zhu, W, 2018) |
| "There are multiple regimens for the treatment of psoriasis including disease- modifying anti rheumatic drugs (DMARDS) and biologic agent, phototherapy and apremilast." | ( Chen, C; Gettas, T; Messiah, R; Metyas, S; Quismorio, A; Tomassian, C, 2019) |
| "To investigate the body location of treatment-resistant psoriasis in patients treated with biologic agents in real-world clinical practice, and to study the association between localization and quality of life." | ( Hjuler, KF; Iversen, L; Kofoed, K; Rasmussen, MK; Skov, L; Zachariae, C, 2019) |
| "Classically, the first line of treatment for nail psoriasis has been topical medication, but the new biological drugs seem to be the most effective treatment." | ( Hernández-Bel, P; Magdaleno-Tapial, J; Ortiz-Salvador, JM; Subiabre-Ferrer, D; Valenzuela-Oñate, C, 2018) |
| "Fumaric acid esters (FAEs) are used to treat psoriasis and are known to cause lymphopenia in roughly 60% of the patients." | ( Altmeyer, P; Bruckner, T; Dickel, B; Dickel, H; Höxtermann, S; Trinder, E, 2019) |
| "For the systemic treatment of nail psoriasis acitretin, methotrexate, cyclosporine, small molecules, and biologics may be employed." | ( Baran, R; Chiheb, S; Daniel, CR; Di Chiacchio, N; Gregoriou, S; Grover, C; Haneke, E; Iorizzo, M; Pasch, M; Piraccini, BM; Rich, P; Richert, B; Rigopoulos, D; Rompoti, N; Rubin, AI; Singal, A; Starace, M; Tosti, A; Triantafyllopoulou, I; Zaiac, M, 2019) |
| "Indeed, some treatments of psoriasis might be impaired by adiposity." | ( Chiricozzi, A; Girolomoni, G; Gisondi, P, 2019) |
| "Methotrexate (MTX) is an efficacious treatment for psoriasis; however, its widespread application is limited by its unpredictable efficacy." | ( Chang, YL; Fang, X; Han, L; Huang, Q; Jin, L; Li, XY; Qian, DF; Wu, MS; Xu, JH; Xu, QH; Yan, KX; Yawalkar, N; Zhang, Q; Zhang, XJ; Zhang, YJ; Zhang, ZH; Zheng, ZZ, 2019) |
| "Even as treatment of psoriasis becomes safer, it is important to recognize both common and uncommon adverse effects of treatment." | ( Cline, A; Feldman, SR; Kepley, AL; Kolli, SS, 2019) |
| "TGP can be used to treat psoriasis with reduced adverse reactions and recurrence rates." | ( Jiang, W; Li, B; Li, H; Li, X; Ma, T; Shen, F; Sun, X; Xie, S; Xu, W; Zheng, Q, 2019) |
| "Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen." | ( Busard, CI; Costanzo, A; De Keyser, E; Hutten, BA; Lambert, J; Lanssens, S; Meuleman, L; Spuls, PI; van den Reek, JM; Zweegers, J, 2019) |
| "Current treatment for psoriasis relies on conventional immunosuppressive agents." | ( Chen, H; Chen, Y; Dai, Z; Deng, J; Han, L; Huang, H; Liu, C; Liu, H; Lu, C; Wei, J; Xu, YY; Yan, Y, 2019) |
| "Following treatment of psoriasis, a decrease in aortic vascular uptake of 18F-FDG was associated with a reduction in AWT at 1 year." | ( Ahlman, MA; Aksentijevich, M; Al Najafi, M; Bluemke, DA; Choi, H; Dey, AK; Elnabawi, YA; Gelfand, JM; Genovese, LD; Goyal, A; Groenendyk, JW; Harrington, CL; Joshi, AA; Kabbany, MT; Mehta, NN; Natarajan, B; Playford, MP; Reddy, AS; Rodante, J; Sadek, A; Shukla, P, 2019) |
| "While many treatments for psoriasis exist, few are convenient and safe long term; even if sufficiently effective, treatments themselves often decrease quality of life and make long-term treatment adherence difficult." | ( Saruwatari, H, 2019) |
| "This study evaluated the treatment of psoriasis with esomeprazole." | ( Bafutto, M; Oliveira, EC; Zaterka, S, 2019) |
| "In summary, TXL may be able to treat psoriasis by regulating Th cells differentiation via inhibiting Notch1 and Jak2/Stat3 pathways." | ( Du, Z; Li, N; Lu, C; Wu, D; Yuan, X; Zhang, M; Zhu, W, 2020) |
| "Pioglitazone may be beneficial in the treatment of psoriasis." | ( Ding, Y; Guan, MM; Kang, XJ; Xiang, F; Yu, SR; Zhang, DZ; Zhang, JZ, 2020) |
| "Use of pioglitazone in the current treatment of psoriasis is beneficial." | ( Ding, Y; Guan, MM; Kang, XJ; Xiang, F; Yu, SR; Zhang, DZ; Zhang, JZ, 2020) |
| "Methotrexate (MTX) is the first-line treatment for psoriasis in China." | ( Chen, M; Chen, W; Chen, X; Kuang, Y; Liu, P; Lu, Y; Lv, C; Qin, Q; Yan, K; Zhang, M; Zhu, W, 2020) |
| "It was also investigated for the treatment of plaque psoriasis, although it is not approved by the Food and Drug Administration for this indication." | ( Georgakopoulos, JR; Ighani, A; Yeung, J, 2020) |
| "The Oral-treatment Psoriasis Trial (OPT) study series demonstrated that tofacitinib is efficacious in the treatment of plaque psoriasis with an acceptable safety profile." | ( Georgakopoulos, JR; Ighani, A; Yeung, J, 2020) |
| "Therapies to treat psoriasis include phototherapy, non‑steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor‑α, interleukin (IL)‑17‑A and IL‑12/IL‑23, which all focus on decreasing the proinflammatory hallmark of psoriasis." | ( Briseño-Lugo, PE; Cancino-Diaz, JC; Cancino-Diaz, ME; Díaz-Toalá, I; Gómez-Chávez, F; Gutiérrez-Gonzalez, G; Mendoza-Figueroa, JS; Pérez-Tapia, SM; Rodríguez-Martínez, S; Torales-Cardeña, A; Vázquez-Sánchez, EA; Zapi-Colín, LA, 2020) |
| "Effective treatment of scalp psoriasis is essential for improving the quality of life of psoriasis patients." | ( Alsenaid, A; Ezmerli, M; Heppt, M; Illigens, BM; Prinz, JC; Srour, J, 2022) |
| "The estimated cost to treat psoriasis in USA is over 13 billion US dollars per year." | ( Awasthi, R; Jindal, S; Kulkarni, GT; Singhare, D, 2020) |
| "Cal/BD formulations are efficacious treatment for psoriasis." | ( Camela, E; Cinelli, E; Fabbrocini, G; Megna, M, 2020) |
| "The major problem in the topical treatment of psoriasis is drug localization through the psoriasis lesions." | ( Anbardar, MH; Chavoshy, F; Tamaddon, AM; Zadeh, BSM, 2020) |
| "The optimized batch was used for the treatment of psoriasis lesions in the mice model." | ( Anbardar, MH; Chavoshy, F; Tamaddon, AM; Zadeh, BSM, 2020) |
| "In these studies, treatment of scalp psoriasis with Cal/BD foam provided good efficacy for adults and adolescents and was generally well tolerated." | ( Lebwohl, M; Petersen, B, 2020) |
| "UVB phototherapy is treatment for psoriasis, which increases phospholipid oxidative modifications in the cell membrane of the skin." | ( Dobrzyńska, I; Domingues, MR; Domingues, P; Skrzydlewska, E; Wroński, A; Łuczaj, W, 2020) |
| "Despite successful treatment of psoriasis by blocking IL-23, the regulation of IL-23 expression in psoriasis patients is largely unknown." | ( De La Torre, R; Ehst, B; Greiling, T; Leitenberger, J; Liu, Y; McClanahan, D; Ortega-Loayza, AG; Sawka, E; Simpson, E; Strunck, J; Wang, Z, 2021) |
| "Regarding the choice of treatment for psoriasis in men with a paternity project, methotrexate should be avoided in the 3 months prior to conception even though the data on many pregnancies occurring on methotrexate are reassuring." | ( Brenaut, É, 2020) |
| "Clinical treatment in psoriasis with secukinumab restored the suppressive function and increased production of TGF-β in Tregs of psoriasis." | ( Bai, X; Dang, E; Li, B; Liu, Y; Wang, G; Wang, L; Xiao, C; Yang, L; Yu, C; Zhang, C, 2021) |
| "To study the new insights in the treatment of psoriasis and future prospects." | ( Easwari, TS; Singh, A, 2021) |
| "A drug used in the treatment of psoriasis of moderate and acute strength is the monoclonal antibody anti-TNF-adalimumab." | ( Adwent, I; Brus, R; Grabarek, BO; Kasela, T; Zawidlak-Węgrzyńska, B, 2021) |
| "Thus, scopolamine has potential for the treatment of psoriasis." | ( Cai, Q; Li, G; Li, M; Li, Q; Song, N; Yu, B; Zhi, Y, 2021) |
| "Response to treatments in psoriasis can be assessed using the PASI response 50, 75, 90 or 100." | ( Belinchón Romero, I; Carrascosa Carrillo, JM; Dauden, E; Ferrándiz Foraster, C; González-Cantero, Á, 2022) |
| "However, products for the topical treatment of mild psoriasis are still required." | ( Gendrisch, F; Haarhaus, B; Krieger, N; Quirin, KW; Schempp, CM; Wölfle, U, 2021) |
| "Wide treatment options used to treat psoriasis is associated with various adverse effects." | ( Devabattula, G; Gangadevi, V; Godugu, C; Pooladanda, V; Thatikonda, S, 2021) |
| "CAL/BDP cream is a novel topical treatment of psoriasis, which in a single product, offers a unique combination of high efficacy combined with favorable safety and excellent treatment convenience." | ( Dhawan, S; Green, LJ; Praestegaard, M; Selmer, J; Stein Gold, L; Vestbjerg, B, 2021) |
| "Among the different treatments for psoriasis, statins have been found to reduce the severity of the disease." | ( Al Salman, M; Azizpour, A; Farid, AS; Ghiasi, M; Mahmoudi, H; Taraz, M, 2021) |
| "Topical treatments of psoriasis are either associated with limited response or with side effects." | ( Chan, TC; Chang, WY; Huang, WC; Krueger, JG; Lee, MS; Tsai, TF, 2021) |
| "More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ." | ( Argenziano, G; Atzori, L; Bianchi, L; Campanati, A; Corazza, M; Damiani, G; De Pità, O; Donini, M; Fargnoli, MC; Feliciani, C; Mazzatenta, C; Mazzotta, A; Offidani, A; Peris, K; Potenza, C; Prignano, F; Stingeni, L; Tiberio, R, 2021) |
| "This study evaluated whether FJDH treated psoriasis and its specific mechanism for the efficacy in mice." | ( Kong, L; Li, M; Lv, W; Meng, S; Qiao, H; Song, C; Sun, Y; Wang, X; Yang, C; Zhu, Y, 2021) |
| "UVB phototherapy is commonly used to treat psoriasis, although this has undesirable side effects, and is often combined with anti-inflammatory compounds." | ( Gęgotek, A; Skrzydlewska, E; Wójcik, P; Žarković, N, 2021) |
| "have a better clinical efficacy in the treatment of psoriasis, there is a lack of overall understanding of the mechanism of their treatment, especially about some immune cells and proteins closely related to psoriasis and their relationship in executive function and biological significance." | ( Cheng, G; Kuang, H; Su, Y; Wang, Q; Wu, L; Zhang, F, 2022) |
| "Apremilast is approved for the treatment of psoriasis and psoriatic arthritis." | ( de la Brassinne, M; Ghislain, PD; Hillary, T; Lam Hoai, XL; Lambert, J; Roquet-Gravy, PP; Segaert, S, 2022) |
| "CAL/BDP PAD-cream is a novel topical treatment for psoriasis, which through PAD™ Technology offers substantial improvement in QoL and treatment satisfaction for patients." | ( Armstrong, A; Koo, J; Pinter, A; Præstegaard, M; Reich, A; Selmer, J, 2022) |
| "In literature, adalimumab treating pustular psoriasis in pediatric has been described in six children who failed in prior treatment." | ( Chen, M; Dong, Z; Du, Y; Wang, F; Yan, Q, 2022) |
| "As a TCM and effective medicine for the treatment of psoriasis, Indigo Naturalis (Baphicacanthus Cusia (Nees) Bremek." | ( Du, A; Han, L; Li, G; Lin, J; Wang, F; Xie, J; Yang, M; Zhang, D; Zhang, Q, 2022) |
| "Despite there being advanced treatment options, psoriasis remains an incurable and recurring disease." | ( Fatima, G; Husain, N; Jabeen, A; Kazmi, MH; Uddin, Q, 2023) |
| "Despite advances in the treatment of psoriasis, namely among biologic agents, an oral, effective and safe new drug can bring several advantages to prescribers and patients." | ( Lé, AM; Puig, L; Torres, T, 2022) |
| "Clinical treatment of psoriasis remains challenging because of possible long-term drug toxicities and loss of therapeutic effects over time." | ( Dai, C; Guo, X; Jiang, F; Wang, J; Wu, X; Yin, Q, 2023) |
| "The systemic treatment of psoriasis has changed markedly with the introduction of many novel drugs." | ( Imafuku, S; Sato, E; Takano-Kawasaki, S; Yamaguchi, K, 2023) |
| "Safe and effective treatments for psoriasis that also address itch are needed." | ( Alonso-Llamazares, J; Berk, DR; Draelos, ZD; Feng, A; Gooderham, MJ; Higham, RC; Kempers, SE; Kircik, LH; Lebwohl, MG; Papp, KA; Pariser, DM; Stein Gold, L; Toth, DP; Yosipovitch, G, 2023) |
| "Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs." | ( Bhatia, N; Jacobson, A; Kircik, L; Lain, E, 2023) |
| "Topical vitamin D analogues are routine treatment for psoriasis, but the effect of oral supplementation has not been established." | ( Danielsen, K; Furberg, AS; Jenssen, M; Jorde, R; Wilsgaard, T, 2023) |
| "A major drawback of using MTX to treat psoriasis is its limited diffusion through the skin, which may cause insufficient penetration of MTX into the basal layer of the epidermis, where psoriatic cells are generated." | ( Al-Nemrawi, NK; Alzoubi, KH; Khafajah, AS, 2023) |
| "CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience." | ( Arenberger, P; Armstrong, A; Augustin, M; Gold, LS; Iversen, L; Pinter, A; Praestegaard, M; Reich, A, 2023) |